HUE027099T2 - Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk - Google Patents

Description

Description

FIELD OF THE INVENTION

[0001] The invention relates to medicine. In particular the invention relates to the diagnosis, prophylaxis and/or treatment of infection by staphylococci.

BACKGROUND OF THE INVENTION

[0002] Staphylococcus is a genus of gram-positive bacteria and a member of the micrococcaceae family. Staphylococci are spherical bacteria that are found primarily on the skin and in the mucous membranes of humans and other warmblooded animals, and aggregate into small, grape-like clumps. Staphylococci can be divided into two groups, i.e. coag-ulase-positive and coagulase-negative staphylococci. Overall, there are about thirty species of staphylococci.

[0003] Staphylococci can cause a wide variety of diseases in humans either through toxin production or invasion. Staphylococcus aureus (S. aureus) has been recognized as one of the most important and lethal human bacterial pathogens since the beginning of the previous century. Until the antibiotic era, more than 80% of the patients growing S. aureus from their blood died. Through infections caused by coagulase-positive S. aureus were generally known to be potentially lethal, coagulase-negative staphylococci has been dismissed as avirulent skin commensals incapable of causing human disease. However, over the past 30 years, coagulase-negative staphylococcal infections have emerged as one of the major complications of medical progress. They are currently the pathogens most commonly isolated from infections of indwelling foreign devices and are the leading cause of nosocomial (hospital-acquired) bacteremias in US hospitals. Staphylococcal infections are commonly treated with antimicrobial agents. However, the ascendancy of staphylococci as pre-eminent nocosomial pathogens also has been associated with a major increase in the proportion of these isolates that are resistant to (multiple) antimicrobial agents. Of the estimated 2 million hospital infections in the US in 2004, 70% was resistant to at least one antibiotic, thereby causing major medical and consequently economic problems. Ninety percent of the staphylococci strains are penicillin resistant, leaving only methicillin and vancomycin to treat the majority of infections. However, with increasing numbers of reports of methicillin-resistant Staphylococcus aureus (MRSA) chemists are faced with the daunting task of generating new antibiotics with novel modes of action. Despite the urgent need for the development of new antibiotics, the major pharmaceutical companies appear to have lost interest in the antibiotic market. In 2002, only 5 out of the more than 500 drugs in phase II or phase III clinical development were new antibiotics. In the last 6 years only 10 antibiotics have been registered and only 2 of those did not exhibit cross-reactivity with existing drugs (and thus not subject to the same patterns of drug resistance). This trend has been attributed to several factors: the cost of new drug development and the relatively small return on investment that infectious disease treatments yield compared to drugs against hypertension, arthritis and lifestyle drugs e.g. for impotence. Another contributing factor is the increasing difficulty in finding new targets, further driving up development costs. Therefore, investigation into novel therapies or preventative measures for (multi-drug-resistant) bacterial infections is urgently needed to meet this impending healthcare crisis.

[0004] Active immunization with vaccines and passive immunization with immunoglobulins are promising alternatives to classical small molecule therapy. A few bacterial diseases that once caused widespread illness, disability, and death can now be prevented through the use of vaccines. The vaccines are based on weakened (attenuated) or dead bacteria, components of the bacterial surface or on inactivated toxins. The immune response raised by a vaccine is mainly directed to immunogenic structures, a limited number of proteins or sugar structures on the bacteria that are actively processed by the immune system. Since these immunogenic structures are very specific to the organism, the vaccine needs to comprise the immunogenic components of all variants of the bacteria against which the vaccine should be protective. As a consequence thereof, vaccines are very complex, take long and are expensive to develop. Further complicating the design of vaccines is the phenomenon of ’antigen replacement’. This occurs when new strains become prevalent that are serologically and thus antigenically distinct from those strains covered by the vaccines. The immune status of the populations at risk for nosocomial infections further complicates vaccine design. These patients are inherently unwell and may even be immunocompromised (due to the effect of immunosuppressive drugs) resulting in delayed or insufficient immunity against the infecting pathogens. Furthermore, except in the case of certain elective procedures, it may not be possible to identify and vaccinate the at risk patients in time to give them sufficient immune protection from infection.

[0005] Direct administration of therapeutic immunoglobulins, also referred to as passive immunization, does not require an immune response from the patient and therefore gives immediate protection. In addition, passive immunization can be directed to bacterial structures that are not immunogenic and that are less specific to the organism. Passive immunization against pathogenic organisms has been based on immunoglobulins derived from sera of human or non-human donors. However, blood-derived products have potential health risks inherently associated with these products. In addition, the immunoglobulins can display batch-to-batch variation and may be of limited availability in case of sudden mass exposures. Recombinantly produced antibodies do not have these disadvantages and thus offer an opportunity to replace immunoglobulins derived from sera.

[0006] Murine monoclonal antibodies directed against staphylococci are known in the art (see WO 03/059259 and WO 03/059260). However, murine antibodies are limited for their use in vivo due to problems associated with administration of murine anti bodies to humans, such as short serum half life, an inability to trigger certain human effector functions and elicitation of an unwanted dramatic immune response against the murine antibody in a human (HAMA).

[0007] In WO 03/059259 and WO 03/059260 the attempts have been made to overcome the problems associated with the use of fully murine antibodies in humans by preparing chimeric antibodies. A disadvantage of these chimeric antibodies is however that they still retain some murine sequences and therefore still elicit an unwanted immune reaction, especially when administered for prolonged periods.

[0008] WO 2004/043405 relates to polysaccharide vaccines for staphylococcal infections, prepared from poly N-acetylglucosamine (PNAG) surface polysaccharide from Staphylococci, and the deacetylated form thereof (dPNAG). WO 2004/043405 also discloses rabbit antiserum to PNAG and dPNAG, coupled to Diphteria Toxoid (DTm).

[0009] WO 2005/103084 discloses an antibody F598 which binds to the poly-N-acetyl glucosamine (PNAG) of staphylococci and has in vitro opsonic killing activity against several S. aureus strains. In addition, the F598 antibody also binds to E. coli bacteria which is a disadvantage because said antibody is not selectively binding to Staphylococcus bacteria.

[0010] Although WO 03/059259, WO 03/059260 and WO 2004/043405 referto human antibodies as desired molecules, the antibodies actually disclosed and used therein are partly of murine or completely of rabbit origin, and none of these documents actually discloses any human antibodies, nor sequences thereof.

[0011] In view of their therapeutic benefit in humans, there is thus still a need for human monoclonal antibodies against Staphylococci. The present invention provides these antibodies and their sequences, and shows that they can be used in medicine, in particular for diagnosis, prevention and/or treatment of staphylococcal infections.

DESCRIPTION OF THE FIGURES

[0012]

Figure 1 shows antibody-mediated phagocytosis of S. aureus strain Cowan harvested during the log phase of growth in the absence of complement with the antibodies CR2430 (white dot), CR5132 (black triangle), CR5133 (black dot), and a negative control monoclonal antibody (white square).

Figure 2 shows antibody-mediated phagocytosis of S. aureus strain Cowan harvested during the stationary phase of growth in the absence of complement with the antibodies CR2430 (white dot), CR5132 (black triangle), CR5133 (black dot), and a negative control monoclonal antibody (white square).

Figure 3 shows antibody-mediated phagocytosis of S. aureus strain SA125 harvested during the stationary phase of growth in the absence of complement with the antibodies CR5132 (black triangle), CR5133 (black dot), and a negative control monoclonal antibody (white square).

Figure 4 shows antibody-mediated phagocytosis of S. epidermidis strain SE131 harvested during the stationary phase of growth in the absence of complement with the antibodies CR5132 (black triangle), CR5133 (black dot), and a negative control monoclonal antibody (white square).

DESCRIPTION OF THE INVENTION

[0013] Here below follow definitions of terms as used in the invention.

DEFINITIONS

Amino acid sequence [0014] The term "amino acid sequence" as used herein refers to naturally occurring or synthetic molecules and to a peptide, oligopeptide, polypeptide or protein sequence.

Binding molecule [0015] As used herein the term "binding molecule" refers to an intact immunoglobulin including monoclonal antibodies, such as chimeric, humanized or human monoclonal antibodies, or to an antigen-binding and/or variable domain comprising fragment of an immunoglobulin that competes with the intact immunoglobulin for specific binding to the binding partner of the immunoglobulin, e.g. staphylococci. Regardless of structure, the antigen-binding fragment binds with the same antigen that is recognized by the intact immunoglobulin. An antigen-binding fragment can comprise a peptide or polypeptide comprising an amino acid sequence of at least 2 contiguous amino acid residues, at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 30 contiguous amino acid residues, at least 35 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of the binding molecule.

[0016] The term "binding molecule", as used herein includes all immunoglobulin classes and subclasses known in the art. Depending on the amino acid sequence of the constant domain of their heavy chains, binding molecules can be divided into the five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., lgA1, lgA2, lgG1, lgG2, lgG3 and lgG4.

[0017] Antigen-binding fragments include, inter alia, Fab, F(ab’), F(ab’)2, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, (poly)peptides that contain at least a fragment of an immunoglobulin that is sufficient to confer specific antigen binding to the (poly)peptide, etc. The above fragments may be produced synthetically or by enzymatic or chemical cleavage of intact immunoglobulins or they may be genetically engineered by recombinant DNA techniques. The methods of production are well known in the art and are described, for example, in Antibodies: A Laboratory Manual, Edited by: E. Harlow and D, Lane (1988), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. A binding molecule or antigen-binding fragment thereof may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different.

[0018] The binding molecule can be a naked or unconjugated binding molecule but can also be part of an immuno-conjugate. A naked or unconjugated binding molecule is intended to refer to a binding molecule that is not conjugated, operatively linked or otherwise physically or functionally associated with an effector moiety or tag, such as inter alia a toxic substance, a radioactive substance, a liposome, an enzyme. It will be understood that naked or unconjugated binding molecules do not exclude binding molecules that have been stabilized, multimerized, humanized or in any other way manipulated, other than by the attachment of an effector moiety or tag. Accordingly, all post-translationally modified naked and unconjugated binding molecules are included herewith, including where the modifications are made in the natural binding molecule-producing cell environment, by a recombinant binding molecule-producing cell, and are introduced by the hand of man after initial binding molecule preparation. Of course, the term naked or unconjugated binding molecule does not exclude the ability of the binding molecule to form functional associations with effector cells and/or molecules after administration to the body, as some of such interactions are necessary in order to exert a biological effect. The lack of associated effector group or tag is therefore applied in definition to the naked or unconjugated binding molecule in vitro, not in vivo.

Biological sample [0019] As used herein, the term "biological sample" encompasses a variety of sample types, including blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures, or cells derived therefrom and the progeny thereof. The term also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides. The term encompasses various kinds of clinical samples obtained from any species, and also includes cells in culture, cell supernatants and cell lysates.

Complementarity determining regions (CDR) [0020] The term "complementarity determining regions" as used herein means sequences within the variable regions of binding molecules, such as immunoglobulins, that usually contribute to a large extent to the antigen binding site which is complementary in shape and charge distribution to the epitope recognized on the antigen. The CDR regions can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, e.g., by solubilization in SDS. Epitopes may also consist of posttranslational modifications of proteins.

Deletion [0021] The term "deletion", as used herein, denotes a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent as compared to the parent, often the naturally occurring, molecule.

Expression-reaulatina nucleic acid sequence [0022] The term "expression-regulating nucleic acid sequence" as used herein refers to polynucleotide sequences necessary for and/or affecting the expression of an operably linked coding sequence in a particular host organism. The expression-regulating nucleic acid sequences, such as inter alia appropriate transcription initiation, termination, promoter, enhancer sequences; repressor or activator sequences; efficient RNA processing signals such as splicing and polya-denylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either homologous or heterologous to the host organism. The identification and employment of expression-regulating sequences is routine to the person skilled in the art.

Functional variant [0023] The term "functional variant", as used herein, refers to a binding molecule that comprises a nucleotide and/or amino acid sequence that is altered by one or more nucleotides and/or amino acids compared to the nucleotide and/or amino acid sequences of the parent binding molecule and that is still capable of competing for binding to the binding partner, e.g. staphylococci, with the parent binding molecule. In other words, the modifications in the amino acid and/or nucleotide sequence of the parent binding molecule do not significantly affect or alter the binding characteristics of the binding molecule encoded by the nucleotide sequence or containing the amino acid sequence, i. e. the binding molecule is still able to recognize and bind its target. The functional variant may have conservative sequence modifications including nucleotide and amino acid substitutions, additions and deletions. These modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and random PCR-mediated mutagenesis, and may comprise natural as well as non-natural nucleotides and amino acids.

[0024] Conservative amino acid substitutions include the ones in which the amino acid residue is replaced with an amino acid residue having similar structural or chemical properties. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan). It will be clear to the skilled artisan that other classifications of amino acid residue families than the one used above can also be employed. Furthermore, a variant may have non-conservative amino acid substitutions, e.g., replacement of an amino acid with an amino acid residue having different structural or chemical properties. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing immunological activity may be found using computer programs well known in the art.

[0025] A mutation in a nucleotide sequence can be a single alteration made at a locus (a point mutation), such as transition or transversion mutations, or alternatively, multiple nucleotides maybe inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleotide sequence. The mutations may be performed by any suitable method known in the art.

Host [0026] The term "host", as used herein, is intended to refer to an organism or a cell into which a vector such as a cloning vector or an expression vector has been introduced. The organism or cell can be prokaryotic or eukaryotic. It should be understood that this term is intended to refer not only to the particular subject organism or cell, but to the progeny of such an organism or cell as well. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent organism or cell, but are still included within the scope of the term "host" as used herein.

Human [0027] The term "human", when applied to binding molecules as defined herein, refers to molecules that are either directly derived from a human or based upon a human sequence. When a binding molecule is derived from or based on a human sequence and subsequently modified, it is still to be considered human as used throughout the specification. In other words, the term human, when applied to binding molecules is intended to include binding molecules having variable and constant regions derived from human germline immunoglobulin sequences or based on variable or constant regions occurring in a human or human lymphocyte and modified in some form. Thus, the human binding molecules may include amino acid residues not encoded by human germline immunoglobulin sequences, comprise substitutions and/or deletions (e.g., mutations introduced by for instance random or site-specific mutagenesis in vitro or by somatic mutation in vivo). "Based on" as used herein refers to the situation that a nucleic acid sequence may be exactly copied from a template, or with minor mutations, such as by error-prone PCR methods, or synthetically made matching the template exactly or with minor modifications. Semi-synthetic molecules based on human sequences are also considered to be human as used herein.

Insertion [0028] The term "insertion", also known as the term "addition", denotes a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the parent sequence.

Intrinsic activity [0029] The term "intrinsic activity", when applied to binding molecules as defined herein, refers to binding molecules that are capable of binding to certain protein or carbohydrate antigens on the surface of pathogens such as bacteria and that can inhibit the ability of the pathogen to grow and divide normally. Such binding molecules can for example block the entry of specific nutrients required for growth or the transport of toxic waste elements from the bacteria. Through the latter action they may also increase the sensitivity of bacteria to the action of antibiotic drugs.

Isolated [0030] The term "isolated", when applied to binding molecules as defined herein, refers to binding molecules that are substantially free of other proteins or polypeptides, particularly free of other binding molecules having different antigenic specificities, and are also substantially free of other cellular material and/or chemicals. For example, when the binding molecules are recombinantly produced, they are preferably substantially free of culture medium, and when the binding molecules are produced by chemical synthesis, they are preferably substantially free of chemical precursors or other chemicals, i.e., they are separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. The term "isolated" when applied to nucleic acid molecules encoding binding molecules as defined herein, is intended to refer to nucleic acid molecules in which the nucleotide sequences encoding the binding molecules are free of other nucleotide sequences, particularly nucleotide sequences encoding binding molecules that bind binding partners other than staphylococci. Furthermore, the term "isolated" refers to nucleic acid molecules that are substantially separated from other cellular components that naturally accompany the native nucleic acid molecule in its natural host, e.g., ribosomes, polymerases, or genomic sequences with which it is naturally associated. Moreover, "isolated" nucleic acid molecules, such as cDNA molecules, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

Monoclonal antibody [0031] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity fora particular epitope. Accordingly, the term "human monoclonal antibody" refers to an antibody displaying a single binding specificity which has variable and constant regions derived from or based on human germline immunoglobulin sequences or derived from completely synthetic sequences. The method of preparing the monoclonal antibody is not relevant.

Naturally occurring [0032] The term "naturally occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring.

Nucleic acid molecule [0033] The term "nucleic acid molecule" as used in the present invention refers to a polymeric form of nucleotides and includes both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. The term also includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, méthylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha ano-meric nucleic acids, etc.). The above term is also intended to include any topological conformation, including single-stranded, double-stranded, partially duplexed, triplex, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule. A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, e.g., for anti-sense therapy, hybridization probes and PCR primers.

Operablv linked [0034] The term "operably linked" refers to two or more nucleic acid sequence elements that are usually physically linked and are in a functional relationship with each other. For instance, a promoter is operably linked to a coding sequence, if the promoter is able to initiate or regulate the transcription or expression of a coding sequence, in which case the coding sequence should be understood as being "under the control of the promoter.

Opsonic activity [0035] "Opsonic activity" refers to the ability of an opsonin (generally either a binding molecule, e.g. an antibody, or serum complement factors) to bind to the surface of a pathogen either by specific antigenic recognition (in the case of antibodies) or through the catalytic effect of surface bound molecules (e.g. the increased deposition of C3b as a result of surface bound antibodies). Phagocytosis of opsonized pathogens is enhanced due to the specific recognition of receptors on the phagocyte for the opsonin (the Fc receptor in case the antibodies themselves are the opsonins and the complement receptor in case complement is the opsonin). Certain bacteria, especially encapsulated bacteria that resist phagocytosis due to the presence of the capsule, become extremely attractive to phagocytes such as neutrophils and macrophages when coated with an opsonic antibody and their rate of clearance from the bloodstream and infected organs is strikingly enhanced. Opsonic activity may be measured in any conventional manner (e.g. the opsonic phagocytic killing assay).

Pharmaceutically acceptable excipient [0036] By "pharmaceutically acceptable excipient" is meant any inert substance that is combined with an active molecule such as a drug, agent, or binding molecule for preparing an agreeable or convenient dosage form. The "pharmaceutically acceptable excipient" is an excipient that is non-toxic to recipients at the dosages and concentrations employed, and is compatible with other ingredients of the formulation comprising the drug, agent or binding molecule.

Specifically Binding [0037] The term "specifically binding", as used herein, in reference to the interaction of a binding molecule, e.g. an antibody, and its binding partner, e.g. an antigen, means that the interaction is dependent upon the presence of a particular structure, e.g. an antigenic determinant or epitope, on the binding partner. In other words, the antibody preferentially binds or recognizes the binding partner even when the binding partner is present in a mixture of other molecules or organisms. The binding may be mediated by covalent or non-covalent interactions or a combination of both. In yet other words, the term "specifically binding" means immunospecifically binding to an antigen or a fragment thereof and not immunospecifically binding to other antigens. A binding molecule that immunospecifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), BIACORE, or other assays known in the art. Binding molecules or fragments thereof that immunospecifically bind to an antigen may be cross-reactive with related antigens. Preferably, binding molecules or fragments thereof that immunospecifically bind to an antigen do not cross-react with other antigens.

Substitutions [0038] A "substitution", as used herein, denotes the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

Therapeutically effective amount [0039] The term "therapeutically effective amount" refers to an amount of the binding molecule as defined herein that is effective for preventing, ameliorating and/or treating a condition resulting from infection with Staphylococcus.

Treatment [0040] The term "treatment" refers to therapeutic treatment as well as prophylactic or preventative measures to cure or halt or at least retard disease progress. Those in need of treatment include those already inflicted with a condition resulting from infection with Staphylococcus as well as those in which infection with Staphylococcus is to be prevented. Subjects partially or totally recovered from infection with Staphylococcus might also be in need of treatment. Prevention encompasses inhibiting or reducing the spread of Staphylococcus or inhibiting or reducing the onset, development or progression of one or more of the symptoms associated with infection with Staphylococcus.

Vector [0041] The term "vector" denotes a nucleic acid molecule into which a second nucleic acid molecule can be inserted for introduction into a host where it will be replicated, and in some cases expressed. In other words, a vector is capable of transporting a nucleic acid molecule to which it has been linked. Cloning as well as expression vectors are contemplated by the term "vector", as used herein. Vectors include, but are not limited to, plasmids, cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC) and vectors derived from bacteriophages or plant or animal (including human) viruses. Vectors comprise an origin of replication recognized by the proposed host and in case of expression vectors, promoter and other regulatory regions recognized by the host. A vector containing a second nucleic acid molecule is introduced into a cell by transformation, transfection, or by making use of viral entry mechanisms. Certain vectors are capable of autonomous replication in a host into which they are introduced (e.g., vectors having a bacterial origin of replication can replicate in bacteria). Other vectors can be integrated into the genome of a host upon introduction into the host, and thereby are replicated along with the host genome.

SUMMARY OF THE INVENTION

[0042] The invention provides human binding molecules capable of specifically binding to staphylococci and exhibiting killing and/or growth inhibiting activity against staphylococci. The invention also pertains to nucleic acid molecules encoding at least the binding region of the human binding molecules. The invention further provides for the use of the human binding molecules of the invention in the prophylaxis and/or treatment of a subject having, or at risk of developing, a Staphylococcus infection. Besides that, the invention pertains to the use of the human binding molecules of the invention in the diagnosis/detection of Staphylococcus.

DETAILED DESCRIPTION OF THE INVENTION

[0043] In a first aspect the present invention encompasses binding molecules capable of specifically binding to staphylococci. Preferably, the binding molecules are human binding molecules. Preferably, the binding molecules of the invention exhibit killing activity against staphylococci. In a further aspect the binding molecules of the invention are capable of specifically binding to and/or have killing activity against at least two different Staphylococcus species. Preferably the binding molecules of the invention are capable of specifically binding to and/or have killing activity against at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty different Staphylococcus species. Staphylococcus species that the binding molecules of the invention are capable of specifically binding to and/or have killing activity against are selected from the group consisting of S. aureus, S. auricularis, S. capitis, S. caprae, S. caseolyticus, S. chromogenes, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. hyicus, S. intermedium, S. lentus, S. lugdunensis, S. saprophyticus, S. schleifen, S. sciuri, S. simulans, S. warned, and S. xylosus. In an embodiment the binding molecules of the invention are capable of specifically binding to and have killing activity against different strains within one Staphylococcus species. In a further embodiment the binding molecules of the invention are capable of specifically binding to and have killing activity against a Staphylococcus strain in the lag phase, log phase, stationary phase and/or death phase. Preferably, they specifically bind to and have killing activity against a Staphylococcus strain in the log phase and stationary phase. In another embodiment, the binding molecules of the invention may even be capable of specifically binding to and/or have killing activity against at least one other Gram-positive bacterium and/or Gram-negative bacterium including, but not limited to, Group A streptococci; streptococcus pyrogenes, Group B streptococci; streptococcus agalactiae, streptococcus milled, streptococcus pneumoniae, Viridans streptococci; streptococcus mutans, Enterococcus; Enterococcus faecalis and Enterococcus faecium, Corynebacterium diphtheriae, Corynebacterium ulcerans, Corynebacterium pseudotuberculosis, Corynebacterium jeikeium, Corynebacterium xerosis, Corynebacterium pseudodiphtheriticum, Bacillus anthracis, Bacillus cereus, Listeria monocytogenes, Clostridium perfringens, Clostridium tetani, Clostridium botulinum, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium leprae, Actinomyces israelii, Norcardia asteroides, Norcardia brasiliensis, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumoniae, Salmonella typhi, Salmonella paratyphi A, B&.C, Salmonella enteritidis, Salmonella cholerae-suis, Salmonella virchow, Salmonella typhimurium, Shigella dysenteriae, Shigella boydii, Shigella flexneri, Shigella sonnei, Pseudomonas aeruginosa, Pseudomonas mallei, Vibrio cholerae, Vibrio parahaemo-lyticus, Vibrio vulnificus, Vibrio alginolyticus, Campylobacter pylori, Helicobacter pylori, Campylobacter jejuni, Bacter-oides fragilis, Neisseria gonorrhoeae, Neisseria meningitidis, Branhamella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Bordetella pertussis, Brucella abodus, Brucella abortus, Brucella melitensis, Legionella pneumophila, Treponema pallidum, Treponema carateum, Leptospira interrogans, Leptospira biflexa, Borrelia recurrentis, Borrelia burgdorferi, Mycoplasma pneumoniae, Coxiella burnetii, Clamydia trachomatis, Clamydia psittaci, Clamydia pneumoniae. The binding molecules of the invention may be capable of specifically binding to staphylococci and optionally other Gram-positive and/or Gram-negative bacteria that are viable, living and/or infective or that are in inactivated/attenuated form. Methods for inactivating/attenuating bacteria are well known in the art and include, but are not limited to, antibiotic treatment, UV treatment, formaldehyde treatment, etc.

[0044] The binding molecules of the invention may also be capable of specifically binding to one or more fragments of staphylococci (and other Gram-positive and/or Gram-negative bacteria) such as inter alia a preparation of one or more proteins and/or (poly)peptides derived from staphylococci or one or more recombinantly produced staphylococci proteins and/or polypeptides. For methods of treatment and/or prevention of staphylococcal infections the binding molecules are preferably capable of specifically binding to surface accessible proteins of staphylococci. For diagnostical purposes the binding molecules may also be capable of specifically binding to proteins not present on the surface of staphylococci. The nucleotide and/or amino acid sequence of proteins of various Staphylococcus species and strains can be found in the GenBank-database, EMBL-database and/or other databases. It is well within the reach of the skilled person to find such sequences in the respective databases.

[0045] Alternatively, binding molecules of the invention may also be capable of specifically binding to other staphylococcal molecules including, but not limited to, surface factors that inhibit phagocytic engulfment; factors that enhance their survival in phagocytes; invasins that lyse eukaryotic cell membranes; exotoxins that damage host tissues or otherwise provoke symptoms of disease; polysaccharides; other cell wall components such as teichoic acid, lipoteichoic acid, ribitol, peptidoglycan, pentaglycine oligopeptide, N-acetylglucosamine, N-acetylmuramic acid, N-acetylgalactos-aminuronic acid, /V-acetylfucosamine, A/-acetylglucosaminuronic acid, N-acetylmannosaminuronic acid, O-acetyl, glucosamine, muramic acid, galactosaminuronic acid, fucosamine, glucosaminuronic acid, mannosaminuronic acid and linkage units between any of these components.

[0046] In another embodiment the binding molecules of the invention are capable of specifically binding to a fragment of the above-mentioned proteins and/or other molecules, wherein the fragment at least comprises an antigenic determinant recognized by the binding molecules of the invention. An "antigenic determinant" as used herein is a moiety that is capable of binding to a binding molecule of the invention with sufficiently high affinity to form a detectable antigenbinding molecule complex.

[0047] The binding molecules of the invention can be intact immunoglobulin molecules such as polyclonal or monoclonal antibodies or the binding molecules can be antigen-binding fragments including, but not limited to, Fab, F(ab’), F(ab’)2, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, and (poly)peptides that contain at least a fragment of an immunoglobulin that is sufficient to confer specific antigen binding to staphylococci or a fragment thereof. In a preferred embodiment the binding molecules of the invention are human monoclonal antibodies.

[0048] The binding molecules of the invention can be used in non-isolated or isolated form. Furthermore, the binding molecules of the invention can be used alone or in a mixture comprising at least one binding molecule (or variant or fragment thereof) of the invention. In other words, the binding molecules can be used in combination, e.g., as a pharmaceutical composition comprising two or more binding molecules of the invention, variants or fragments thereof. For example, binding molecules having different, but complementary activities can be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect, but alternatively, binding molecules having identical activities can also be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect. Optionally, the mixture further comprises at least one other therapeutic agent. Preferably, the therapeutic agent such as e.g. an antibiotic is useful in the prophylaxis and/or treatment of a staphylococcal infection.

[0049] Typically, binding molecules according to the invention can bind to their binding partners, i.e. staphylococci or fragments thereof, with an affinity constant (Kd-value) that is lower than 0.2*10-4 M, 1.0*10-5 M, 1.0*10-6 M, 1.0*10-7 M, preferably lower than 1.0*10-8 M, more preferably lower than 1.0*10-9 M, more preferably lower than 1.0*10_1° M, even more preferably lower than 1.0*10-11 M, and in particular lower than 1.0*10‘12 M. The affinity constants can vary for antibody isotypes. For example, affinity binding for an IgM isotype refers to a binding affinity of at least about 1.0*10-7 M. Affinity constants can for instance be measured using surface plasmon resonance, for example using the BIACORE system (Pharmacia Biosensor AB, Uppsala, Sweden).

[0050] The binding molecules according to the invention may bind to staphylococci or a fragment thereof in soluble form such as for instance in a sample or in suspension or may bind to staphylococci or a fragment thereof bound or attached to a carrier or substrate, e.g., microtiter plates, membranes and beads, etc. Carriers or substrates may be made of glass, plastic (e.g., polystyrene), polysaccharides, nylon, nitrocellulose, or Teflon, etc. The surface of such supports may be solid or porous and of any convenient shape. Furthermore, the binding molecules may bind to staphylococci in purified/isolated or non-purified/non-isolated form.

[0051] The binding molecules of the invention exhibit killing activity. Killing activity as meant herein includes, but is not limited to, opsonic activity or any other activity increasing/augmenting/enhancing phagocytosis and/or phagocytic killing of bacteria, e.g. staphylococci; intrinsic (killing) activity, e.g. reduce or inhibit bacterial growth or directly kill bacteria; increase the sensitivity of bacteria to antibiotic treatment; or any combination thereof. Opsonic activity can for instance be measured as described herein. Alternative assays measuring opsonic activity are described in for instance Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. Assays to measure the other mentioned activities are also known.

[0052] The binding molecules disclosed herein comprise at least a CDR3 region, preferably a heavy chain CDR3 region, comprising the amino acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:15. The CDR regions of the binding molecules of the invention are shown in Table 12. CDR regions are according to Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, NIH, USA (fifth edition). In an embodiment binding molecules may comprise two, three, four, five or even all six CDR regions of the binding molecules of the invention.

[0053] The binding molecules disclosed herein comprise a heavy chain comprising the variable heavy chain of the amino acid sequence selected from the group consisting of SEQ ID NO:28 and SEQ ID NO:30. In a further aspect, the binding molecules disclosed herein comprise a light chain comprising the variable light chain of the amino acid sequence selected from the group consisting of SEQ ID NO:34 and SEQ ID NO:36. Table 13 specifies the heavy and light chain variable regions of the binding molecule of the invention.

[0054] In another aspect the binding molecules of the invention are capable of specifically binding to one specific Staphylococcus species, preferably one specific Staphylococcus strain. In other words, they are species- and even strain-specific. Preferably, the binding molecules of the invention exhibit killing activity against the specific Staphylococcus species/strain. In a preferred embodiment the Staphylococcus species is S. aureus and the strain is S. aureus strain Cowan. The binding molecules of the invention may be capable of specifically binding to and exhibit killing activity against the specific Staphylococcus species/strain in any phase, e.g. log and/or stationary phase. The binding molecules disclosed herein comprise at least a CDR3 region, preferably a heavy chain CDR3 region, comprising the amino acid sequence of SEQ ID NO:3. The CDR regions of the binding molecules are shown in Table 12. CDR regions are according to Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, NIH, USA (fifth edition). In an embodiment binding molecules may comprise two, three, four, five or even all six CDR regions of the binding molecules of the invention. Also disclosed herein are binding molecules comprising a heavy chain comprising the variable heavy chain of the amino acid sequence of SEQ ID NO:26 and a light chain comprising the variable light chain of the amino acid sequence of SEQ ID NO:32. Table 13 specifies the heavy and light chain variable regions of the binding molecule disclosed herein.

[0055] Also disclosed herein are functional variants of the binding molecules as defined herein. Molecules are considered to be functional variants of a binding molecule, if the variants are capable of competing for specifically binding to staphylococci (or other Gram-positive and/or Gram-negative bacteria) or a fragment thereof with the parent human binding molecules. In other words, when the functional variants are still capable of binding to staphylococci or a fragment thereof. Preferably, the functional variants are capable of competing for specifically binding to the at least two (or more) different Staphylococcus species or frag ments thereof that are specifically bound by the parent human binding molecules. Furthermore, molecules are considered to be functional variants of a binding molecule according to the invention, if they have killing activity against staphylococci, preferably against the at least two (or more) Staphylococcus species against which the parental binding molecule exhibits killing activity. In another embodiment the functional variants of a binding molecule according to the invention also have killing activity against other Gram-positive and/or Gram-negative bacteria. Functional variants include, but are not limited to, derivatives that are substantially similar in primary structural sequence, but which contain e.g. in vitro or in vivo modifications, chemical and/or biochemical, that are not found in the parental binding molecule. Such modifications include inter alia acetylation, acylation, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, cross-linking, disulfide bond formation, glycosylation, hydroxylation, méthylation, oxidation, pegylation, proteolytic processing, phosphorylation, and the like.

[0056] Alternatively, functional variants can be binding molecules as defined in the present invention comprising an amino acid sequence containing substitutions, insertions, deletions or combinations thereof of one or more amino acids compared to the amino acid sequences of the parent binding molecules. Furthermore, functional variants can comprise truncations of the amino acid sequence at either or both the amino or carboxyl termini. Functional variants as disclosed herein may have the same or different, either higher or lower, binding affinities compared to the parental binding molecule but are still capable of binding to staphylococci or a fragment thereof. For instance, functional variants may have increased or decreased binding affinities for staphylococci or a fragment thereof compared to the parent binding molecules. Preferably, the amino acid sequences of the variable regions, including, but not limited to, framework regions, hypervariable regions, in particular the CDR3 regions, are modified. Generally, the light chain and the heavy chain variable regions comprise three hypervariable regions, comprising three CDRs, and more conserved regions, the so-called framework regions (FRs). The hypervariable regions comprise amino acid residues from CDRs and amino acid residues from hypervariable loops. Functional variants as disclosed herein have at least about 50% to about 99%, preferably at least about 60% to about 99%, more preferably at least about 70% to about 99%, even more preferably at least about 80% to about 99%, most preferably at least about 90% to about 99%, in particular at least about 95% to about 99%, and in particular at least about 97% to about 99% amino acid sequence homology with the parent human binding molecules as defined herein. Computer algorithms such as inter alia Gap or Bestfit known to a person skilled in the art can be used to optimally align amino acid sequences to be compared and to define similar or identical amino acid residues. Functional variants can be obtained by altering the parent binding molecules or parts thereof by general molecular biology methods known in the art including, but not limited to, error-prone PCR, oligonucleotide-directed mutagenesis, site-directed mutagenesis and heavy nad/or light chain shuffling. The functional variants as disclosed herein have killing activity against staphylococci. The killing activity may either be identical, or be higher or lower compared to the parent binding molecules. Furthermore, the functional variants having killing activity may have a further activity suitable in staphylococcal control. Other activities are mentioned above. Flenceforth, when the term (human) binding molecule is used, this also encompasses functional variants of the (human) binding molecule.

[0057] Disclosed herein is a panel of useful human monoclonal antibodies that have opsonic phagocytic killing activity against Staphylococci, said antibodies comprising the heavy and light chain variable regions of any one of the antibodies named CR2430, CR5132, CR5133 CR6166, CR6171, CR6176, CR6187, CR6193, CR6249, CR6273, CR6389, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6453, CR6464, CR6471, CR6516, CR6517, CR6526, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, or CR6625, or comprising variable regions with sequences that are at least 80%, preferably at least 90%, more preferably at least 95%, identical thereto. Preferably the sequences of the complete antibodies are at least 80%, more preferably at least 90%, still more preferably at least 95% identical to the sequences of these antibodies as disclosed herein. The antibodies fell into five distinct groups, based on a target competition assay. Group A consisted of CR5132, CR5133, CR6187 and CR6453; Group B consisted of CR5140 and CR6171 ; Group C consisted of CR6176; Group D consisted of CR6526; and Group E consisted of the rest of the panel CR6166, CR6193, CR6249, CR6273, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6464, CR6471, CR6516, CR6517, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, CR6625. Based on the potency, one antibody from each group was identified as preferred antibody, and the preferred antibodies are: CR5133, CR6166, CR6171, CR6176 and CR6526. These antibodies were all shown to bind and have opsonic phagocytic killing activity against at least two different Staphylococcus species (S. aureus and S. epidermidis), and against at least 3 different strains of S. aureus (502, Mn8, Newman). Also disclosed herein are compositions comprising at least 2, at least 3, at least 4, at least 5, or more, of the human monoclonal antibodies of the invention. In preferred embodiments, at least 2 of said antibodies in the composition are from different target groups. This has the advantage that different targets on the staphylococci are recognized and thus the chances of killing the bacteria are increased. Of course, higher affinity mutants or mutants with other advantageous properties can be prepared according to routine methods, based on the sequences of the antibodies as disclosed herein. Such improved antibodies are included within the scope of the present invention, when the variable regions of heavy and light chain are at least 80%, preferably at least 90%, still more preferably at least 95% identical to the sequences of the variable regions of the antibodies disclosed herein.

[0058] Also disclosed herein are immunoconjugates, i.e. molecules comprising at least one binding molecule as defined herein and further comprising at least one tag, such as inter alia a detectable moiety/agent. Also contemplated in the present invention are mixtures of immunoconjugates according to the invention or mixtures of at least one immunoconjugates according to the invention and another molecule, such as a therapeutic agent or another binding molecule or immunoconjugate. In a further embodiment, the immunoconjugates of the invention may comprise more than one tag. These tags can be the same or distinct from each other and can be joined/conjugated non-covalently to the binding molecules. The tag(s) can also be joined/conjugated directly to the human binding molecules through covalent bonding. Alternatively, the tag(s) can be joined/conjugated to the binding molecules by means of one or more linking compounds. Techniques for conjugating tags to binding molecules are well known to the skilled artisan.

[0059] The tags of the immunoconjugates of the present invention may be therapeutic agents, but they can also be detectable moieties/agents. Tags suitable in therapy and/or prevention may be toxins or functional parts thereof, antibiotics, enzymes, other binding molecules that enhance phagocytosis or immune stimulation. Immunoconjugates comprising a detectable agent can be used diagnostically to, for example, assess if a subject has been infected with a Staphylococcus species or monitor the development or progression of a staphylococcal infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. However, they may also be used for other detection and/or analytical and/or diagnostic purposes. Detectable moieties/agents include, but are not limited to, enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and non-radioactive paramagnetic metal ions. The tags used to label the binding molecules for detection and/or analytical and/or diagnostic purposes depend on the specific detection/analysis/diagnosis techniques and/or methods used such as inter alia immunohistochemical staining of (tissue) samples, flow cytometric detection, scanning laser cytometric detection, fluorescent immunoassays, enzyme-linked immunosorbent assays (ELISA’s), radioimmunoassays (RIA’s), bioassays (e.g., phagocytosis assays), Western blotting applications, etc. Suitable labels for the detection/analysis/diagnosis techniques and/or methods known in the art are well within the reach of the skilled artisan.

[0060] Furthermore, the human binding molecules or immunoconjugates of the invention can also be attached to solid supports, which are particularly useful for in vitro immunoassays or purification of staphylococci or a fragment thereof. Such solid supports might be porous or nonporous, planar or non-planar. The binding molecules of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. Examples include, but are not limited to, the hexa-histidine tag, the hemagglutinin (HA) tag, the myc tag or the flag tag. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate. In another aspect the binding molecules of the invention may be conjugated/attached to one or more antigens. Preferably, these antigens are antigens which are recognized by the immune system of a subject to which the binding molecule-antigen conjugate is administered. The antigens may be identical, but may also differ from each other. Conjugation methods for attaching the antigens and binding molecules are well known in the art and include, but are not limited to, the use of cross-linking agents. The binding molecules of the invention will bind to staphylococci and the antigens attached to the binding molecules will initiate a powerful T-cell attack on the conjugate, which will eventually lead to the destruction of the staphylococci.

[0061] Next to producing immunoconjugates chemically by conjugating, directly or indirectly, via for instance a linker, the immunoconjugates can be produced as fusion proteins comprising the binding molecules of the invention and a suitable tag. Fusion proteins can be produced by methods known in the art such as, e.g., recombinantly by constructing nucleic acid molecules comprising nucleotide sequences encoding the binding molecules in frame with nucleotide sequences encoding the suitable tag(s) and then expressing the nucleic acid molecules.

[0062] It is another aspect of the present invention to provide a nucleic acid molecule encoding at least a binding molecule or immunoconjugate according to the invention. Such nucleic acid molecules can be used as intermediates for cloning purposes, e.g. in the process of affinity maturation as described above. In a preferred embodiment, the nucleic acid molecules are isolated or purified.

[0063] The skilled man will appreciate that functional variants of these nucleic acid molecules are also disclosed herein. Functional variants are nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the parent nucleic acid molecules.

[0064] The nucleic acid molecules disclosed herein encode binding molecules comprising a CDR3 region, preferably a heavy chain CDR3 region, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:9 and SEQ ID NO:15. In a further embodiment the nucleic acid molecules encode binding molecules comprising two, three, four, five or even all six CDR regions of the binding molecules of the invention.

[0065] Also disclosed herein are nucleic acid molecules that encode binding molecules comprising a heavy chain comprising the variable heavy chain of the amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:30. Also disclosed herein are nucleic acid molecules that encode binding molecules comprising a light chain comprising the variable light chain of the amino acid sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:34 and SEQ ID NO:36.

[0066] It is another aspect of the invention to provide vectors, /. e. nucleic acid constructs, comprising one or more nucleic acid molecules according to the present invention. Vectors can be derived from plasmids such as inter alia F, R1, RP1, Col, pBR322, TOL, Ti, etc; cosmids; phages such as lambda, lambdoid, M13, Mu, P1, P22, Qß, T-even, T-odd, T2, T4, T7, etc; plant viruses. Vectors can be used for cloning and/or for expression of the binding molecules of the invention and might even be used for gene therapy purposes. Vectors comprising one or more nucleic acid molecules according to the invention operably linked to one or more expression-regulating nucleic acid molecules are also covered by the present invention. The choice of the vector is dependent on the recombinant procedures followed and the host used. Introduction of vectors in host cells can be effected by inter alia calcium phosphate transfection, virus infection, DEAE-dextran mediated transfection, lipofectamin transfection or electroporation. Vectors may be autonomously replicating or may replicate together with the chromosome into which they have been integrated. Preferably, the vectors contain one or more selection markers. The choice of the markers may depend on the host cells of choice, although this is not critical to the invention as is well known to persons skilled in the art. They include, but are not limited to, kanamycin, neomycin, puromycin, hygromycin, zeocin, thymidine kinase gene from Herpes simplex virus (HSV-TK), dihydrofolate reductase gene from mouse (dhfr). Vectors comprising one or more nucleic acid molecules encoding the human binding molecules as described above operably linked to one or more nucleic acid molecules encoding proteins or peptides that can be used to isolate the human binding molecules are also covered by the invention. These proteins or peptides include, but are not limited to, glutathione-S-transferase, maltose binding protein, metal-binding polyhistidine, green fluorescent protein, luciferase and beta-galactosidase.

[0067] Hosts containing one or more copies of the vectors mentioned above are an additional subject of the present invention. Preferably, the hosts are host cells. Host cells include, but are not limited to, cells of mammalian, plant, insect, fungal or bacterial origin. Bacterial cells include, but are not limited to, cells from Gram-positive bacteria or Gram-negative bacteria such as several species of the genera Escherichia, such as E. coli, and Pseudomonas. In the group of fungal cells preferably yeast cells are used. Expression in yeast can be achieved by using yeast strains such as inter alia Pichia pastoris, Saccharomyces cerevisiae and Hansenula polymorpha. Furthermore, insect cells such as cells from Drosophila and Sf9 can be used as host cells. Besides that, the host cells can be plant cells such as inter alia cells from crop plants such as forestry plants, or cells from plants providing food and raw materials such as cereal plants, or medicinal plants, or cells from ornamentals, or cells from flower bulb crops. Transformed (transgenic) plants or plant cells are produced by known methods, for example, Agrobacterium-mediated gene transfer, transformation of leaf discs, protoplast transformation by polyethylene glycol-induced DNA transfer, electroporation, sonication, microinjection or holistic gene transfer. Additionally, a suitable expression system can be a baculovirus system. Expression systems using mammalian cells such as Chinese Hamster Ovary (CHO) cells, COS cells, BHK cells or Bowes melanoma cells are preferred in the present invention. Mammalian cells provide expressed proteins with posttranslational modifications that are most similar to natural molecules of mammalian origin. Since the present invention deals with molecules that may have to be administered to humans, a completely human expression system would be particularly preferred. Therefore, even more preferably, the host cells are human cells. Examples of human cells are inter alia HeLa, 911, AT1080, A549, 293 and HEK293T cells. In preferred embodiments, the human producer cells comprise at least a functional part of a nucleic acid sequence encoding an adenovirus E1 region in expressible format. In even more preferred embodiments, said host cells are derived from a human retina and immortalized with nucleic acids comprising adenoviral E1 sequences, such as 911 cells or the cell line deposited at the European Collection of Cell Cultures (ECACC), CAMR, Salisbury, Wiltshire SP4 OJG, Great Britain on 29 February 1996 under number 96022940 and marketed under the trademark PER.C6® (PER.C6 is a registered trademark of Crucell Holland B.V.). For the purposes of this application "PER.C6" refers to cells deposited under number 96022940 or ancestors, passages up-stream or downstream as well as descendants from ancestors of deposited cells, as well as derivatives of any of the foregoing. Production of recombinant proteins in host cells can be performed according to methods well known in the art. The use of the cells marketed under the trademark PER.C6® as a production platform for proteins of interest has been described in WO 00/63403.

[0068] A method of producing a binding molecule according to the invention is an additional part of the invention. The method comprises the steps of a) culturing a host according to the invention under conditions conducive to the expression of the binding molecule, and b) optionally, recovering the expressed binding molecule. The expressed binding molecules or immunoconjugates can be recovered from the cell free extract, but preferably they are recovered from the culture medium. The above method of producing can also be used to make functional variants of the binding molecules and/or immunoconjugates of the present invention. Methods to recover proteins, such as binding molecules, from cell free extracts or culture medium are well known to the man skilled in the art. Binding molecules, functional variants and/or immunoconjugates as obtainable by the above-described method are also a part of the present invention.

[0069] Alternatively, next to the expression in hosts, such as host cells, the binding molecules and immunoconjugates of the invention can be produced synthetically by conventional peptide synthesizers or in cell-free translation systems using RNA nucleic acid derived from DNA molecules according to the invention. Binding molecules and immunoconjugates as obtainable by the above described synthetic production methods or cell-free translation systems are also a part of the present invention.

[0070] In yet another embodiment, binding molecules of the present invention can also be produced in transgenic, non-human, mammals such as inter alia rabbits, goats or cows, and secreted into for instance the milk thereof.

[0071] In yet another alternative embodiment, binding molecules according to the present invention, preferably human binding molecules specifically binding to staphylococci or a fragment thereof, may be generated by transgenic nonhuman mammals, such as for instance transgenic mice or rabbits, that express human immunoglobulin genes. Preferably, the transgenic non-human mammals have a genome comprising a human heavy chain transgene and a human light chain transgene encoding all or a portion of the human binding molecules as described above. The transgenic nonhuman mammals can be immunized with a purified or enriched preparation of staphylococci or a fragment thereof. Protocols for immunizing non-human mammals are well established in the art. See Using Antibodies: A Laboratory Manual, Edited by: E. Harlow, D. Lane (1998), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York and Current Protocols in Immunology, Edited by: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober (2001), John Wiley & Sons Inc., New York. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund’s complete adjuvant and Freund’s incomplete adjuvant, but may also include naked DNA immunizations. In another embodiment, the human binding molecules are produced by B cells or plasma cells derived from the transgenic animals. In yet another embodiment, the human binding molecules are produced by hybri-domas, which are prepared by fusion of B cells obtained from the above-described transgenic non-human mammals to immortalized cells. B cells, plasma cells and hybridomas as obtainable from the above-described transgenic non-human mammals and human binding molecules as obtainable from the above-described transgenic non-human mammals, B cells, plasma cells and hybridomas are also a part of the present invention.

[0072] Also disclosed herein is a method of identifying a binding molecule, such as a human binding molecule, e.g. a human monoclonal antibody or fragment thereof, specifically binding to at least two different bacterial organisms or nucleic acid molecules encoding such binding molecules and com prises the steps of: (a) contacting a collection of binding molecules on the surface of replicable genetic packages with a first bacterial organism under conditions conducive to binding, (b) selecting at least once for a replicable genetic package binding to the first bacterial organism, (c) optionally, separating the replicable genetic package binding to the first bacterial organism from replicable genetic packages that do not bind to the first bacterial organism, contacting the separated replicable genetic packages with a second bacterial organism under conditions conducive to binding and selecting at least once for a replicable genetic package binding to the second bacterial organism, and (d) separating and recovering the replicable genetic package binding to the first and/or second bacterial organism from replicable genetic packages that do not bind to the first and/or second bacterial organism. Of course, the above methods extended with selections on third and further bacterial organisms are also part of the present invention.

[0073] A replicable genetic package as used herein can be prokaryotic or eukaryotic and includes cells, spores, yeasts, bacteria, viruses, (bacterio)phage, ribosomes and polysomes. A preferred replicable genetic package is a phage. The binding molecules, such as for instance single chain Fvs, are displayed on the replicable genetic package, i. e. they are attached to a group or molecule located at an exterior surface of the replicable genetic package. The replicable genetic package is a screenable unit comprising a binding molecule to be screened linked to a nucleic acid molecule encoding the binding molecule. The nucleic acid molecule should be replicable either in vivo (e.g., as a vector) or in vitro (e.g., by PCR, transcription and translation). In vivo replication can be autonomous (as for a cell), with the assistance of host factors (as for a virus) or with the assistance of both host and helper virus (as for a phagemid). Replicable genetic packages displaying a collection of binding molecules is formed by introducing nucleic acid molecules encoding exogenous binding molecules to be displayed into the genomes of the replicable genetic packages to form fusion proteins with endogenous proteins that are normally expressed from the outer surface of the replicable genetic packages. Expression of the fusion proteins, transport to the outer surface and assembly results in display of exogenous binding molecules from the outer surface of the replicable genetic packages.

[0074] The selection step(s) in the method according to the present invention can be performed with bacterial organisms that are live and still infective or inactivated. Inactivation of bacterial organism may be performed by bacterial inactivation methods well known to the skilled artisan such as inter alia treatment with low pH, i.e. pH 4 for 6 hours to 21 days; treatment with organic solvent/detergent, i.e. addition of organic solvents and detergents (Triton X-100 orTween-80) to the bacterium; UV/light irradiation; gamma-irradiation; and treatment with relevant antibiotics. Methods to test, if a bacterial organism is still alive, infective and/or viable or partly or completely inactivated are well known to the person skilled in the art. The bacterial organisms used in the above method may be non-isolated, e.g. present in serum and/or blood of an infected individual. The bacterial organisms used may also be isolated as discrete colonies after overnight culture at 37°C on a suitable medium such as sheep blood agar.

[0075] In an embodiment the first and/or second bacterial organisms are in suspension when contacted with the replicable genetic packages. Alternatively, they may also be coupled to a carrier when contact takes place. In another embodiment the first and second bacterial organism are from a different bacterial family, e.g. the first is from a Gramnegative bacterium and the second is from a Gram-positive bacterium. This way, binding molecules capable of specifically binding to Gram-positive and Gram-negative bacteria can be found. Preferably, the first and second bacterial organism are both Gram-positive bacteria. The first and second bacterial organism can both be staphylococci. In one embodiment the first and second bacterial organism are different strains from the same bacterial species, e.g. a Staphylococcus species such as S. aureus or S. epidermidis. This way, species-specific binding molecules can be found that are capable of specifically binding to different strains within one species. In another embodiment the first and second bacterial organism are each a member of a different Staphylococcus species, e.g. the first and second Staphylococcus species are selected from the group consisting of S. aureus and S. epidermidis. This way, binding molecules capable of specifically binding to different species within one bacterial genus can be found. Alternatively, first and second bacterial organisms can both be enterococci. In one embodiment the first and second bacterial organism are different strains from the same bacterial species, e.g. an Enterococcus species such as E. faecalis or E. faecium. This way, species-specific binding molecules can be found that are capable of specifically binding to different strains within one species. In another embodiment the first and second bacterial organism are each a member of a different Enterococcus species, e.g. the first and second Enterococcus species are selected from the group consisting of E. faecalis and E. faecium.

[0076] Alternatively, the selection step may be performed in the presence of a fragment of the bacterial organisms such as e.g. cell membrane preparations, cell membrane preparations that have been enzymically treated to remove proteins (e.g. with protease K), cell membrane preparations that have been enzymically treated to remove carbohydrate moieties (e.g. with periodate), recombinant proteins or polysaccharides. In yet another embodiment, the selection step may be performed in the presence of one or more proteins or (poly)peptides derived from the bacterial organisms, fusion proteins comprising these proteins or (poly)peptides, and the like. Extracellularly exposed parts of these proteins can also be used as selection material. The live or inactivated bacterial organisms or fragments thereof may be immobilized to a suitable material before use. Alternatively, live or inactivated bacteria in suspension are used. In an embodiment the selection can be performed on different materials derived from bacterial organisms. For instance, the first selection round can be performed on live or inactivated bacterial organisms in suspension, while the second and third selection round can be performed on recombinant bacterial proteins and polysaccharides, respectively. Of course, other combinations are also contemplated herein. Different bacterial materials can also be used during one selection/panning step. In a further aspect the invention provides methods wherein the bacterial organisms used in the selection step(s) are derived from the same or different growth phases of the bacteria, e.g. the lag phase, log phase, stationary phase or death phase. This way, phase-specific anti-bacterial binding molecules may be found. For instance, the first bacterial organism may be a S. aureus in stationary phase, while the second bacterial organism is a S. aureus in log phase or the first bacterial organism may be a S. aureus in lag phase, while the second bacterial organism is a S. epidermidis in lag phase. Further combinations are well within the reach of the skilled artisan.

[0077] Alsodisclosed herein is a method asdescribed abovewherein, if the first and/or second Staphylococcus species is a S. aureus strain, Protein A present on the surface of the S. aureus strain is blocked before the S. aureus strain is contacted with replicable genetic packages. Suitable blocking agent may be rabbit serum, purified rabbit immunoglobulin, fetal calf serum, pooled human serum [0078] Also disclosed herein is a method of obtaining a binding molecule specifically binding to at least two different bacterial organisms or a nucleic acid molecule encoding such a binding molecule, wherein the method comprises the steps of a) performing the above described method of identifying binding molecules, and b) isolating from the recovered replicable genetic package the binding molecule and/or the nucleic acid molecule encoding the binding molecule. The collection of binding molecules on the surface of replicable genetic packages can be a collection of scFvsorFabs. Once a new scFv or Fab has been established or identified with the above-mentioned method of identifying binding molecules or nucleic acid molecules encoding the binding molecules, the DNA encoding the scFv or Fab can be isolated from the bacteria or phages and combined with standard molecular biological techniques to make constructs encoding bivalent scFvs or complete human immunoglobulins of a desired specificity (e.g. IgG, IgA or IgM). These constructs can be transfected into suitable cell lines and complete human monoclonal antibodies can be produced (see Fluls etal., 1999; Boel et al., 2000).

[0079] As mentioned before the preferred replicable genetic package is a phage. Phage display methods for identifying and obtaining (human) binding molecules, e.g. (human) monoclonal antibodies, are by now well-established methods known by the person skilled in the art. They are e.g. described in US Patent Number 5,696,108; Burton and Barbas, 1994; de Kruif etal., 1995b; and Phage Display: A Laboratory Manual. Edited by: CF Barbas, DR Burton, JK Scott and GJ Silverman (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. For the construction of phage display libraries, collections of human monoclonal antibody heavy and light chain variable region genes are expressed on the surface of bacteriophage, preferably filamentous bacteriophage, particles, in for example single-chain Fv (scFv) or in Fab format (see de Kruif etal., 1995b). Large libraries of antibody fragment-expressing phages typically contain more than 1.0*109 antibody specificities and may be assembled from the immunoglobulin V regions expressed in the B-lymphocytes of immunized- or non-immunized individuals. The phage library of binding molecules, preferably scFv phage library, is prepared from RNA isolated from cells obtained from a subject that has been vaccinated against a bacterium, recently vaccinated against an unrelated pathogen, recently suffered from a chronic or acute bacterial infection, e.g. staphylococcal infection, or from a healthy individual. RNA can be isolated from inter alia bone marrow or peripheral blood, preferably peripheral blood lymphocytes or on isolated B cells or even on subpopulations of B cells. The subject can be an animal vaccinated against a bacterium or an animal that has or has had a bacterial infection.

Preferably, the animal is a human subject that has been vaccinated against a bacterium or has or has had a chronic bacterial infection or an acute bacterial infection. Preferably, the human subject has recently recovered from the bacterial infection.

[0080] Alternatively, phage display libraries may be constructed from immunoglobulin variable regions that have been partially assembled in vitro to introduce additional antibody diversity in the library (semi-synthetic libraries). For example, in vitro assembled variable regions contain stretches of synthetically produced, randomized or partially randomized DNA in those regions of the molecules that are important for antibody specificity, e.g. CDR regions. Phage antibodies specific for bacteria such as staphylococci can be selected from the library by exposing the bacteria or material thereof to a phage library to allow binding of phages expressing antibody fragments specific for the bacteria or material thereof. Nonbound phages are removed by washing and bound phages eluted for infection of E.coli bacteria and subsequent propagation. Multiple rounds of selection and propagation are usually required to sufficiently enrich for phages binding specifically to the bacteria or material thereof. If desired, before exposing the phage library to the bacteria or material thereof the phage library can first be subtracted by exposing the phage library to non-target material such as bacteria of a different family, species and/or strain or bacteria in a different growth phase or material of these bacteria. These subtractor bacteria or material thereof can be bound to a solid phase or can be in suspension. Phages may also be selected for binding to complex antigens such as complex mixtures of bacterial proteins or (poly)peptides optionally supplemented with bacterial polysaccharides or other bacterial material. Host cells expressing one or more proteins or (poly)peptides of bacteria such as staphylococci may also be used for selection purposes. A phage display method using these host cells can be extended and improved by subtracting non-relevant binders during screening by addition of an excess of host cells comprising no target molecules or non-target molecules that are similar, but not identical, to the target, and thereby strongly enhance the chance of finding relevant binding molecules. Of course, the subtraction may be performed before, during or after the screening with bacterial organisms or material thereof. The process is referred to as the Mabstract® process (Mabstract® is a registered trademark of Crucell Holland B.V., see also US Patent Number 6,265,.

[0081] Also disclosed herein is a method of obtaining a binding molecule potentially having killing activity against at least two different bacterial organisms, wherein the method comprises the steps of (a) performing the method of obtaining a binding molecule specifically binding to at least two different bacterial organisms or a nucleic acid molecule encoding such a binding molecule as described above, and (b) verifying if the binding molecule isolated has killing activity against at least two different bacterial organisms. Assays for verifying if a binding molecule has killing activity such as opsonic activity are well known in the art (see for instance Manual of Molecular and Clinical Laboratory Immunology, 7th Edition). In a further embodiment the binding molecule is also tested for any other activity. Other useful activities are mentioned above.

[0082] In a further aspect the invention pertains to a binding molecule having killing activity against at least two, preferably at least three or more, different bacterial organisms, such as e.g. staphylococci, and being obtainable by the methods as described above. A pharmaceutical composition comprising the binding molecule, the pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient is also an aspect of the present invention. Pharmaceutically acceptable excipients are well known to the skilled person. The pharmaceutical composition according to the invention may further comprise at least one other therapeutic agent. Suitable agents are also well known to the skilled artisan.

[0083] In yet a further aspect, the invention provides compositions comprising at least one binding molecule preferably a human monoclonal antibody according to the invention, , at least one immunoconjugate according to the invention or a combination thereof. In addition to that, the compositions may comprise inter alia stabilizing molecules, such as albumin or polyethylene glycol, or salts. Preferably, the salts used are salts that retain the desired biological activity of the binding molecules and do not impart any undesired toxicological effects. If necessary, the human binding molecules of the invention may be coated in or on a material to protect them from the action of acids or other natural or non-natural conditions that may inactivate the binding molecules.

[0084] In yet a further aspect, the invention provides compositions comprising at least one nucleic acid molecule as defined in the present invention. The compositions may comprise aqueous solutions such as aqueous solutions containing salts (e.g., NaCI or salts as described above), detergents (e.g., SDS) and/or other suitable components.

[0085] Furthermore, the present invention pertains to pharmaceutical compositions comprising at least one binding molecule such as a human monoclonal antibody of the invention (or functional fragment or variant thereof), at least one immunoconjugate according to the invention, at least one composition according to the invention, or combinations thereof. The pharmaceutical composition of the invention further comprises at least one pharmaceutically acceptable excipient.

[0086] In an embodiment the pharmaceutical compositions may comprise two or more binding molecules that have killing activity against a bacterial organism, e.g. a Staphylococcus species. In an embodiment, the binding molecules exhibit synergistic killing activity, when used in combination. In other words, the compositions comprise at least two binding molecules having killing activity, characterized in that the binding molecules actsynergistically in killing a bacterial organism such as e.g. a Staphylococcus species. As used herein, the term "synergistic" means that the combined effect of the binding molecules when used in combination is greater than their additive effects when used individually. The synergistically acting binding molecules may bind to different structures on the same of distinct fragments of the bacterial organism. In an embodiment the binding molecules acting synergistically in killing a bacterial organism may also be capable of killing other bacterial organisms synergistically. Away of calculating synergy is by means of the combination index. The concept of the combination index (Cl) has been described by Chou and Talalay, 1984. The two or more binding molecules having synergistic activity have distinct modes of action. For instance a first binding molecule may have opsonizing activity, while the second binding molecule has another activity increasing/augmenting/enhancing phagocytosis or a first binding molecule may have intrinsic (killing) activity, e.g. reduce or inhibit bacterial growth or directly kill bacteria, while the second binding molecule increases the sensitivity of bacteria to antibiotic treatment. It is to be understood that other combinations are also contemplated herein.

[0087] A pharmaceutical composition according to the invention can further comprise at least one other therapeutic, prophylactic and/or diagnostic agent. Preferably, the pharmaceutical composition comprises at least one other prophylactic and/or therapeutic agent. Preferably, said further therapeutic and/or prophylactic agents are agents capable of preventing and/or treating a bacterial, e.g. staphylococcal, infection and/or a condition resulting from such an infection. Therapeutic and/or prophylactic agents include, but are not limited to, anti-bacterial agents. Such agents can be binding molecules, small molecules, organic or inorganic compounds, enzymes, polynucleotide sequences, antimicrobial peptides, etc. Other agents that are currently used to treat patients infected with bacterial infections such as staphylococcal infections are antibiotics such as methicillin, 2nd and 3111 generation cephalosporins, aminoglycosides, Carbapenems, Macrolides, Ketolides, Quinolones and miscellaneous antibiotics such as daptomycin, linezolid, nitrofurantoin, quinu-pristin/dalfopristin, trimethoprim/sulfa, vancomycin. These can be used in combination with the binding molecules of the invention. Agents capable of preventing and/or treating an infection with bacteria and/or a condition resulting from such an infection that are in the experimental phase might also be used as other therapeutic and/or prophylactic agents useful in the present invention.

[0088] The binding molecules or pharmaceutical compositions of the invention can be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not limited to, murine sepsis and peritonitis models, rat sepsis and endocarditis models, and rabbit endocarditis models.

[0089] Typically, pharmaceutical compositions must be sterile and stable under the conditions of manufacture and storage. The binding molecules, immunoconjugates, nucleic acid molecules or compositions of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable excipient before or at the time of delivery. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0090] Alternatively, the binding molecules, immunoconjugates, nucleic acid molecules or compositions of the present invention can be in solution and the appropriate pharmaceutically acceptable excipient can be added and/or mixed before or at the time of delivery to provide a unit dosage injectable form. Preferably, the pharmaceutically acceptable excipient used in the present invention is suitable to high drug concentration, can maintain properfluidity and, if necessary, can delay absorption.

[0091] The choice of the optimal route of administration of the pharmaceutical compositions will be influenced by several factors including the physico-chemical properties of the active molecules within the compositions, the urgency of the clinical situation and the relationship of the plasma concentrations of the active molecules to the desired therapeutic effect. For instance, if necessary, the binding molecules of the invention can be prepared with carriers that will protect them against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can inter alia be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Furthermore, it may be necessary to coat the binding molecules with, or co-administer the binding molecules with, a material or compound that prevents the inactivation of the human binding molecules. For example, the binding molecules may be administered to a subject in an appropriate carrier, for example, liposomes or a diluent.

[0092] The routes of administration can be divided into two main categories, oral and parenteral administration. The preferred administration route is intravenous.

[0093] Oral dosage forms can be formulated inter alia as tablets, troches, lozenges, aqueous or oily suspensions, dispersable powders orgranules, emulsions, hard capsules, soft gelatin capsules, syrups or elixirs, pills, dragees, liquids, gels, or slurries. These formulations can contain pharmaceutically excipients including, but not limited to, inert diluents, granulating and disintegrating agents, binding agents, lubricating agents, preservatives, colouring, flavoring or sweetening agents, vegetable or mineral oils, wetting agents, and thickening agents.

[0094] The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be inter alia in the form of aqueous or non-aqueous isotonic sterile nontoxic injection or infusion solutions or suspensions. The solutions or suspensions may comprise agents that are nontoxic to recipients at the dosages and concentrations employed such as 1,3-butanediol, Ringer’s solution, Hank’s solution, isotonie sodium chloride solution, oils, fatty acids, local anesthetic agents, preservatives, buffers, viscosity or solubility increasing agents, water-soluble antioxidants, oil-soluble antioxidants, and metal chelating agents.

[0095] In a further aspect, the binding molecules such as human monoclonal antibodies (functional fragments and variants thereof), immunoconjugates, compositions, or pharmaceutical compositions of the invention can be used as a medicament. So, a method of treatment and/or prevention of a bacterial (Gram-positive and/or Gram-negative), e.g. a staphylococcal, infection using the binding molecules, immunoconjugates, compositions, or pharmaceutical compositions of the invention is another part of the present invention. The above-mentioned molecules can inter alia be used in the diagnosis, prophylaxis, treatment, or combination thereof, of a bacterial infection. They are suitable for treatment of yet untreated patients suffering from a bacterial infection and patients who have been or are treated for a bacterial infection. They may be used for patients such as hospitalized infants, premature infants, burn victims, elderly patients, immunocompromised patients, immununosuppressed patients, patient undergoing an invasive procedure, and health care workers. Each administration may protect against further infection by the bacterial organism for up to three or four weeks and/or will retard the onset or progress of the symptoms associated with the infection. The binding molecules of the invention may also increase the effectiveness of existing antibiotic treatment by increasing the sensitivity of the bacterium to the antibiotic, may stimulate the immune system to attack the bacterium in ways other than through opsonization. This activation may result in long lasting protection to the infection bacterium. Furthermore, the binding molecules of the invention may directly inhibit the growth of the bacterium or inhibit virulence factors required for its survival during the infection.

[0096] The above-mentioned molecules or compositions may be employed in conjunction with other molecules useful in diagnosis, prophylaxis and/or treatment. They can be used in vitro, ex vivo or in vivo. For instance, the binding molecules such as human monoclonal antibodies (or functional variants thereof), immunoconjugates, compositions or pharmaceutical compositions of the invention can be co-administered with a vaccine against the bacterial organism (if available). Alternatively, the vaccine may also be administered before or after administration of the molecules of the invention. Instead of a vaccine, anti-bacterial agents can also be employed in conjunction with the binding molecules of the present invention. Suitable anti-bacterial agents are mentioned above.

[0097] The molecules are typically formulated in the compositions and pharmaceutical compositions of the invention in a therapeutically or diagnostically effective amount. Alternatively, they may be formulated and administered separately. For instance the other molecules such as the anti-bacterial agents may be applied systemically, while the binding molecules of the invention may be applied intrathecally or intraventricularly.

[0098] Dosage regimens can be adjusted to provide the optimum desired response {e.g., a therapeutic response). A suitable dosage range may for instance be 0.1 -100 mg/kg body weight, preferably 0.5-15 mg/kg body weight. Furthermore, for example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. The molecules and compositions according to the present invention are preferably sterile. Methods to render these molecules and compositions sterile are well known in the art. The other molecules useful in diagnosis, prophylaxis and/or treatment can be administered in a similar dosage regimen as proposed for the binding molecules of the invention. If the other molecules are administered separately, they may be administered to a patient prior to {e.g., 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 7 days, 2 weeks, 4 weeks or 6 weeks before), concomitantly with, or subsequent to {e.g., 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 7 days, 2 weeks, 4 weeks or 6 weeks after) the administration of one or more of the human binding molecules or pharmaceutical compositions of the invention. The exact dosing regimen is usually sorted out during clinical trials in human patients.

[0099] Human binding molecules and pharmaceutical compositions comprising the human binding molecules are particularly useful, and often preferred, when to be administered to human beings as in vivo therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of a monoclonal murine, chimeric or humanized binding molecule.

[0100] In another aspect, the invention concerns the use of the binding molecules such as killing human monoclonal antibodies (functional fragments and variants thereof), immunoconjugates, nucleic acid molecules, compositions or pharmaceutical compositions according to the invention in the preparation of a medicamentforthe diagnosis, prophylaxis, treatment, or combination thereof, of a bacterial (Gram-positive and/or Gram-negative), e.g. staphylococcal infection.

[0101] Next to that, kits comprising at least one binding molecule such as a killing human monoclonal antibody (functional fragments and variants thereof), at least one immunoconjugate, at least one nucleic acid molecule, at least one composition, at least one pharmaceutical composition, at least one vector, at least one host according to the invention or a combination thereof are also a part of the present invention. Optionally, the above-described components of the kits of the invention are packed in suitable containers and labeled for diagnosis, prophylaxis and/or treatment of the indicated conditions. The above-mentioned components may be stored in unit or multi-dose containers as an aqueous, preferably sterile, solution or as a lyophilized, preferably sterile, formulation for reconstitution. The containers may be formed from a variety of materials such as glass or plastic and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The kit may further comprise more containers comprising a pharmaceutically acceptable buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, culture medium for one or more of the suitable hosts and, possibly, even at least one other therapeutic, prophylactic or diagnostic agent. Associated with the kits can be instructions customarily included in commercial packages of therapeutic, prophylactic or diagnostic products, that contain information about for example the indications, usage, dosage, manufacture, administration, contra-indications and/or warnings concerning the use of such therapeutic, prophylactic or diagnostic products.

[0102] The binding molecules of the invention may also be used to coat medical devices or polymeric biomaterials.

[0103] Also disclosed herein is a method of detecting a bacterial organism (Gram-positive and/or Gram-negative) in a sample, wherein the method comprises the steps of (a) contacting a sample with a diagnostically effective amount of a binding molecule (functional fragments and variants thereof) or an immunoconjugate according to the invention, and (b) determining whether the binding molecule or immunoconjugate specifically binds to a molecule of the sample. Preferably, the method is used to detect a Staphylococcus in a sample. The sample may be a biological sample including, but not limited to blood, serum, urine, tissue or other biological material from (potentially) infected subjects, or a non-biological sample such as water, drink, etc. The (potentially) infected subjects may be human subjects, but also animals that are suspected as carriers of such a bacterial organism might be tested for the presence of the organism using the human binding molecules or immunoconjugates of the invention. The sample may first be manipulated to make it more suitable for the method of detection. Manipulation means inter alia treating the sample suspected to contain and/or containing the bacterial organism in such a way that the organism will disintegrate into antigenic components such as proteins, (poly)peptides or other antigenic fragments. Preferably, the human binding molecules or immunoconjugates of the invention are contacted with the sample under conditions which allow the formation of an immunological complex between the human binding molecules and the bacterial organism or antigenic components thereof that may be present in the sample. The formation of an immunological complex, if any, indicating the presence of the bacterial organism in the sample, is then detected and measured by suitable means. Such methods include, inter alia, homogeneous and heterogeneous binding immunoassays, such as radio-immunoassays (RIA), ELISA, immunofluorescence, immunohis-tochemistry, FACS, BIACORE and Western blot analyses.

[0104] Preferred assay techniques, especially for large-scale clinical screening of patient sera and blood and blood-derived products are ELISA and Western blot techniques. ELISA tests are particularly preferred. For use as reagents in these assays, the binding molecules or immunoconjugates of the invention are conveniently bonded to the inside surface of microtiter wells. The binding molecules or immunoconjugates of the invention may be directly bonded to the microtiter well. However, maximum binding of the binding molecules or immunoconjugates of the invention to the wells might be accomplished by pre-treating the wells with polylysine prior to the addition of the binding molecules or immunoconjugates of the invention. Furthermore, the binding molecules or immunoconjugates of the invention may be covalently attached by known means to the wells. Generally, the binding molecules or immunoconjugates are used between 0.01 to 100 ^g/ml for coating, although higher as well as lower amounts may also be used. Samples are then added to the wells coated with the binding molecules or immunoconjugates of the invention.

[0105] Furthermore, binding molecules of the invention can be used to identify specific binding structures of a bacterial organism e.g. a Staphylococcus. The binding structures can be epitopes on proteins and/or polypeptides. They can be linear, but also structural and/or conformational. In one embodiment, the binding structures can be analyzed by means of PEPSCAN analysis (see inter alia\NO 84/03564, WO 93/09872, Slootstraetal., 1996). Alternatively, a random peptide library comprising peptides from a protein of a bacterial organism can be screened for peptides capable of binding to the binding molecules of the invention. The binding structures/peptides/epitopes found can be used as vaccines and for the diagnosis of bacterial infections. In case fragments other than proteins and/or polypeptides are bound by the binding molecules binding structures can be identified by mass spectrometry, high performance liquid chromatography and nuclear magnetic resonance.

[0106] Also disclosed herein is a method of screening a binding molecule (or a functional fragment or variant thereof) for specific binding to the same epitope of a bacterial organism (Gram-positive and/or Gram-negative), e.g. Staphylococcus, as the epitope bound by a human binding molecule of the invention, wherein the method comprises the steps of (a) contacting a binding molecule to be screened, a binding molecule of the invention and a bacterial organism or fragment thereof, (b) measure if the binding molecule to be screened is capable of competing for specifically binding to the bacterial organism orfragment thereof with the binding molecule of the invention. In afurtherstep it may be determined, if the screened binding molecules that are capable of competing for specifically binding to the bacterial organism or fragment thereof have killing activity, e.g. opsonic activity. A binding molecule that is capable of competing for specifically binding to the bacterial organism or a fragment thereof with the binding molecule of the invention is another part of the present invention. In the above-described screening method, "specifically binding to the same epitope" also contemplates specific binding to substantially or essentially the same epitope as the epitope bound by the a binding molecule of the invention. The capacity to block, or compete with, the binding of the binding molecules of the invention to the bacterial organism typically indicates that a binding molecule to be screened binds to an epitope or binding site on the bacterial organism that structurally overlaps with the binding site on the bacterial organism that is immunospecifically recognized by the binding molecules of the invention. Alternatively, this can indicate that a binding molecule to be screened binds to an epitope or binding site which is sufficiently proximal to the binding site immunospecifically recognized by the binding molecules of the invention to sterically or otherwise inhibit binding of the binding molecules of the invention to the bacterial organism.

[0107] In general, competitive inhibition is measured by means of an assay, wherein an antigen composition, i.e. a composition comprising a bacterial organism or fragments thereof, is admixed with reference binding molecules, i.e. the binding molecules of the invention, and binding molecules to be screened. Usually, the binding molecules to be screened are present in excess. Protocols based upon ELISAs and Western blotting are suitable for use in such simple competition studies. By using species or isotype secondary antibodies one will be able to detect only the bound reference binding molecules, the binding of which will be reduced by the presence of a binding molecule to be screened that recognizes substantially the same epitope. In conducting a binding molecule competition study between a reference binding molecule and any binding molecule to be screened (irrespective of species or isotype), one may first label the reference binding molecule with a detectable label, such as, e.g., biotin, an enzymatic, a radioactive or other label to enable subsequent identification. Binding molecules identified by these competition assays ("competitive binding molecules" or "cross-reactive binding molecules") include, but are not limited to, antibodies, antibody fragments and other binding agents that bind to an epitope or binding site bound by the reference binding molecule, i.e. a binding molecule of the invention, as well as antibodies, antibody fragments and other binding agents that bind to an epitope or binding site sufficiently proximal to an epitope bound by the reference binding molecule for competitive binding between the binding molecules to be screened and the reference binding molecule to occur. Preferably, competitive binding molecules of the invention will, when present in excess, inhibit specific binding of a reference binding molecule to a selected target species by at least 10%, preferably by at least 25%, more preferably by at least 50%, and most preferably by at least 75%-90% or even greater. The identification of one or more competitive binding molecules that bind to about, substantially, essentially or at the same epitope as the binding molecules of the invention is a straightforward technical matter. As the identification of competitive binding molecules is determined in comparison to a reference binding molecule, /. e. a binding molecule of the invention, it will be understood that actually determining the epitope to which the reference binding molecule and the competitive binding molecule bind is not in any way required in order to identify a competitive binding molecule that binds to the same or substantially the same epitope as the reference binding molecule.

EXAMPLES

[0108] To illustrate the invention, the following examples are provided. The examples are not intended to limit the scope of the invention in any way.

Example 1

Construction of scFv phage display libraries using RNA extracted from donors screened for opsonic activity [0109] Samples of blood were taken from donors reporting a recent gram-positive bacterial infection as well as healthy adults between 25-50 years of age. Peripheral blood leukocytes were isolated by centrifugation and the blood serum was saved and frozen at - 80°C. Donor serum was screened for opsonic activity using a FACS-based phagocytosis assay (Cantinieaux et al., 1989) and compared to a pool of normal healthy donor serum. Sera from donors having a higher phagocytic activity compared to normal serum were chosen to use for the generation of phage display libraries. Total RNA was prepared from the peripheral blood leukocytes of these donors using organic phase separation and subsequent ethanol precipitation. The obtained RNA was dissolved in RNAse-free water and the concentration was determined by OD 260nm measurement. Thereafter, the RNA was diluted to a concentration of 100 ng/μΙ. Next, 1 μg of RNA was converted into cDNA as follows: To 10 μΙ total RNA, 13 μΙ DEPC-treated ultrapure water and 1 μΙ random hexamers (500 ng/μΙ) were added and the obtained mixture was heated at 65°C for 5 minutes and quickly cooled on wet-ice. Then, 8 μΙ 5X First-Strand buffer, 2 μΙ dNTP (10 mM each), 2 μΙ DTT (0.1 M), 2 μΙ RNAse-inhibitor (40 U/μΙ) and 2 μΙ Superscript™ III MMLV reverse transcriptase (200 U/μΙ) were added to the mixture, incubated at room temperature for 5 minutes and incubated for 1 hour at 50°C. The reaction was terminated by heat inactivation, i.e. by incubating the mixture for 15 minutes at 75°C. The obtained cDNA products were diluted to a final volume of 200 μΙ with DEPC-treated ultrapure water. The OD 260 nm of a 50 times diluted solution (in 10 mM Tris buffer) of the dilution of the obtained cDNA products was used to determine the cDNA concentration. For each donor 5 to 10 μΙ of the diluted cDNA products were used as template for PCR amplification of the immunoglobulin gamma heavy chain family and kappa or lambda light chain sequences using specific oligonucleotide primers (see T ables 1 -7). In addition, for one donor PCR amplification of the immunoglobulin mu heavy chain family and kappa or lambda light chain sequences was carried out. PCR reaction mixtures contained, besides the diluted cDNA products, 25 pmol sense primer and 25 pmol anti-sense primer in a final volume of 50 μΙ of 20 mM Tris-HCI (pH 8.4), 50 mM KCI, 1.5 mM MgCI2, 250 μΜ dNTPs and 1.25 units Taq polymerase. In a heated-lid thermal cycler having a temperature of 96°C, the mixtures obtained were quickly melted for 2 minutes, followed by 30 cycles of: 30 seconds at 96°C, 30 seconds at 55°C or 60°C and 60 seconds at 72°C. Finally, the samples were incubated 10 minutes at 72°C and refrigerated at 4°C until further use.

[0110] In a first round amplification, each of eighteen light chain variable region sense primers (twelve for the lambda light chain (see Table 1; the HuVL1A-Back, HuVL1B-Back and HuVL1C-Back sense primers were mixed to equimolarity before use, as well as the HuVL9-Back and HuVL10-Back sense primers) and six for the kappa light chain (see Table 2)) were combined with an anti-sense primer recognizing the C-kappa constant region called HuCK-FOR 5’-ACACTCTC-CCCTGTTGAAGCTCTT-3’ (SEQ ID NO:37) or C-lambda constant region HuCL2-FOR 5’-TGAACATTCTGTAG-GGGCCACTG-3’ (SEQ ID NO:38) and HuCL7-FOR 5’-AGAGCATTCTGCAGGGGCCACTG-3’ (SEQ ID NO:39) (the HuCL2-FOR and HuCL7-FOR anti-sense primers were mixed to equimolarity before use), yielding 15 products of about 650 base pairs. These products were purified on agarose gel and isolated from the gel using Qiagen gel-extraction columns. 1/10 of each of the isolated products was used in an identical PCR reaction as described above using eighteen sense primers, whereby each lambda light chain sense primer was combined with one of the three Jlambda-region specific anti-sense primers and each kappa light chain sense primer was combined with one of the five Jkappa-region specific anti-sense primers (see Table 3; the HuVL1A-Back-SAL, HuVL1B-Back-SAL and HuVL1C-Back-SAL sense primers were mixed to equimolarity before use, as well as the HuVL9-Back-SAL and HuVL10-Back-SAL sense primers). The sense primers used in the second amplification were the same primers as used in the first amplification, but extended with restriction sites (see Table 3) to enable directed cloning in the phage display vector PDV-C06 (SEQ ID NO:40). This resulted in 57 products of approximately 400 base pairs that were pooled as shown in Table 4 to maintain the natural distribution of the different J segments and light chain families within the library and not to over or under represent certain families. The pooled products were purified using Qiagen PCR purification columns. In the next step, 3 μg of pooled products and 100 μς PDV-C06 vector were digested with Sail and Notl and purified from gel. Thereafter, a ligation was performed overnight at 16°C as follows. To 500 ng PDV-C06 vector either 35, 70 or 140 ng pooled products were added in a total volume of 50 μΙ ligation mix containing 50 mM Tris-HCI (pH 7.5), 10 mM MgCI2, 10 mM DTT, 1 mM ATP, 25 μg/ml BSAand 2.5 μΙ T4 DNA Ligase (400 U/μΙ). The ligation mixes were purified by phenol/chloroform extraction, followed by a chloroform extraction and ethanol precipitation, methods well known to the skilled artisan. The DNA obtained was dissolved in 50 μΙ 10 mM Tris-HCI pH 8.5 and per ligation mix 1 or 2 μΙ was electroporated into 40 μΙ of TG1 competent E. coli bacteria according to the manufacturer’s protocol (Stratagene). Transformants were grown overnight at 37°C on 2TY agar supplemented with 50 μg/ml ampicillin and 4.5% glucose. Colonies were counted to determine the optimal vector to insert ratio. From the ligation mix with the optimal ratio, multiple 1 or 2 μΙ aliquots were electroporated as above and transformants were grown overnight at 37°C, typically yielding ~107 colonies. A (sub)library of variable light chain regions was obtained by scraping the transformants from the agar plates. This (sub)library was directly used for plasmid DNA preparation using a Qiagen™ QIAFilter MAXI prep kit.

[0111] Heavy chain immunoglobulin sequences were amplified from the same cDNA preparations in a similar two round PCR procedure and identical reaction parameters as described above for the light chain regions with the proviso that the primers depicted in Tables 5 and 6 were used. The first amplification was performed using a set of eight sense directed primers (see Table 5; the HuVH1B/7A-Back and HuVH1C-Back sense primers were mixed to equimolarity before use) each combined with an IgG specific constant region anti-sense primer called HuCIgG 5’-GTC CAC CTT GGT GTT GCT GGG CTT-3’ (SEQ ID NO:41) yielding seven products of about 650 base pairs. For one donor an IgM specific constant region anti-sense primer called HuCIgM 5’-TGG AAG AGG CAC GTT CTTTTCTTT-3’ (SEQ ID NO:42) was used instead of primer HuCIgG. The products were purified on agarose gel and isolated from the gel using Qiagen gel-extraction columns. 1/10 of each of the isolated products was used in an identical PCR reaction as described above using eight sense primers, whereby each heavy chain sense primerwas combined with one of the four JH-region specific anti-sense primers (see Table 6; the HuVH1B/7A-Back-Sfi and HuVH1C-Back-Sfi sense primers were mixed to equimolarity before use). The sense primers used in the second round were the same primers as used in the first amplification, but extended with restriction sites (see Table 6) to enable directed cloning in the light chain (sub)library vector. This resulted in 28 products of approximately 400 base pairs that were pooled as shown in Table 7 to maintain the natural distribution of the different J segments and heavy chain families within the library and not to over or under represent certain families. The pooled products were purified using Qiagen PCR purification columns. Next, 3 μg of purified products was digested with Sfil and Xhol and ligated in the light chain (sub)library vector, which was cut with the same restriction enzymes, using the same ligation procedure and volumes as described above for the light chain (sub)library. Ligation mix purification and subsequent transformation of the resulting definitive library was also performed as described above for the light chain (sub)library. All bacteria, typically ~107, were harvested in 2TY culture medium containing 50 μg/ml ampicillin and 4.5% glucose, mixed with glycerol to 15% (v/v) and frozen in 1.5 ml aliquots at -80°C. Rescue and selection of each library were performed as described below. The various libraries were named GPB-05-M01, GPB-05-G01, GPB-05-G02, GPB-05-G03, GPB-05-G04 and GPB-05-G05. Two other libraries, RAB-03-G01 and RAB-04-G01, were constructed using a method similar to the procedure above, as described previously in international patent application WO 2005/118644.

Example 2

Constriction of scFv phage display libraries using RNA extracted from memory B cells [0112] Peripheral blood was collected from normal healthy donors, convalescent donors or vaccinated donors by venapunction using EDTA anti-coagulation sample tubes. A blood sample (45 ml) was diluted twice with PBS and 30 ml aliquots were underlayed with 10 ml Ficoll-Hypaque (Pharmacia) and centrifuged at 900xg for 20 minutes at room temperature without breaks. The supernatant was removed carefully to just above the white layer containing the lymphocytic and thrombocytic fraction. Next, this layer was carefully removed (—10 ml), transferred to a fresh 50 ml tube and washed three times with 40 ml PBS and spun at400xg for 10 minutes at room temperature to remove thrombocytes. The obtained pellet containing lymphocytes was resuspended in RPMI medium containing 2% FBS and the cell number was determined by cell counting. Approximately 1x10® lymphocytes were stained for fluorescent cell sorting using CD24, CD27 and surface IgM as markers for the isolation of switched and IgM memory B cells. A Becton Dickinson Digital Vantage apparatus set in Yield Mode was used for physical memory B cell sorting and isolation. Lymphocytes were gated as the small compact population from the FSC/SSC window. Memory B cells (CD24+/CD27+) were subsequently separated from naive B cells (CD24+/CD27-) and memory T cells (CD24-/CD27+). In a next step, IgM memory B cells (lgM+) were separated from switch memory B cells (IgM-) using IgM expression. In this step IgM memory B cells and switch memory B cells were sorted in separate sample tubes. 1x105 to 1x106 cells of each population were collected in DMEM/50% FBS and after completion of the sort they were each centrifuged at 400xg for 10 minutes. The sorted IgM memory B cells were then used as starting material for library construction according to the method described in Example 1, using primer HuCIgM in the first round amplification of heavy chain immunoglobulin sequences. The various libraries obtained were named MEM-05-M01, MEM-05-M02, MEM-05-M03, MEM-05-M04, MEM-05-M05, MEM-05-M06, MEM-05-M07, MEM-05-M08, MEM-05-M09 and MEM-05-M10.

Example 3

Selection of phages carrying single chain Fv fragments specifically binding to staphylococci [0113] Antibody fragments were selected using antibody phage display libraries, general phage display technology and MAbstract® technology, essentially as described in US Patent Number 6,265,150 and in WO 98/15833. The antibody phage libraries used were screened donor libraries prepared as described in Example 1, IgM memory libraries prepared as described in Example 2 and a semi-synthetic scFv phage library (JK1994) which has been described in de Kruif et al., 1995b. The methods and helper phages as described in WO 02/103012 were used in the present invention. For identifying phage antibodies recognizing staphylococci, phage selection experiments were performed using live bacteria in suspension. The clinical isolates used for selection and screening are described in Table 8. The isolates are different based on RFLP-typing.

[0114] Bacteria were grown overnight at 37°C on blood agar plates and scraped into RPMI buffer containing 1 mg/ml of Rabbit IgG and 1 % BSA at a concentration of 5x109 bacteria/ml and incubated for 60 minutes at room temperature. An aliquot of a phage library (approximately 1013 cfu, amplified using CT helper phage (see WO 02/103012)) was blocked in blocking buffer (2% ELK in PBS) for 1-2 hours at room temperature. The blocked phage library was added to the blocked bacterial suspension making a total volume of 1.5 ml and incubated for 2 hours at room temperature in an end-over-end rotor (5 rpm). The suspension was centrifuged at 6800xg for 3 minutes at room temperature and the supernatant was discarded. Bacteria were washed five times with RPMI buffer containing 1% BSA and 0.05% v/v Tween-20, then five times with RPMI buffer containing 1% BSA to remove unbound phages. Bound phages were eluted from the antigen by incubation with 1 ml of 0.1 M triethylamine for 10 minutes at room temperature in an end-over-end rotor (5 rpm). The entire content of the tube was then mixed with 0.5 ml of 1 M Tris-HCI pH 7.5 to neutralize the pH. This mixture was used to infect 5 ml of an XL1-Blue E.coli culture that had been grown at 37°C to an OD 600nm of approximately 0.3. The phages were allowed to infect the XL1-Blue bacteria for 30 minutes at 37°C. Then, the mixture was centrifuged for 10 minutes at 3200*g at room temperature and the bacterial pellet was resuspended in 0.5 ml 2-trypton yeast extract (2TY) medium. The obtained bacterial suspension was divided over two 2TY agar plates supplemented with tetracyclin, amp-icillin and glucose. After overnight incubation of the plates at 37°C, the colonies were scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et at. (1995a) and WO 02/103012. Briefly, scraped bacteria were used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and grown at a temperature of 37°C to an OD 600nm of -0.3. CT helper phages were added and allowed to infect the bacteria after which the medium was changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation was continued overnight at 30°C. The next day, the bacteria were removed from the 2TY medium by centrifugation after which the phages in the medium were precipitated using polyethylene glycol (PEG) 6000/NaCI. Finally, the phages were dissolved in 2 ml of PBS with 1% bovine serum albumin (BSA), filter-sterilized and used for the next round of selection.

[0115] Typically, two rounds of selections were performed before isolation of individual phage antibodies. Selection was carried out twice on the same strain of bacteria or different strains were used sequentially (see Table 8 for selection strains). After the second round of selection, individual E.coli colonies were used to prepare monoclonal phage antibodies. Essentially, individual colonies were grown to log-phase in 96 well plate format and infected with CT helper phages after which phage antibody production was allowed to proceed overnight. The produced phage antibodies were PEG/NaCI-precipitated and filter-sterilized and tested in ELISA and/or FACS for binding to Staphylococcus prepared as described supra.

Example 4

Validation of the staphylococci specific single-chain phage antibodies [0116] Selected single-chain phage antibodies that were obtained in the screens described above were validated in FACS for specific staphylococcal binding activity, i.e. binding to one or more staphylococcal strain prepared as described supra but lacking binding to Enterococcus as measured by a FACS-based enterococcus binding assay. Phage antibodies were blocked with FACS buffer (20 mM HEPES buffer pH 7.5, 100 mM NaCI, 1% BSA) for 20 minutes on ice. For each staining 1x109 bacterial cells, scraped from blood agar plates and washed in FACS buffer, were added to each eppendorf tube. The bacteria were blocked with FACS buffer containing 15% human serum (Biowhittaker) for 30 minutes at room temperature. The bacteria were pelleted by centrifugation at 1700xg for 3 minutes at 4°C and resuspended with the blocked phage antibodies and incubated for 1.5 hours on ice. The bacteria were then washed with FACS buffer and sequentially incubated with murine biotinylated anti-M13 antibodies (RDI) followed by strepavidin-PE. The cells were fixed in buffered 4% formaldehyde and analysed on a FACS caliber. SC05-132 and SC05-133 (both selected from RAB-03-G01 on strain Cowan in suspension) showed staining on all clinical isolates tested indicating that they recognise a pan-staphylococcal target. SC02-430 (selected from JK1994 on strain Cowan in suspension) showed specific binding to the staphylococcal strain Cowan (seeTable 9). In futher selections the single-chain phage antibodies called SC06-166, SC06-171, SC06-176, SC06-187, SC06-193, SC06-249, SC06-273, SC06-389, SC06-403, SC06-406, SC06-410, SC06-446, SC06-450, SC06-452, SC06-453, SC06-464, SC06-471, SC06-516, SC06-517, SC06-526, SC06-528, SC06-531, SC06-533, SC06-536, SC06-537, SC06-538, SC06-540, SC06-544, SC06-566, SC06-625 were obtained. These antibodies bound at least one of the clinical isolates tested (see Table 9). SC06-166, SC06-171, SC06-176 and SC06-187 were selected from immune libraries, while the other phage antibodies were selected from IgM memory B cell libraries.

[0117] To test for non-specific reactivity against non-bacterial antigens an ELISA assay was used. The complex antigens 5% FBS, 2% ELK and 1% BSA were coated overnight to Maxisorp™ ELISA plates. Selected single-chain phage antibodies were incubated for 15 minutes in an equal volume of PBS containing 1 % BSA to obtain blocked phage antibodies. The plates were emptied, and the blocked single-chain phage antibodies were added to the wells. Incubation was allowed to proceed for two hours at room temperature, the plates were washed in PBS containing 0.1% v/v Tween-20 and bound phage antibodies were detected by means of OD 492nm measurement using an anti-M13 antibody conjugated to peroxidase. As a control, the procedure was performed simultaneously without single-chain phage antibody, with a negative control single-chain phage antibody directed against West Nile virus envelope protein (SC04-374). As shown in Table 10, the selected phage antibodies called SC02-430, SC05-132 and SC05-133, did not display any detectable binding to the negative control antigens FBS, ELK and BSA.

Example 5

Characterization of the staphylococci specific scFvs [0118] From the selected specific single-chain phage antibody (scFv) clones plasmid DNA was obtained and nucleotide sequences were determined according to standard techniques. The nucleotide sequences of the scFvs (including restriction sites for cloning) called SC02-430, SC05-132, and SC05-133 are shown in SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23, respectively. The amino acid sequences of the scFvs called SC02-430, SC05-132 and SC05-133 are shown in SEQ ID NO:20, SEQ ID NO:22 and SEQ ID NO:24, respectively.

[0119] The VH and VL gene identity (see Tomlinson IM, Williams SC, Ignatovitch O, Corbett SJ, Winter G. VBASE Sequence Directory. Cambridge United Kingdom: MRC Centre for Protein Engineering (1997)) and the CDR sequences of the scFvs specifically binding staphylococci are depicted in Tables 11 and 12, respectively.

[0120] Similar to the single-chain phage antibodies disclosed above, the nucleotide and amino acid sequence, VL and VH gene identity and CDR sequences of the single-chain phage antibodies called SC06-166, SC06-171, SC06-176, SC06-187, SC06-193, SC06-249, SC06-273, SC06-389, SC06-403, SC06-406, SC06-410, SC06-446, SC06-450, SC06-452, SC06-453, SC06-464, SC06-471, SC06-516, SC06-517, SC06-526, SC06-528, SC06-531, SC06-533, SC06-536, SC06-537, SC06-538, SC06-540, SC06-544, SC06-566 and SC06-625 were determined (data not shown).

Example 6

Construction of fully human immunoglobulin molecules (human monoclonal anti-staphylococci antibodies) from the selected anti-staphylococci single chain Fvs [0121] The heavy and light chain variable region of SC02-430 was PCR-amplified using oligonucleotides to append restriction sites and/or sequences for expression in the IgG expression vectors pSyn-C03-HCy1 (SEQ ID No:43) and pSyn-C04-(^ (SEQ ID No:44). The heavy chain variable region of SC02-430 was cloned into the vector pSyn-C03-HCy1 ; the light chain variable region of SC02-430 was cloned into the vector pSyn-C04-CX. The VL lambda gene was first amplified using the following oligonucleotides set; 5L-B (SEQ ID NO:45) and sy3L-A (SEQ ID NO:46) and the PCR product was cloned into vector pSyn-C04-Cλ. The nucleotide sequence of the construct was verified according to standard techniques known to the skilled artisan. The VH gene was first amplified using the following oligonucleotide set: 5H-F (SEQ ID NO:47) and sy3H-A(SEQ ID NO:48). Thereafter, the PCR product was cloned into vector pSyn-C03-HCy1 and the nucleotide sequence was verified according to standard techniques known to the skilled person in the art.

[0122] Heavy and light chain variable regions of the scFv called SC05-132, SC05-133, SC06-166, SC06-171, SC06-176, SC06-187, SC06-193, SC06-249, SC06-273, SC06-389, SC06-403, SC06-406, SC06-410, SC06-446, SC06-450, SC06-452, SC06-453, SC06-464, SC06-471, SC06-516, SC06-517, SC06-526, SC06-528, SC06-531, SC06-533, SC06-536, SC06-537, SC06-538, SC06-540, SC06-544, SC06-566, SC06-625 were cloned directly by restriction digest for expression in the IgG expression vectors plg-C911-HCgamma1 (SEQ ID NO:49) and plg-C909-Ckappa (SEQ ID NO:50) or plg-C910-Clambda (SEQ ID NO:115). The heavy chain variable regions of the scFvs called SC05-132, SC05-133, SC06-166, SC06-171, SC06-176, SC06-187, SC06-193, SC06-249, SC06-273, SC06-389, SC06-403, SC06-406, SC06-410, SC06-446, SC06-450, SC06-452, SC06-453, SC06-464, SC06-471, SC06-516, SC06-517, SC06-526, SC06-528, SC06-531, SC06-533, SC06-536, SC06-537, SC06-538, SC06-540, SC06-544, SC06-566 and SC06-625 were cloned into the vector plg-C911-HCgamma1 by restriction digest using the enzymes Sfil and Xhol and the light chain variable regions of the scFvs called SC05-132, SC05-133, SC06-166, SC06-171, SC06-176, SC06-187, SC06-193, SC06-249, SC06-273, SC06-389, SC06-403, SC06-406, SC06-410, SC06-446, SC06-450, SC06-452, SC06-453, SC06-464, SC06-471, SC06-516, SC06-517, SC06-526, SC06-528, SC06-531, SC06-533, SC06-536, SC06-537, SC06-538, SC06-540, SC06-544, SC06-566 and SC06-625 were cloned into the vector plg-C909-Ckappa or plg-C910-Clambda by restriction digest using the enzymes Sail and Notl. Thereafter the nucleotide sequences were verified according to standard techniques known to the person skilled in the art.

[0123] The resulting expression plasmids pgG102-430C03, pgG105-132C911, pgG105-133C911, pgG106-166C911, pgG106-171C911, pgG106-176C911, pgG106-187C911, pgG106-193C911, pgG106-249C911, pgG106-273C911, pgG106-389C911, pgG106-403C911, pgG106-406C911, pgG106-410C911, pgG106-446C911, pgG106-450C911, pgG106-452C911, pgG106-453C911, pgG106-464C911, pgG106-471C911, pgG106-516C911, pgG 106-517C911, pgG106-526C911, pgG106-528C911, pgG106-531C911, pgG106-533C911, pgG106-536C911, pgG106-537C911, pgG106-538C911, pgG106-540C911, pgG106-544C911, pgG106-566C911, and pgG106-625C911 encoding the antistaphylococci human lgG1 heavy chains and pSyn-C04-V12, pgG105-132C909, pgG105-133C909, pgG106-166C910, pgG106-171C910, pgG106-176C909, pgG106-187C909, pgG106-193C910, pgG106-249C910, pgG106-273C910, pgG106-389C910, pgG106-403C910, pgG106-406C910, pgG106-410C910, pgG106-446C910, pgG106-450C910, pgG106-452C909, pgG106-453C909, pgG106-464C910, pgG106-471C910, pgG106-516C909, pgG106-517C910, pgG106-526C910, pgG106-528C910, pgG106-531C910, pgG106-533C909, pgG106-536C909, pgG106-537C910, pgG106-538C910, pgG106-540C910, pgG106-544C910, pgG106-566C910, pgG106-625C910 encoding the anti-staphylococci human Ig light chains were transiently expressed in combination in 293T cells and supernatants containing human IgG 1 antibodies were obtained. The nucleotide sequences of the heavy chains of the antibodies called CR2430, CR5132, CR5133, CR6166, CR6171, CR6176, CR6187, CR6193, CR6249, CR6273, CR6389, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6453, CR6464, CR6471, CR6516, CR6517, CR6526, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, and CR6625 are shown in SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156, SEQ ID NO:158, SEQ ID NQ:160, SEQ ID NO:162, SEQ ID NO:164, SEQ IDNO:166, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:172 and SEQ ID NO:174, respectively. The amino acid sequences of the heavy chains of the antibodies called CR2430, CR5132, CR5133, CR6166, CR6171, CR6176, CR6187, CR6193, CR6249, CR6273, CR6389, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6453, CR6464, CR6471, CR6516, CR6517, CR6526, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, and CR6625 are shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:133, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:151, SEQ ID NO:153, SEQ ID NO:155, SEQ ID NO:157, SEQ IDNO:159, SEQ ID NO:161, SEQ ID NO:163, SEQ ID NO:165, SEQ ID NO:167, SEQ ID NO:169, SEQ ID NO:171, SEQ ID NO:173 and SEQ ID NO:175, respectively. The nucleotide sequences of the light chain of antibodies CR2430, CR5132, CR5133, CR6166, CR6171, CR6176, CR6187, CR6193, CR6249, CR6273, CR6389, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6453, CR6464, CR6471, CR6516, CR6517, CR6526, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, and CR6625 are shown in SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:176, SEQ ID NO:178, SEQ ID NO:180, SEQ ID NO:182, SEQ ID NO:184, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:190, SEQ ID NO:192, SEQ ID NO:194, SEQ ID NO:196, SEQ ID NO:198, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:204, SEQ ID NO:206, SEQ ID NO:208, SEQ ID NO:210, SEQ ID NO:212, SEQ ID NO:214, SEQ ID NO:216, SEQ ID NO:218, SEQ ID NO:220, SEQ ID NO:222, SEQ ID NO:224, SEQ ID NO:226, SEQ ID NO:228, SEQ ID NO:230, SEQ ID NO:232 and SEQ ID NO:234, respectively. The amino acid sequences of the light chain of antibodies CR2430, CR5132, CR5133 CR6166, CR6171, CR6176, CR6187, CR6193, CR6249, CR6273, CR6389, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6453, CR6464, CR6471, CR6516, CR6517, CR6526, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, and CR6625 are shown in SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:177, SEQ ID NO:179, SEQ ID NO:181, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:187, SEQ ID NO:189, SEQ ID NO:191, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:219, SEQ ID NO:221, SEQ ID NO:223, SEQ ID NO:225, SEQ ID NO:227, SEQ ID NO:229, SEQ ID NO:231, SEQ ID NO:233 and SEQ ID NO:235, respectively. A person skilled in the art can determine the variable regions of the heavy and light chains of the above antibodies and single chain phage antibodies by following Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, NIH, USA (fifth edition). A person skilled in the art can determine the CDR regions of the heavy and light chains of the above antibodies and single chain phage antibodies by following Kabat et at. (1991), Chothia and Lesk (1987) ora combination of both. Alternatively, the variable and CDR regions can be determined using the VBASE database, a database well known to persons skilled in the art of antibodies. Sequences of the antibodies of the invention can be compared with immunoglobulin sequences in the VBASE database (see Tomlinson IM, Williams SC, Ignatovitch O, Corbett SJ, Winter G. VBASE Sequence Directory. Cambridge United Kingdom: MRC Centre for Protein Engineering (1997)) ht-tp://vbase.mrc-cpe.cam.ac.uk/; MRC Centre for Protein Engineering) and on the basis thereof variable regions and CDR regions can be determined. The variable regions of the some of the antibodies are given in Table 13. Human antistaphylococci IgG 1 antibodies were validated for their ability to bind to staphylococci by FACS essentially as described for scFvs (see Table 14). The negative control was an anti-West Nile virus antibody (CR4374). Alternatively, batches of greater than 1 mg of each antibody were produced and purified using standard procedures.

Example 7

In vitro opsonic phagocytic activity of staphylococcal specific IgGs as measured by FACS

[0124] The opsonic activity of anti-staphylococcal IgGs was measured in an opsonophagocytotic (OPA) assay using freshly differentiated HL-60 cells. During the OPA assay fluorescent bacteria were mixed with differentiated HL-60 cells and serially diluted IgGs. Bacteria were grown to stationary or to logarithmic (log) phase prior to labelling. To grow the bacteria to stationary phase different staphylococcal isolates were incubated overnight on sheep blood agar plates at 37°C. The bacteria were resuspended in 5 ml of bicarbonate buffer (0.1 M NaHC03, pH 8.0), harvested by centrifugation at 800xg for 10 minutes at room temperature and diluted until a concentration of 2.9x109 bacteria/ml. Bacteria that were grown until logarithmic phase were first cultured overnight in LB medium at 37°C, then the culture was diluted 10 times and grown for an additional 3 hours in LB medium at 37°C. Bacteria were harvested by centrifugation at 800xg for 10 minutes and resuspended in bicarbonate buffer washed until a concentration of 2.9x109 bacteria/ml Fifty microliters of a 5,6-carboxyfluorescein, succinimidyl ester solution ((FAM-SE; Molecular Probes, Eugene, Oregon); 10 mg/ml in dimethyl sulfoxide (Fisher Scientific Co., Fair Lawn, N.J.)) was added to 1 ml of 2.9x109 bacteria and the mixture was incubated for 1 hour at 37°C without shaking. The labeled bacteria were washed three times in 20 ml opsonophagocytosis bufFer (Hanks balanced salt solution with Ca2+ and Mg2+ and 0.2% bovine serum albumin), until no free dye in the supernatant was observed. FAM-SE-labeled bacteria were resuspended in 8 ml OPA buffer and stored in aliquots of 500 μΙ at -20°C under protection from light.

[0125] HL-60 cells (human promyelocytic leukemia cells; ECACC NO 98070106) were grown in cell densities of 1-9X105 cells/ml in RPMI 1640 medium containing 2 mM L-glutamine supplemented with 10% heat-inactivated fetal bovine serum (HyClone Laboratories, Logan, Utah) and penicillin/streptomycin. Cells between passage 6 and 35 were used for differentiation. The cells were differentiated into granulocytes by culturing in the same medium supplemented with 5x10-7 M all-trans-retinoic acid (Sigma), 6x10"12 M vitamin-D3 (Sigma) and 30 ng/ml human recombinant G-CSF (R&D). HL-60 cells were harvested by centrifugation at 160xg for 10 minutes and washed twice in 15 ml of wash buffer (Hanks balanced salt solution, without Ca2+ and Mg2+, containing 0.2% bovine serum albumin). The cells were washed once in opsonophagocytosis buffer, resuspended in 4 ml opsonophagocytosis buffer and counted in a hemocytometer. The cell concentration was adjusted to 5x106 cells/ml.

[0126] The anti-staphylococal IgGs and a control IgG (CR4374) were serially diluted in opsonophagocytosis buffer in a total volume of 20 μΙ to obtain dilutions having an IgG concentration of 2.50 μg/ml, 1.20 μg/ml, 0.60 μg/ml, 0.30 μg/ml, 0.15 μg/ml, 0.075 μg/ml, 0.0375 μg/ml and 0.019 μg/ml. Opsonic activity of dilutions was measured in the OPA assay in a round bottom plate that was blocked with 1% BSA in PBS. As a control, the assay was performed with no IgG. A 15 μΙ aliquot of a bacterial suspension containing 5.4x 106 cells was added to each well of the plate. When a bacterial suspension from S. aureus strain Cowan or S. epidermidis was used, the IgG/bacterium suspension was first incubated for 30 minutes at 37°C while the plate was horizontally shaking (1300 rpm) in a Heidolph titramax 1000. Next, 15 μΙ of the differentiated HL-60 cells (total: 75x103 cells) were added to each well of the plate and the plate was incubated while shaking at 37°C for 30-45 minutes. The final volume in the well was 50 μΙ. The reaction was stopped by adding 50 μΙ of wash buffer containing 4% v/v formaldehyde. The content in each well was resuspended and transferred to polystyrene disposable tubes for flow cytometric analysis. The samples were stored in the dark at 4°C until analyzation. The tubes were vortexed for 3 seconds before sampling in the flow cytometer. To control the differentiation of the HL-60 cells the expression of the complement receptor CD11b was measured. Fc-receptors of differentiated and non-differentiated cells were first blocked with rabbit IgG for 15 minutes on ice and the cells were subsequently labelled with CDUbAPC (BD) for 15 minutes on ice. Cells were considered properly differentiated when the mean fluorescent intensity (MFI) analyzed was at least between 10- to 100-fold higher compared to that of non-differentiated cells. Samples were assayed with a FACSCalibur immunocytometry system (Becton Dickinson and Co., Paramus, N.J.) and were analyzed with CELLQuest software (version 1.2 for Apple system 7.1 ; Becton Dickinson). 7,000 gated HL-60 granulocytes were analyzed pertube. FAM-SE was excited at a wavelength of 488 nm and the FAM-SE fluorescence signal of gated viable HL-60 cells was measured for each antibody dilution. IgGs were defined as positive in the phagocytic assay when concentration dependent phagocytosis could be observed greater or equal to two times that of the control IgG. lgGsCR2430, CR5132and CR5133 demonstrated opsonic activity against S. aureus strain Cowan in both the log (see Figure 1) and stationary growth phase (see Figure 2). The three IgGs where more effective in enhancing phagocytic activity during the log phase of growth. IgGs CR5132 and CR5133 enhanced phagocytosis of S. aureus strain SA125 compared to the negative control antibody (see Figure 3) and antibody CR5133 significantly enhanced phagocytic activity of the differentiated HL60 cells against S. epidermidis strain SE131, when compared to the negative control antibody (see Figure 4).

Example 8

Breadth of staphylococci specific lgG1 binding activity [0127] To determine the extent to which the targets of selected human anti-staphylococcal lgG1 antibodies were conserved on staphylococci and other gram positive bacteria FACS assays were carried out on a extended panel of clinical bacterial isolates essentially as described before for scFvs (see Table 15). From the assay was deducted that CR5132 and CR5133 bound to all strains tested. CR5140 did bind all strains tested with the exception of S. hominis KV111, S. warnen KV112, S. warned KV114, S. epidermidis KV115, S. haemolyticus KV117, S. warnedvd65, S. warned vd66, S. warned vd732, S. hominis vd136, S. hominis vd139, and S. hominis K136. CR6171 did bind all strains tested with the exception of S. epidermidis KV110, S. hominis KV111, S. warned KV112, S. saprophytocis KV113, S. warned KV114, S. haemolyticus KV117, S. hominis KV118, S. haemolyticus K119, S. warned vd65, S. warned vd66, S. warned vd732, S. hominis vd136, S. hominis vd139, and S. hominis K136. Finally, CR6453 did bind all strains tested with the exception of S. hominis vd136 and S. hominis K136.

[0128] In addition, using the same FACS based approach antibodies from the panel were demonstrated to bind to other gram-positive bacteria. The antibodies CR5132 and CR6453 were shown to bind Listeria monocytogenes, Bacillus cereus and Streptococcus group A and CR5132 also bound to Propionibacterium spp. The antibodies CR5133, CR5140 and CR6171 were shown to bind Streptococcus group A and CR5140 was also shown to bind Enterococcus faecalis (data not shown).

Example 9

In vitro opsonic phagocytic activity of staphylococcal specific IgGs measured by opsonophagocytic killing assay (OPKA) [0129] To better determine the functional activity of the antibody panel an opsonophagocytic assay was conducted to quantify the killing activity of anti-staphylococcal human lgG1 against the Staphylococcus aureus strains 502, Mn8 and Newman and Staphylococcus epidermidis strain M187. Freshly drawn human blood (10 to 30 ml) was mixed with an equal volume of dextran-heparin buffer (4.5 g of dextran, Sigma Chemical, St. Louis; 28.4 mg of heparin sodium in 500 ml of distilled water), and the mixture was incubated at 37°C for 1 hour. The upper layer containing the leukocytes was collected by centrifugation, and hypotonic lysis of the remaining erythrocytes was accomplished by suspension of the cell pellet in 1% (w/v) NF4CI. The leukocyte population was subsequently washed in RPMI with 15% (v/v) fetal bovine serum. Trypan blue staining and counting in a hemocytometerwere used to determine the concentration of live leukocytes, and the final leukocyte concentration was adjusted to2x107cells/ml. The phagocytosis assay was performed in duplicate with or without 100 μΙ of leukocyte suspension added to 100 μΙ of bacteria (concentration adjusted spectrophotometrically to 2x107 per ml and confirmed by viable counts), 100 μΙ of anti-staphylococcal human lgG1 diluted in RPMI, and 100 μΙ of baby rabbit complement. The reaction mixture was incubated on a rotor rack at 37°C for 90 minutes; samples were taken at time 0 and after 90 minutes, diluted in 1% Proteose Peptone (Difco Laboratories, Detroit, Mich.), and plated onto tryptic soy agar plates. The killing activity (%) of the antibodies was calculated as the mean number of CFU surviving in the sample containing leukocytes subtracted from the mean number of CFU surviving in the sample without leukocytes, divided by the latter and amplified by 100. The killing activity of the anti-staphylococcal human IgG 1 was tested at two concentrations 1250 and 12.5 ng/ml (see Table 16).

[0130] The results show that antibodies CR5132, CR5133, CR6446, CR6453, and CR6566 have more than 20% killing activity against S. epidermidis strain M187, even at a low concentration of 12.5 ng/ml.

Example 10 lgG1 competition assay [0131] To establish wether antibodies in the panel competed for binding to the same target a competition ELISA was developed. The S. epidermidis strain SE132 was streaked onto a blood agar plate and incubated overnight at 37°C. Colonies were scraped from the plate using 5 ml of 50 mM carbonate buffer (8 volumes of 0.2 M Na2C03,17 volumes of 0.2 M NaFIC03 and 75 volumes of distilled water) and centrifuged for 3 minutes at 4000 rpm. The obtained pellet was resuspended in 500 μΙ of carbonate buffer, centrifuged again and the pellet was resuspended in 500 μΙ carbonate buffer. Cell density was determined by measuring OD600 of a dilution series of the bacteria. The S. epidermidis strain was diluted to a density of 5x109 cells/ml and 100 μΙ (5x108 cells) per well was coated overnight at 4°C on Nunc-lmmuno Maxisorp F96 plates. After incubation, the wells were washed three times with PBS and blocked for one hour at room temperature with 300 μΙ 2% (v/v) ELK in PBS per well. In separate tubes 25 μΙ of each scFv-phage maxiprep (produced as above) diluted to subsaturating levels (as determined by ELISA above) was mixed with 25 μΙ blocking buffer (4% (v/v) ELK/PBS) and 50 μΙ of lgG1 supernatant diluted to 10 μg/ml in PBS and incubated for 20 minutes on ice. After removing the blocking solution, 100 μΙ of the blocked phages and IgG 1 mixture was added to each well and incubated for one hour at room temperature. The wells were washed three times with PBS/0.01 %(v/v) Tween and once with PBS. After washing, 100 μΙ of anti-M13 FIRP (1:5000 in 2% (v/v) ELK in PBS) was added per well and incubated for 60 minutes at room temperature. The wells were washed again and staining was visualized by adding 100 μΙ OPD-solution to each well. Reaction was stopped after 5-10 minutes by adding 50 μΙ 1 M Fi2S04 to each well and OD measured at 492nm. The experiment was repeated twice with the entire panel of antibodies and a control IgG 1 CR4374. The results showed that the antibodies fell into five distinct groups. Group A consisted of CR5132, CR5133, CR6187 and CR6453; Group B consisted of CR5140 and CR6171; Group C consisted of CR6176; Group D consisted of CR6526; and Group E consisted of the rest of the panel CR6166, CR6193, CR6249, CR6273, CR6403, CR6406, CR6410, CR6446, CR6450, CR6452, CR6464, CR6471, CR6516, CR6517, CR6528, CR6531, CR6533, CR6536, CR6537, CR6538, CR6540, CR6544, CR6566, CR6625. The binding activity and functional activity of the antibodies was consistent with the grouping.

Example 11

Target identification of IgG 1 in group A

[0132] To determine the binding target of the panel antibodies, representatives of each of the groups determined above (within each group the most potent antibody based on opsonic activity was chosen) was incubated with LTA extracted from S. aureus in a solid phase ELISA (see Table 17). A solution of 1 μg/ml lipoteichoic acid (Sigma) in PBS was coated on wells overnight at room temperature. Plates were washed once with PBS and blocked with 400 μΙ 2% (v/v) ELK in PBS. A serial dilution of each anti-staphylococcal IgG 1 supernatant and negative control supernatant CR4374 and positive control anti-LTA murine mAb 12248 (Abeam) was incubated per well for one hour at room temperature. Wells were washed five times with PBS and 100 μΙ of anti-human HRP (1/2000) or antimouse HRP (1/2000) diluted in PBSE was added and incubated for one hour at room temperature. Wells were visualized and read as above. The results clearly demonstrate that CR5133 from group A binds strongly to LTA. The positive control murine monoclonal 12248 showed similar results. In contrast, none of the antibodies from the other groups nor the negative control antibody showed significant reactivity with LTA. Antibodies CR5132 and CR6453 from Group A were consistently shown to bind LTA, CR6187 however did not show binding reactivity to LTA (data not shown). This maybe due to a lower affinity of CR6187 compared to the other antibodies in the group.

Example 12

In vitro opsonic phagocytic activity of staphylococcal specific IgGs against Staphylococcus epidermidis and Staphylococcus aureus grown under different culture conditions and measured by opsonophagocytic killing assay (OPKA) [0133] To determine if the bacterial killing activity of the most potent and non-competitive opsonophagocytic anti-staphylococcal IgG 1 antibodies identified above is affected by different bacterial growth conditions, the opsonophagocytic assay described above was conducted against the Staphylococcus aureus strain Newman and Staphylococcus epidermidis strain RP62A grown in different media and under different conditions. LBA is immune serum taken from an infected patient and served as a positive control. The killing activity of the anti-staphylococcal human IgG 1 was tested at five concentrations 10,000, 300, 10, 0.3, 0.01 ng/ml or-5, -6.5, -8, -9.5, -11 log [g/ml] against both staphylococcal strains either grown to mid logarithmic phase (Fig. 5A, B) or to static phase (Fig. 5G, H) or in medium consisting of 1% glucose (Fig. 5C, D) or 100% human plasma (Fig. 5E, F).

[0134] The results show that the antibodies CR5133, CR6166, CR6171, CR6176 and CR6526 have robust opsonophagocytic activity against the two staphylococcal strains under all the growth conditions tested. Importantly, they were significantly different from the negative control antibody CR3009, which showed little or no activity. This suggests that the targets of the antibody panel are stably expressed under a variety of bacterial growth conditions, a factor potentially important for therapeutic application where the target bacteria may be present in nutrient poor conditions.

Example 13

In vivo protective activity of staphylococcal specific IgGs in a lethal Staphylococcus aureus challenge model [0135] A bacterial titration experiment in mice is carried out to determine the optimal inoculation dose to produce 80%-100% lethality. Animals are inoculated i.p. with S. aureus strains Mn8 at doses of 5x109 and 5x108. Animals are observed for 5 days and survival is used as an endpoint. The dose that results in 0% survival after 5 days is chosen as the challenge dose for further experiments.

[0136] Using the dose determined above for the bacterial inoculum, a set of challenge experiments is conducted to assess the protective activity of the panel of Staphylococcal binding mAb (CR5133, CR6166, CR6171, CR6176 and CR6526) that have demonstrated in vitro opsonic phagocytic activity. For each experiment, purified mAb’s (one isotype control lgG1 and 5 test lgG1) are injected i.p. (0.5-1 ml in PBS), at a dose of 15 mg/kg. 5 mAb are tested against S. aureus Mn8.

[0137] After 24 hours animals are inoculated i.p. with the S. aureus strain at the inoculation dose determined above. Immediately prior to inoculation, a small amount of blood (-50-100 ml) is collected (using the tail cut method) to measure circulating antibody levels. The blood is kept at room temperature between 30 min and 2 hours, to allow the blood to clot, then centrifuged at 4°C for 5 min. The serum is removed and stored at -20°C. A human lgG1 ELISA is performed on all blood samples prior to inoculation and after sacrifice. Animals with no measurable antibody in their blood prior to inoculation are excluded from further analysis.

[0138] Mice are observed daily for five days and sacrificed when showing signs of severe distress. Survival is scored in each group at the end of five days. To validate each experiment there must be less than 20% survival in the negative control lgG1 group. Further experiments are carried out in the model described above where the antibodies are titrated at half-log doses from 10 mg/kg to determine their protective potency in vivo.

Table 3: Human kappa chain variable region primers extended with Sail restriction sites (sense), human kappa chain J-region primers extended with Notl restriction sites (anti-sense), human lambda chain variable region primers extended with Sail restriction sites (sense) and human lambda chain J-region primers extended with Notl restriction sites (anti-sense).

Table 4: Percentage of the different light chain products in the final mixture, based on concentrations determined by agarose gel analysis.

Table 6: Human IgG heavy chain variable region primers extended with Sfil/Ncol restriction sites (sense) and human IgG heavy chain J-region primers extended with Xhol/BstEII restriction sites (anti-sense).

REFERENCES

[0139]

Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA and Logtenberg T (2000), Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J. Immunol. Methods 239:153-166.

Burton DR and Barbas CF (1994), Human antibodies from combinatorial libraries. Adv. Immunol. 57:191-280. Cantinieaux B, Hariga C, Courtoy P, Hupin J and Fondu P (1989) Staphylococcus aureus phagocytosis. A new cytofluorometric method using FITC and paraformaldehyde. J Immunol. Methods 121:203-208.

Chothia and Lesk (1987), Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196:901-917.

Chou, TC and P Talalay (1984), Quantitative analysis of dose-efFect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regül. 22:27-55.

De Kruif J, Terstappen L, Boel E and Logtenberg T (1995a), Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sei. USA 92:3938.

De Kruif J, Boel E and Logtenberg T (1995b), Selection and application of human single-chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248:97-105.

Huis G, Heijnen IJ, Cuomo E, van der Linden J, Boel E, van de Winkel J and Logtenberg T (1999), Antitumor immune effector mechanisms recruited by phage display-derived fully human lgG1 and lgA1 monoclonal antibodies. Cancer Res. 59:5778-5784.

Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JP, Meloen RH (1996), Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol. Divers. 1:87-96.

SEQUENCE LISTING

[0140] <110> Crucell Holland B.V.

Throsby, Mark

Geuijen, Cecilia Anna Wilhelmina De Kruif, Cornells Adriaan <120> Human binding molecules having killing activity against staphylococci and uses thereof <130> 0143 EP 01 DIV <160> 235 <170> Patentln version 3.3 <210> 1 <211>7

<212> PRT <213> Homo sapiens <400> 1

Ser Gly Gly Tyr Tyr Trp Ser 1 5 <210>2 <211> 16 <212> PRT <213> Homo sapiens <400>2

Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Ser Ser Leu Lys Ser 15 10 15 <210>3 <211> 8 <212> PRT <213> Homo sapiens <400>3

Thr Val Met Asn Ser Phe Phe Asp 1 5 <210>4 <211> 14 <212> PRT <213> Homo sapiens <400>4

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser 15 10 <210> 5 <211>7 <212> PRT <213> Homo sapiens <400> 5

Glu Val Ser Lys Arg Pro Ser 1 5 <210> 6 <211>9 <212> PRT <213> Homo sapiens <400>6

Cys Ser Tyr Alá Gly Ser Ser Trp Val 1 5 <210>7 <211>5 <212> PRT <213> Homo sapiens <400>7

Asn Tyr Trp Met Thr 1 5 <210>8 <211> 17 <212> PRT <213> Homo sapiens <400>8

Asn Ile Asn Arg Asp Gly Ser Asp Lys Tyr His Val Asp Ser Val Glu 1 5 10 15

Gly <210>9 <211 > 11 <212> PRT <213> Homo sapiens <400>9

Gly Gly Arg Thr Thr Ser Trp Tyr Trp Arg Asn 15 10 <210> 10 <211> 11 <212> PRT <213> Homo sapiens <400> 10

Arg Ala Ser Gin Ser Ile Ser Ser Trp Leu Ala 15 10 <210> 11 <211>7

<212> PRT <213> Homo sapiens <400> 11

Lys Alá Ser Ser Leu Glu Ser 1 5 <210 12 <211>9 <212> P RT <213> Homo sapiens <400 12

Gin Gin Tyr Asn Ser Tyr Pro Leu Thr 1 5 <210> 13 <211>5 <212> PRT <213> Homo sapiens <400> 13

Asp Tyr Tyr Met Thr 1 5 <210> 14 <211> 17 <212> PRT <213> Homo sapiens <400> 14

His Ile Ser Gly Ser Gly Ser Thr lie Tyr Tyr Ala Asp Ser Val Arg 15 10 15

Gly <210> 15 <211> 11 <212> PRT <213> Homo sapiens <400> 15

Gly Gly Arg Ala Thr Ser Tyr Tyr Trp Val His 15 10 <210> 16 <211 > 11 <212> PRT <213> Homo sapiens <400> 16

Arg Ala Ser Gin Ser Val Ser Gly Tyr Leu Gly 15 10 <210> 17 <211>7

<212> PRT <213> Homo sapiens <400> 17

Gly Ala Ser Ser Arg Ala Ihr 1 5 <210> 18 <211>9

<212> PRT <213> Homo sapiens <400> 18

Gin Gin Tyr Gly Ser Ser Pro Leu Thr 1 5

<210> 19 <211 >726 <212> DNA <213> Artificial sequence <220 <223> SC02-430 <400> 19 taggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60 acctgcactg tctctggtgg ctccatcagc agtggtggtt actactggag ctggatccgg 120 cagcccccag ggaagggact ggagtggatt gggtacatct attacagtgg gagcacctac 180 tacaactcgt ccctcaagag tcgagttacc atatcagtag acacgtctaa gaaccagttc 240 tccctgaagc tgagctctgt gactgccgcg gacacggccg tgtattactg tgcaaagacg 300 gttatgaatt cgttctttga ctggggccaa ggtaccctgg tcaccgtctc gagtggtgga 360 ggcggttcag gcggaggtgg ctctggcggt ggcggatcgg aaattgagct cacgcagccg 420 ccctccgtgt ctgggtctcc tggacagtcg atcaccatct cctgcactgg aaccagcagt 480 gatgttggga gttataacct tgtctcctgg taccaacagc acccaggcaa agcccccaaa 540 ctcatgattt atgaggtcag taagcggccc tcaggggttt ctaatcgctt ctctggctcc 600 aagtctggca acacggcctc cctgacaatc tctgggctcc aggctgagga cgaggctgat 660 tattactgct gctcatatgc aggtagtagc tgggtgttcg gcggagggac caagctgacc 720 gtccta 726

<210> 20 <211 >242 <212> PRT <213> Artificial sequence <220> <223> SC02-430 <400> 20

Gin Val Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin 15 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30

Gly Tyr Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45

Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Ser Ser 50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95

Cys Ala Lys Thr Val Met Asn Ser Phe Phe Asp Trp Gly Gin Gly Thr 100 105 110

Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser H5 120 125

Gly Gly Gly Gly Ser Glu Ile Glu Leu Thr Gin Pro Pro Ser Val Ser 130 135 140

Gly Ser Pro Gly Gin Ser Ile Ihr Ile Ser Cys Thr Gly Ihr Ser Ser 145 150 155 160

Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gin Gin His Pro Gly 165 170 175

Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly 180 185 190

Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu 195 200 205

Thr Ile Ser Gly Leu Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys 210 215 220

Ser Tyr Ala Gly Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr 225 230 235 240

Val Leu

<210> 21 <211> 726 <212> DNA <213> Artificial sequence <220> <223> SC05-132 <400> 21 gaggtgctgg agtctggggg aggcttggtc cagccggggg ggtccctgag actgtcctgt 60 tcagactctg gattctcctt taataactat tggatgacct gggtccgcca ggctccgggg 120 aaggggctgg agtgggtggc caacataaat cgagatggaa gtgacaagta ccatgtagac 180 tctgtggagg gccgattcac catctccaga gacaactcca agaactcact atacctgcaa 240 atgaacaacc tgagagccga cgacgcggcg gtatattttt gtgcgagagg cggccggact 300 actagctggt attggagaaa ctggggccag ggaaccctgg tcaccgtctc gagcggtacg 360 ggcggttcag gcggaaccgg cagcggcact ggcgggtcga cggacatcca gatgacccag 420 tctccttcca ccctgtctgc atctgtagga gacagagtca ccatcacttg ccgggccagt 480 cagagtatta gtagctggtt ggcctggtat cagcagaaac cagggaaagc ccctaagctc 540 ctgatctata aggcgtctag tttagaaagt ggggtcccat caaggttcag cggcagtgga 600 tctgggacag aattcactct caccatcagc agcctgcagc ctgatgattt tgcaacttat 660 tactgccaac agtataatag ttaccccctc actttcggcg gagggaccaa gctggagatc 720 aaacgt 726

<210> 22 <211> 242 <212> PRT <213> Artificial sequence <220> <223> SC05-132 <400> 22

Glu Val Leu Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu 15 10 15

Arg Leu Ser Cys Ser Asp Ser Gly Phe Ser Phe Asn Asn Tyr Trp Met 20 25 30

Thr Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn 35 40 45

Ile Asn Arg Asp Gly Ser Asp Lys Tyr His Val Asp Ser Val Glu Gly 50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gin 65 70 75 80

Met Asn Asn Leu Arg Ala Asp Asp Ala Ala Val Tyr Phe Cys Ala Arg 85 90 95

Gly Gly Arg Thr Thr Ser Trp Tyr Trp Arg Asn Trp Gly Gin Gly Thr 100 105 110

Leu Val Thr Val Ser Ser Gly Thr Gly Gly Ser Gly Gly Thr Gly Ser 115 120 125

Gly Thr Gly Gly Ser Thr Asp lie Gin Met Thr Gin Ser Pro Ser Thr 130 135 140

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser 145 150 155 160

Gin Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys 165 170 175

Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val 180 185 190

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ihr Glu Phe Ihr Leu Ihr 195 200 205

Ile Ser Ser Leu Gin Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 210 215 220

Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240

Lys Arg

<210> 23 <211> 732 <212> DNA <213> Artificial sequence <220> <223> SC05-133 <400> 23 gaggtgcagc tggtggagac tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 tcctgctcag cctctagatt cagcttcagg gactactaca tgacgtggat ccgccaggct 120 ccagggaagg ggccggaatg ggtttcacac ataagtggca gtggcagtac gatttactac 180 gcagactctg tgaggggccg attcaccatc tccagggaca acgccaagag ctccttgtat 240 ctgcaaatgg atagcctaca ggccgacgac acggccgtat attactgtgc gagagggggt 300 cgcgccacca gttactactg ggtccactgg ggcccgggaa ccctggtcac cgtctcgagc 360 ggtacgggcg gttcaggcgg aaccggcagc ggcactggcg ggtcgacgga aattgtgttg 420 acgcagtctc cagccaccct gtctttgtct ccaggggaaa gagccaccct ctcctgcagg 480 gccagtcaga gtgttagcgg ctacttaggc tggtaccaac agaaacctgg ccaggctccc 540 aggctcctca tctatggtgc atccagcagg gccactggca tcccagacag gttcagtggc 600 agtgggtctg ggacagactt cactctcacc atcagccggc tggagcctga agattttgca 660 gtgtattact gtcagcagta tggtagctca ccgctcactt tcggcggagg gaccaagctg 720 gagatcaaac gt 732

<210> 24 <211 >244 <212> PRT <213> Artificial sequence <220 <223> SC05-133 <400 24

Glu Val Gin Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15

Ser Leu Arg Leu Ser Cys Ser Ala Ser Arg Phe Ser Phe Arg Asp Tyr 20 25 30

Tyr Met Thr Trp Ile Arg Gin Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45

Ser His Ile Ser Gly Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val 50 55 60

Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 65 70 75 80

Leu Gin Met Asp Ser Leu Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Gly Arg Ala Thr Ser Tyr Tyr Trp Val His Trp Gly Pro 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Thr Gly Gly Ser Gly Gly Thr 115 120 125

Gly Ser Gly Thr Gly Gly Ser Thr Glu Ile Val Leu Thr Gin Ser Pro 130 135 140

Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg 145 150 155 160

Ala Ser Gin Ser Val Ser Gly Tyr Leu Gly Trp Tyr Gin Gin Lys Pro 165 170 175

Gly Gin Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr 180 185 190

Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 195 200 205

Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 210 215 220

Gin Gin Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu 225 230 235 240

Glu Ile Lys Arg <210> 25 <211 > 1344 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1344) <400> 25 cag gtg cag ctg cag gag tcc ggc cca gga ctg gtg aag cct tea cag 48

Gin Val Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin 15 10 15 acc ctg tcc etc acc tgc act gtc tet ggt ggc tec ate age agt ggt 96

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 ggt tac tac tgg agc tgg atc egg cag ccc cca ggg aag gga ctg gag 144

Gly Tyr Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45 tgg att ggg tac atc tat tac agt ggg agc acc tac tac aac teg tcc 192

Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Ser Ser 50 55 60 ctc aag agt cga gtt acc ata tea gta gac acg tet aag aac cag ttc 240

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80 tcc ctg aag ctg age tet gtg act gcc geg gac acg gcc gtg tat tac 288

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 tgt gca aag acg gtt atg aat teg ttc ttt gac tgg ggc cag ggc acc 336

Cys Ala Lys Thr Val Met Asn Ser Phe Phe Asp Trp Gly Gin Gly Thr 100 105 110 ctg gtg acc gtc tcc age get age acc aag ggc ccc age gtg ttc ccc 384

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 ctg gcc ccc age age aag age acc age ggc ggc aca gcc gcc ctg ggc 432

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg agc tgg aac 480

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 agc ggc gcc ttg acc agc ggc gtg cac acc ttc ccc gcc gtg ctg cag 528

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175 age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age 576

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age 624

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc 672

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 cac acc tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc gga ccc tcc 720

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg 768

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc 816

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gee 864

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 aag acc aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg 912

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac 960

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 aag tgc aag gtg age aac aag gee ctg cet gee ccc ate gag aag acc 1008

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 325 330 335 ate age aag gee aag ggc cag ccc egg gag ccc cag gtg tac acc ctg 1056

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350 ccc ccc age egg gag gag atg acc aag aac cag gtg tcc etc acc tgt 1104

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365 ctg gtg aag ggc ttc tac ccc age gac ate gee gtg gag tgg gag age 1152

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 aac ggc cag ccc gag aac aac tac aag acc acc ccc cet gtg ctg gac 1200

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 age gac ggc age ttc ttc ctg tac age aag etc acc gtg gac aag age 1248

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac gag gee 1296

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 ctg cac aac cac tac acc cag aag age ctg age ctg age ccc ggc aag 1344

Leu His Asn His Tyr Ihr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 26 <211> 448 <212> PRT <213> Homo sapiens <400> 26

Gin Val Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin 15 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30

Gly Tyr Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45

Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Ser Ser 50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95

Cys Ala Lys Thr Val Met Asn Ser Phe Phe Asp Trp Gly Gin Gly Thr 100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Ihr Pro Pro Val Leu Asp 385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 27 <211> 1344 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1344) <400> 27 gag gtg ctg gag tct ggg gga ggc ttg gtc cag ccg ggg ggg tcc ctg 48

Glu Val Leu Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu 15 10 15 aga ctg tcc tgt tea gac tct gga ttc tcc ttt aat aac tat tgg atg 96

Arg Leu Ser Cys Ser Asp Ser Gly Phe Ser Phe Asn Asn Tyr Trp Met 20 25 30 acc tgg gtc ege cag get ccg ggg aag ggg ctg gag tgg gtg gcc aac 144

Thr Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn 35 40 45 ata aat ega gat gga agt gac aag tac cat gta gac tct gtg gag ggc 192

Ile Asn Arg Asp Gly Ser Asp Lys Tyr His Val Asp Ser Val Glu Gly 50 55 60 cga ttc acc atc tcc aga gac aac tcc aag aac tea cta tac ctg caa 240

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gin 65 70 75 80 atg aac aac ctg aga gcc gac gac gcg gcg gta tat ttt tgt gcg aga 288

Met Asn Asn Leu Arg Ala Asp Asp Ala Ala Val Tyr Phe Cys Ala Arg 85 90 95 ggc ggc egg act act age tgg tat tgg aga aac tgg ggc cag gga acc 336

Gly Gly Arg Thr Thr Ser Trp Tyr Trp Arg Asn Trp Gly Gin Gly Thr 100 105 110 ctg gtc acc gtc teg agt get age acc aag ggc ccc age gtg ttc ccc 384

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 ctg gcc ccc age age aag age acc age ggc ggc aca gcc gcc ctg ggc 432

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg agc tgg aac 480

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 age ggc gee ttg ace age ggc gtg cac acc ttc ccc gee gtg ctg cag 528

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175 age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age 576

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age 624

Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser 195 200 205 aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc 672

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga ccc tee 720

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg 768

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc 816

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gee 864

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 aag acc aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg 912

Lys Ihr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac S60

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 aag tgc aag gtg age aac aag gee ctg cct gee ccc ate gag aag acc 1008

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 325 330 335 ate age aag gee aag ggc cag ccc egg gag ccc cag gtg tac acc ctg 1056

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350 ccc ccc age egg gag gag atg acc aag aac cag gtg tcc etc acc tgt 1104

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365 ctg gtg aag ggc ttc tac ccc age gac ate gee gtg gag tgg gag age 1152

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 aac ggc cag ccc gag aac aac tac aag acc acc ccc cet gtg ctg gac 1200

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 age gac ggc age ttc ttc ctg tac age aag etc ace gtg gac aag age 1248

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac gag gee 1296

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 ctg cac aac cac tac acc cag aag age ctg age ctg age ccc ggc aag 1344

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 28 <211> 448 <212> PRT <213> Homo sapiens <400> 28

Glu Val Leu Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu 15 10 15

Arg Leu Ser Cys Ser Asp Ser Gly Phe Ser Phe Asn Asn Tyr Trp Met 20 25 30

Thr Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn 35 40 45

Ile Asn Arg Asp Gly Ser Asp Lys Tyr His Val Asp Ser Val Glu Gly 50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gin 65 70 75 80

Met Asn Asn Leu Arg Ala Asp Asp Ala Ala Val Tyr Phe Cys Ala Arg 85 90 95

Gly Gly Arg Thr Thr Ser Trp Tyr Trp Arg Asn Trp Gly Gin Gly Thr 100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Aon Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 29 <211 > 1350 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1350) <400> 29 gag gtg cag ctg gtg gag act ggg gga ggc ttg gtc aag cct gga ggg 48

Glu Val Gin Leu Val Glu Ihr Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 tcc ctg aga etc tcc tgc tea gee tet aga ttc age ttc agg gac tac 96

Ser Leu Arg Leu Ser Cys Ser Ala Ser Arg Phe Ser Phe Arg Asp Tyr 20 25 30 tac atg aeg tgg ate ege cag get cca ggg aag ggg ccg gaa tgg gtt 144

Tyr Met Thr Trp Ile Arg Gin Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45 tea cac ata agt ggc agt ggc agt aeg att tac tac gca gac tet gtg 192

Ser His lie Ser Gly Ser Gly Ser Thr lie Tyr Tyr Ala Asp Ser Val 50 55 60 agg ggc ega ttc ace ate tcc agg gac aac gee aag age tcc ttg tat 240

Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 65 70 75 80 ctg caa atg gat age eta cag gee gac gac aeg gee gta tat tac tgt 288

Leu Gin Met Asp Ser Leu Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 geg aga ggg ggt ege gee ace agt tac tac tgg gtc cac tgg ggc ccg 336

Ala Arg Gly Gly Arg Ala Thr Ser Tyr Tyr Trp Val His Trp Gly Pro 100 105 110 gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age gtg 384

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee gee 432

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Alá 130 135 140 ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age 480

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 tgg aac age ggc gee ttg ace age ggc gtg cac acc ttc ccc gee gtg 528

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc 576

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 age age age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag 624

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac 672

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 aag acc cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga 720

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg atc 768

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag 816

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac 864

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac egg 912

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300 gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag 960

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320 gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc atc gag 1008

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag gtg tac 1056

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350 acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tcc etc 1104

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365 acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg gag tgg 1152

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg 1200

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg gac 1248

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac 1296

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 gag gee ctg cac aac cac tac acc cag aag age ctg age ctg age ccc 1344

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445 ggc aag 1350

Gly Lys 450 <210> 30 <211 >450

<212> PRT <213> Homo sapiens <400> 30

Glu Val Gin Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15

Ser Leu Arg Leu Ser Cys Ser Ala Ser Arg Phe Ser Phe Arg Asp Tyr 20 25 30

Tyr Met Thr Trp Ile Arg Gin Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45

Ser His Ile Ser Gly Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val 50 55 60

Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 65 70 75 80

Leu Gin Met Asp Ser Leu Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Gly Arg Ala Thr Ser Tyr Tyr Trp Val His Trp Gly Pro 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly' Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445

Gly Lys 450 <210> 31 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 31 cag tcc gcc ctg acc cag ccc cgc tea gtg tet ggg tet cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 teg ate acc atc tcc tgc act gga acc age agt gat gtt ggg agt tat 96

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr 20 25 30 aac ett gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa ctc 144

Asn Leu Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc agt aag egg ccc tea ggg gtt tet aat ege ttc 192

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tet ggc tcc aag tet ggc aac acg gcc tcc ctg aca ate tet ggg ctc 240

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc tgc tea tat gca ggt agt 288

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Alá Gly Ser 85 90 95 age tgg gtg ttc gga act ggc acc aag gtg acc gtg ctg aag ett acc 336

Ser Trp Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Lys Leu Thr 100 105 110 gtg ctg ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc 384

Val Leu Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc ctc atc 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac agc 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Alá Asp Ser 145 150 155 160 agc ccc gtg aag gcc ggc gtg gag acc acc acc ccc agc aag cag agc 528

Ser Pro Val Lys Alá Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc agc agc tac ctg agc ctc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Alá Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag agc cac egg agc tac agc tgc cag gtg acc cac gag ggc agc 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc agc 660

Thr Val Glu Lys Thr Val Alá Pro Thr Glu Cys Ser 210 215 220 <210> 32 <211 >220

<212> PRT <213> Homo sapiens <400> 32

Gin Ser Ala Leu Thr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr 20 25 30

Asn Leu Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Alá Gly Ser 85 90 95

Ser Trp Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Lys Leu Thr 100 105 110

Val Leu Gly Gin Pro Lys Ala Ala Pro Ser Val Ihr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 33 <211> 645 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(645) <400> 33 teg aeg gac ate cag atg ace cag tet cet tee ace ctg tet gca tet 48

Ser Thr Asp lie Gin Met Ihr Gin Ser Pro Ser Thr Leu Ser Ala Ser 15 10 15 gta gga gac aga gtc ace ate act tgc egg gee agt cag agt att agt 96

Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Ser 20 25 30 age tgg ttg gee tgg tat cag cag aaa cca ggg aaa gee cet aag etc 144

Ser Trp Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu 35 40 45 ctg ate tat aag geg tet agt tta gaa agt ggg gtc cca tea agg ttc 192

Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe 50 55 60 age ggc agt gga tet ggg aca gaa ttc act etc ace ate age age ctg 240

Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu 65 70 75 80 cag cet gat gat ttt gca act tat tac tgc caa cag tat aat agt tac 288

Gin Pro Asp Asp Phe Alá Thr Tyr Tyr Cys Gin Gin Tyr Asn Ser Tyr 85 90 95 ccc etc act ttc ggc gga ggg acc aag ctg gag ate aaa cgt geg gcc 336

Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala 100 105 110 gca ccc age gtg ttc ate ttc ccc ccc tee gac gag cag ctg aag age 384

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser 115 120 125 ggc acc gcc age gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag 432

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 gcc aag gtg cag tgg aag gtg gac aac gcc ctg cag age ggc aac age 480

Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 145 150 155 160 cag gag age gtg acc gag cag gac age aag gac tee acc tac age ctg 528

Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 age age acc etc acc ctg age aag gee gac tac gag aag cac aag gtg 576

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 tac gcc tgc gag gtg acc cac cag ggc ctg age age ccc gtg acc aag 624

Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 age ttc aac egg ggc gag tgt 645

Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 34 <211 > 215 <212> PRT <213> Homo sapiens <400 34

Ser Thr Asp lie Gin Met Thr Gin Ser Pro Ser Thr Leu Ser Ala Ser 15 10 15

Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Ser 20 25 30

Ser Trp Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu 35 40 45

Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe 50 55 60

Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu 65 70 75 80

Gin Pro Asp Asp Phe Alá Thr Tyr Tyr Cys Gin Gin Tyr Asn Ser Tyr 85 90 95

Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala 100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser 115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140

Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 145 150 155 160

Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190

Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys 195 200 205

Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 35 <211> 645

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(645) <400> 35 teg aeg gaa att gtg ttg aeg cag tet cca gee ace ctg tet ttg tet 48

Ser Thr Glu Ile Val Leu Thr Gin Ser Pro Ala Thr Leu Ser Leu Ser 15 10 15 cca ggg gaa aga gee acc etc tee tgc agg gee agt cag agt gtt age 96

Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser 20 25 30 ggc tac tta ggc tgg tac caa cag aaa cct ggc cag get ccc agg etc 144

Gly Tyr Leu Gly Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu 35 40 45 etc ate tat ggt gca tee age agg gee act ggc ate cca gac agg ttc 192

Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly lie Pro Asp Arg Phe 50 55 60 agt ggc agt ggg tet ggg aca gac ttc act etc acc ate age egg ctg 240

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu 65 70 75 80 gag cct gaa gat ttt gca gtg tat tac tgt cag cag tat ggt age tea 288

Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ser Ser 85 90 95 ccg etc act ttc ggc gga ggg acc aag ctg gag ate aaa cgt geg gee 336

Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala 100 105 110 gca ccc age gtg ttc ate ttc ccc ccc tee gac gag cag ctg aag age 384

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser 115 120 125 ggc acc gee age gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag 432

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 gee aag gtg cag tgg aag gtg gac aac gcc ctg cag age ggc aac age 480

Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 145 150 155 160 cag gag age gtg acc gag cag gac age aag gac tee acc tac age ctg 528

Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 age age acc etc acc ctg age aag gcc gac tac gag aag cac aag gtg 576

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 tac gcc tgc gag gtg acc cac cag ggc ctg age age ccc gtg acc aag 624

Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 age ttc aac cgg ggc gag tgt 645

Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 36 <211> 215 <212> PRT <213> Homo sapiens <400 36

Ser Thr Glu Ile Val Leu Thr Gin Ser Pro Ala Thr Leu Ser Leu Ser 15 10 15

Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser 20 25 30

Gly Tyr Leu Gly Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu 35 40 45

Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe 50 55 60

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu 65 70 75 80

Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ser Ser 85 90 95

Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala 100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser 115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140

Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 145 150 155 160

Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190

Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys 195 200 205

Ser Phe Asn Arg Gly Glu Cys 210 215

<210> 37 <211 >24 <212> DNA <213> Artificial sequence <220>

<223> Anti-sense primer HuCK-FOR <400 37 acactctccc ctgttgaagc tett 24

<210> 38 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Anti-sense primer HuCL2-FOR <400> 38 tgaacattct gtaggggcca ctg 23

<210> 39 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Anti-sense primer HuCL7-FOR <400> 39 agageattet gcaggggcca ctg 23

<210> 40 <211> 4941 <212> DNA <213> Artificial sequence <220> <223> Vector PDV-C06 <400> 40 aagcttgcat gcaaattcta tttcaaggag acagtcataa tgaaatacct attgcctacg 60 gcagccgctg gattgttatt actcgcggcc cagccggcca tggccgaggt gtttgactaa 120 tggggcgcgc ctcagggaac cctggtcacc gtctcgagcg gtacgggcgg ttcaggcgga 180 accggcagcg gcactggcgg gtcgacggaa attgtgctca cacagtctcc agccaccctg 240 tctttgtctc caggggaaag agccaccctc tcctgcaggg ccagtcagag tgttagcagc 300 tacttagcct ggtaccaaca gaaacctggc caggctccca ggctcctcat ctatgatgca 360 tccaacaggg ccactggcat cccagccagg ttcagtggca gtgggtctgg gacagacttc 420 actctcacca tcagcagcct agagcctgaa gattttgcag tttattactg tcagcagcgt 480 agcaactggc ctccggcttt cggcggaggg accaaggtgg agatcaaacg tgcggccgca 540 catcatcatc accatcacgg ggccgcatat accgatattg aaatgaaccg cctgggcaaa 600 ggggccgcat agactgttga aagttgttta gcaaaacctc atacagaaaa ttcatttact 660 aacgtctgga aagacgacaa aactttagat cgttacgcta actatgaggg ctgtctgtgg 720 aatgctacag gcgttgtggt ttgtactggt gacgaaactc agtgttacgg tacatgggtt 780 cctattgggc ttgctatccc tgaaaatgag ggtggtggct ctgagggtgg cggttctgag 840 ggtggcggtt ctgagggtgg cggtactaaa cctcctgagt acggtgatac acctattccg 900 ggctatactt atatcaaccc tctcgacggc acttatccgc ctggtactga gcaaaacccc 960 gctaatccta atccttctct tgaggagtct cagcctctta atactttcat gtttcagaat 1020 aataggttcc gaaataggca gggtgcatta actgtttata cgggcactgt tactcaaggc 1080 actgaccccg ttaaaactta ttaccagtac actcctgtat catcaaaagc catgtatgac 1140 gcttactgga acggtaaatt cagagactgc gctttccatt ctggctttaa tgaggatcca 1200 ttcgtttgtg aatatcaagg ccaatcgtct gacctgcctc aacctcctgt caatgctggc 1260 ggcggctctg gtggtggttc tggtggcggc tctgagggtg gcggctctga gggtggcggt 1320 tctgagggtg gcggctctga gggtggcggt tccggtggcg gctccggttc cggtgatttt 1380 gattatgaaa aaatggcaaa cgctaataag ggggctatga ccgaaaatgc cgatgaaaac 1440 gcgctacagt ctgacgctaa aggcaaactt gattctgtcg ctactgatta cggtgctgct 1500 atcgatggtt tcattggtga cgtttccggc cttgctaatg gtaatggtgc tactggtgat 1560 tttgctggct ctaattccca aatggctcaa gtcggtgacg gtgataattc acctttaatg 1620 aataatttcc gtcaatattt accttctttg cctcagtcgg ttgaatgtcg cccttatgtc 1680 tttggcgctg gtaaaccata tgaattttct attgattgtg acaaaataaa cttattccgt 1740 ggtgtctttg cgtttctttt atatgttgcc acctttatgt atgtattttc gacgtttgct 1800 aacatactgc gtaataagga gtcttaataa gaattcactg gccgtcgttt tacaacgtcg 1860 tgactgggaa aaccctggcg ttacccaact taatcgcctt gcagcacatc cccctttcgc 1920 cagctggcgt aatagcgaag aggcccgcac cgatcgccct tcccaacagt tgcgcagcct 1980 gaatggcgaa tggcgcctga tgcggtattt tctccttacg catctgtgcg gtatttcaca 2040 ccgcatacgt caaagcaacc atagtacgcg ccctgtagcg gcgcattaag cgcggcgggt 2100 gtggtggtta cgcgcagcgt gaccgctaca cttgccagcg ccctagcgcc cgctcctttc 2150 gctttcttcc cttcctttct cgccacgttc gccggctttc cccgtcaagc tctaaatcgg 2220 gggctccctt tagggttccg atttagtgct ttacggcacc tcgaccccaa aaaacttgat 2280 ttgggtgatg gttcacgtag tgggccatcg ccctgataga cggtttttcg ccctttgacg 2340 ttggagtcca cgttctttaa tagtggactc ttgttccaaa ctggaacaac actcaaccct 2400 atctcgggct attcttttga tttataaggg attttgccga tttcggccta ttggttaaaa 2460 aatgagctga tttaacaaaa atttaacgcg aattttaaca aaatattaac gtttacaatt 2520 ttatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca gccccgacac 2580 ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc tcccggcatc cgcttacaga 2640 caagctgtga ccgtctccgg gagctgcatg tgtcagaggt tttcaccgtc atcaccgaaa 2700 cgcgcgagac gaaagggcct cgtgatacgc ctatttttat aggttaatgt catgataata 2760 atggtttctt agacgtcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt 2820 ttatttttct aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaatg 2880 cttcaataat attgaaaaag gaagagtatg agtattcaac atttccgtgt cgcccttatt 2940 cccttttttg cggcattttg ccttcctgtt tttgctcacc cagaaacgct ggtgaaagta 3000 aaagatgctg aagatcagtt gggtgcacga gtgggttaca tcgaactgga tctcaacagc 3060 ggtaagatcc ttgagagttt tcgccccgaa gaacgttttc caatgatgag cacttttaaa 3120 gttctgctat gtggcgcggt attatcccgt attgacgccg ggcaagagca actcggtcgc 3180 cgcatacact attctcagaa tgacttggtt gagtactcac cagtcacaga aaagcatctt 3240 acggatggca tgacagtaag agaattatgc agtgctgcca taaccatgag tgataacact 3300 gcggccaact tacttctgac aacgatcgga ggaccgaagg agctaaccgc ttttttgcac 3360 aacatggggg atcatgtaac tcgccttgat cgttgggaac cggagctgaa tgaagccata 3420 ccaaacgacg agcgtgacac cacgatgcct gtagcaatgg caacaacgtt gcgcaaacta 3480 ttaactggcg aactacttac tctagcttcc cggcaacaat taatagactg gatggaggcg 3540 gataaagttg caggaccact tctgcgctcg gcccttccgg ctggctggtt tattgctgat 3600 aaatctggag ccggtgagcg tgggtctcgc ggtatcattg cagcactggg gccagatggt 3660 aagccctccc gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga 3720 aatagacaga tcgctgagat aggtgcctca ctgattaagc attggtaact gtcagaccaa 3780 gtttactcat atatacttta gattgattta aaacttcatt tttaatttaa aaggatctag 3840 gtgaagatcc tttttgataa tctcatgacc aaaatccctt aacgtgagtt ttcgttccac 3900 tgagcgtcag accccgtaga aaagatcaaa ggatcttctt gagatccttt ttttctgcgc 3950 gtaatctgct gcttgcaaac aaaaaaacca ccgctaccag cggtggtttg tttgccggat 4020 caagagctac caactctttt tccgaaggta actggcttca gcagagcgca gataccaaat 4080 actgtccttc tagtgtagcc gtagttaggc caccacttca agaactctgt agcaccgcct 4140 acatacctcg ctctgctaat cctgttacca gtggctgctg ccagtggcga taagtcgtgt 4200 cttaccgggt tggactcaag acgatagtta ccggataagg cgcagcggtc gggctgaacg 4260 gggggttcgt gcacacagcc cagcttggag cgaacgacct acaccgaact gagataccta 4320 cagcgtgagc tatgagaaag cgccacgctt cccgaaggga gaaaggcgga caggtatccg 4380 gtaagcggca gggtcggaac aggagagcgc acgagggagc ttccaggggg aaacgcctgg 4440 tatctttata gtcctgtcgg gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc 4500 tcgtcagggg ggcggagcct atggaaaaac gccagcaacg cggccttttt acggttcctg 4560 gccttttgct ggccttttgc tcacatgttc tttcctgcgt tatcccctga ttctgtggat 4620 aaccgtatta ccgcctttga gtgagctgat accgctcgcc gcagccgaac gaccgagcgc 4680 agcgagtcag tgagcgagga agcggaagag cgcccaatac gcaaaccgcc tctccccgcg 4740 cgttggccga ttcattaatg cagctggcac gacaggtttc ccgactggaa agcgggcagt 4800 gagcgcaacg caattaatgt gagttagctc actcattagg caccccaggc tttacacttt 4860 atgcttccgg ctcgtatgtt gtgtggaatt gtgagcggat aacaatttca cacaggaaac 4920 agctatgacc atgattacgc c 4941

<210> 41 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Anti-sense primer HuCIgG <400> 41 gtccaccttg gtgttgctgg gctt 24

<210> 42 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Anti-sense primer HuCIgM <400> 42 tggaagaggc acgttctttt cttt 24

<210> 43 <211> 6778 <212> DNA <213> Artificial sequence <220> <223> Vector pSyn-C03-HCgammal <400> 43 gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgct aggtggtcaa tattggccat tagccatatt 240 attcattggt tatatagcat aaatcaatat tggctattgg ccattgcata cgttgtatcc 300 atatcataat atgtacattt atattggctc atgtccaaca ttaccgccat gttgacattg 360 attattgact agttattaat agtaatcaat tacggggtca ttagttcata gcccatatat 420 ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 480 ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 540 ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 600 tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 660 tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg tattagtcat 720 cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat agcggtttga 780 ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 840 aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg 900 taggcgtgta cggtgggagg tctatataag cagagctcgt ttagtgaacc gtcagatcgc 960 ctggagacgc catccacgct gttttgacct ccatagaaga caccgggacc gatccagcct 1020 ccgcggccgg gaacggtgca ttggaagctg gcctggatgg cctgactctc ttaggtagcc 1080 ttgcagaagt tggtcgtgag gcactgggca ggtaagtatc aaggttacaa gacaggttta 1140 aggagatcaa tagaaactgg gcttgtcgag acagagaaga ctcttgcgtt tctgataggc 1200 acctattggt cttactgaca tccactttgc ctttctctcc acaggtgtcc actcccagtt 1260 caattacagc tcgccaccat ggcctgcccc ggcttcctgt gggccctggt gatcagcacc 1320 tgcctggaat tcagcatgag cagcgctagc accaagggcc ccagcgtgtt ccccctggcc 1380 cccagcagca agagcaccag cggcggcaca gccgccctgg gctgcctggt gaaggactac 1440 ttccccgagc ccgtgaccgt gagctggaac agcggcgcct tgaccagcgg cgtgcacacc 1500 ttccccgccg tgctgcagag cagcggcctg tacagcctga gcagcgtggt gaccgtgccc 1550 agcagcagcc tgggcaccca gacctacatc tgcaacgtga accacaagcc cagcaacacc 1620 aaggtggaca aacgcgtgga gcccaagagc tgcgacaaga cccacacctg ccccccctgc 1680 cctgcccccg agctgctggg cggaccctcc gtgttcctgt tcccccccaa gcccaaggac 1740 accctcatga tcagccggac ccccgaggtg acctgcgtgg tggtggacgt gagccacgag 1800 gaccccgagg tgaagttcaa ctggtacgtg gacggcgtgg aggtgcacaa cgccaagacc I860 aagccccggg aggagcagta caacagcacc taccgggtgg tgagcgtgct caccgtgctg 1920 caccaggact ggctgaacgg caaggagtac aagtgcaagg tgagcaacaa ggccctgcct 1980 gcccccatcg agaagaccat cagcaaggcc aagggccagc cccgggagcc ccaggtgtac 2040 accctgcccc ccagccggga ggagatgacc aagaaccagg tgtccctcac ctgtctggtg 2100 aagggcttct accccagcga catcgccgtg gagtgggaga gcaacggcca gcccgagaac 2160 aactacaaga ccaccccccc tgtgctggac agcgacggca gcttcttcct gtacagcaag 2220 ctcaccgtgg acaagagccg gtggcagcag ggcaacgtgt tcagctgcag cgtgatgcac 2280 gaggccctgc acaaccacta cacccagaag agcctgagcc tgagccccgg caagtgataa 2340 tctagagggc ccgtttaaac ccgctgatca gcctcgactg tgccttctag ttgccagcca 2400 tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc 2460 ctttcctaat aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg 2520 gggggtgggg tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct 2580 ggggatgcgg tgggctctat ggcttctgag gcggaaagaa ccagctgggg ctctaggggg 2640 tatccccacg cgccctgtag cggcgcatta agcgcggcgg gtgtggtggt tacgcgcagc 2700 gtgaccgcta cacttgccag cgccctagcg cccgctcctt tcgctttctt cccttccttt 2760 ctcgccacgt tcgccggctt tccccgtcaa gctctaaatc gggggctccc tttagggttc 2820 cgatttagtg ctttacggca cctcgacccc aaaaaacttg attagggtga tggttcacgt 2880 agtgggccat cgccctgata gacggttttt cgccctttga cgttggagtc cacgttcttt 2940 aatagtggac tcttgttcca aactggaaca acactcaacc ctatctcggt ctattctttt 3000 gatttataag ggattttgcc gatttcggcc tattggttaa aaaatgagct gatttaacaa 3060 aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt agggtgtgga aagtccccag 3120 gctccccagc aggcagaagt atgcaaagca tgcatctcaa ttagtcagca accaggtgtg 3180 gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag catgcatctc aattagtcag 3240 caaccatagt cccgccccta actccgccca tcccgcccct aactccgccc agttccgccc 3300 attctccgcc ccatggctga ctaatttttt ttatttatgc agaggccgag gccgcctctg 3350 cctctgagct attccagaag tagtgaggag gcttttttgg aggcctaggc ttttgcaaaa 3420 agctcccggg agcttgtata tccattttcg gatctgatca agagacagga tgaggatcgt 3480 ttcgcatgat tgaacaagat ggattgcacg caggttctcc ggccgcttgg gtggagaggc 3540 tattcggcta tgactgggca caacagacaa tcggctgctc tgatgccgcc gtgttccggc 3600 tgtcagcgca ggggcgcccg gttctttttg tcaagaccga cctgtccggt gccctgaatg 3660 aactgcagga cgaggcagcg cggctatcgt ggctggccac gacgggcgtt ccttgcgcag 3720 ctgtgctcga cgttgtcact gaagcgggaa gggactggct gctattgggc gaagtgccgg 3780 ggcaggatct cctgtcatct caccttgctc ctgccgagaa agtatccatc atggctgatg 3840 caatgcggcg gctgcatacg cttgatccgg ctacctgccc attcgaccac caagcgaaac 3900 atcgcatcga gcgagcacgt actcggatgg aagccggtct tgtcgatcag gatgatctgg 3960 acgaagagca tcaggggctc gcgccagccg aactgttcgc caggctcaag gcgcgcatgc 4020 ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg cttgccgaat atcatggtgg 4080 aaaatggccg cttttctgga ttcatcgact gtggccggct gggtgtggcg gatcgctatc 4140 aggacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa tgggctgacc 4200 gcttcctcgt gctttacggt atcgccgctc ccgattcgca gcgcatcgcc ttctatcgcc 4260 ttcttgacga gttcttctga gcgggactct ggggttcgaa atgaccgacc aagcgacgcc 4320 caacctgcca tcacgagatt tcgattccac cgccgccttc tatgaaaggt tgggcttcgg 4380 aatcgttttc cgggacgccg gctggatgat cctccagcgc ggggatctca tgctggagtt 4440 cttcgcccac cccaacttgt ttattgcagc ttataatggt tacaaataaa gcaatagcat 4500 cacaaatttc acaaataaag catttttttc actgcattct agttgtggtt tgtccaaact 4560 catcaatgta tcttatcatg tctgtatacc gtcgacctct agctagagct tggcgtaatc 4620 atggtcatag ctgtttcctg tgtgaaattg ttatccgctc acaattccac acaacatacg 4680 agccggaagc ataaagtgta aagcctgggg tgcctaatga gtgagctaac tcacattaat 4740 tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg tcgtgccagc tgcattaatg 4800 aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg cttcctcgct 4860 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 4920 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 4980 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 5040 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 5100 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 5150 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 5220 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 5280 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 5340 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 5400 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 5460 tagaagaaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 5520 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtttttttg tttgcaagca 5580 gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc 5640 tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag 5700 gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata 5760 tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 5820 ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg 5880 ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc 5940 tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc 6000 aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc 6060 gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc 6120 gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc 6180 ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa 6240 gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat 6300 gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata 6360 gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 6420 tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag 6480 gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc 6540 agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 6600 aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata 6660 ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta 6720 gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtc 6778

<210> 44 <211> 6283 <212> DNA <213> Artificial sequence <220> <223> Vector pSyn-C04-Clambda <400> 44 gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgttaa ttaacatgaa 180 gaatctgctt agggttaggc gttttgcgct gcttcgctag gtggtcaata ttggccatta 240 gccatattat tcattggtta tatagcataa atcaatattg gctattggcc attgcatacg 300 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 360 tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt agttcatagc 420 ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgcctgg ctgaccgccc 480 aacgaccccc gcccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg 540 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat 600 caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc 660 tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta catctacgta 720 ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 780 cggtttgact cacggggatt tccaagtctc caccccattg acgtcaatgg gagtttgttt 840 tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa 900 atgggcggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt 960 cagatcgcct ggagacgcca tccacgctgt tttgacctcc atagaagaca ccgggaccga 1020 tccagcctcc gcggccggga acggtgcatt ggaatcgatg actctcttag gtagccttgc 1080 agaagttggt cgtgaggcac tgggcaggta agtatcaagg ttacaagaca ggtttaagga 1140 gatcaataga aactgggctt gtcgagacag agaagactct tgcgtttctg ataggcacct 1200 attggtctta ctgacatcca ctttgccttt ctctccacag gtgtccactc ccagttcaat 1260 tacagctcgc caccatggcc tgccccggct tcctgtgggc cctggtgatc agcacctgcc 1320 tcgagatccc cggaccgcgg ccgcaagctt accgtgctgg gccagcccaa ggccgctccc 1380 agcgtgaccc tgttcccccc ctcctccgag gagctgcagg ccaacaaggc caccctggtg 1440 tgcctcatca gcgacttcta ccctggcgcc gtgaccgtgg cctggaaggc cgacagcagc 1500 cccgtgaagg ccggcgtgga gaccaccacc cccagcaagc agagcaacaa caagtacgcc 1560 gccagcagct acctgagcct cacccccgag cagtggaaga gccaccggag ctacagctgc 1620 caggtgaccc acgagggcag caccgtggag aagaccgtgg cccccaccga gtgcagctaa 1680 tagacttaag tttaaaccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg 1740 ttgtttgccc ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt 1800 cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg 1850 gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg catgctgggg 1920 atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct agggggtatc 1980 cccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 2040 ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg 2100 ccacgttcgc cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat 2160 ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg 2220 ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 2280 gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt 2340 tataagggat tttggccatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat 2400 ttaacgcgaa ttaattctgt ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc 2460 cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca ggtgtggaaa 2520 gtccccaggc tccccagcag gcagaagtat gcaaagcatg catctcaatt agtcagcaac 2580 catagtcccg cccctaactc cgcccatccc gcccctaact ccgcccagtt ccgcccattc 2640 tccgccccat ggctgactaa ttttttttat ttatgcagag gccgaggccg cctctgcctc 2700 tgagctattc cagaagtagt gaggaggctt ttttggaggc ctaggctttt gcaaaaagct 2760 cccgggagct tgtatatcca ttttcggatc tgatcagcac gtgatgaaaa agcctgaact 2820 caccgcgacg tctgtcgaga agtttctgat cgaaaagttc gacagcgtct ccgacctgat 2880 gcagctctcg gagggcgaag aatctcgtgc tttcagcttc gatgtaggag ggcgtggata 2940 tgtcctgcgg gtaaatagct gcgccgatgg tttctacaaa gatcgttatg tttatcggca 3000 ctttgcatcg gccgcgctcc cgattccgga agtgcttgac attggggaat tcagcgagag 3060 cctgacctat tgcatctccc gccgtgcaca gggtgtcacg ttgcaagacc tgcctgaaac 3120 cgaactgccc gctgttctgc agccggtcgc ggaggccatg gatgcgatcg ctgcggccga 3180 tcttagccag acgagcgggt tcggcccatt cggaccgcaa ggaatcggtc aatacactac 3240 atggcgtgat ttcatatgcg cgattgctga tccccatgtg tatcactggc aaactgtgat 3300 ggacgacacc gtcagtgcgt ccgtcgcgca ggctctcgat gagctgatgc tttgggccga 3360 ggactgcccc gaagtccggc acctcgtgca cgcggatttc ggctccaaca atgtcctgac 3420 ggacaatggc cgcataacag cggtcattga ctggagcgag gcgatgttcg gggattccca 3480 atacgaggtc gccaacatct tcttctggag gccgtggttg gcttgtatgg agcagcagac 3540 gcgctacttc gagcggaggc atccggagct tgcaggatcg ccgcggctcc gggcgtatat 3600 gctccgcatt ggtcttgacc aactctatca gagcttggtt gacggcaatt tcgatgatgc 3650 agcttgggcg cagggtcgat gcgacgcaat cgtccgatcc ggagccggga ctgtcgggcg 3720 tacacaaatc gcccgcagaa gcgcggccgt ctggaccgat ggctgtgtag aagtactcgc 3780 cgatagtgga aaccgacgcc ccagcactcg tccgagggca aaggaatagc acgtgctacg 3840 agatttcgat tccaccgccg ccttctatga aaggttgggc ttcggaatcg ttttccggga 3900 cgccggctgg atgatcctcc agcgcgggga tctcatgctg gagttcttcg cccaccccaa 3960 cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacaa atttcacaaa 4020 taaagcattt ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta 4080 tcatgtctgt ataccgtcga cctctagcta gagcttggcg taatcatggt catagctgtt 4140 tcctgtgtga aattgttatc cgctcacaat tccacacaac atacgagccg gaagcataaa 4200 gtgtaaagcc tggggtgcct aatgagtgag ctaactcaca ttaattgcgt tgcgctcact 4260 gcccgctttc cagtcgggaa acctgtcgtg ccagctgcat taatgaatcg gccaacgcgc 4320 ggggagaggc ggtttgcgta ttgggcgctc ttccgcttcc tcgctcactg actcgctgcg 4380 ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa tacggttatc 4440 cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc aaaaggccag 4500 gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc ctgacgagca 4560 tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat aaagatacca 4620 ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc cgcttaccgg 4680 atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct cacgctgtag 4740 gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg aaccccccgt 4800 tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc cggtaagaca 4860 cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga ggtatgtagg 4920 cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa gaacagtatt 4980 tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta gctcttgatc 5040 cggcaaacaa accaccgctg gtagcggttt ttttgtttgc aagcagcaga ttacgcgcag 5100 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 5160 cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 5220 ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 5280 tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 5340 atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 5400 tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 5450 aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc 5520 catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 5580 gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 5640 ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 5700 aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 5760 atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 5820 cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc 5880 gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 5940 agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 6000 gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 6060 caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag 6120 ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 6180 tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 6240 aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 6283

<210> 45 <211> 52 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide 5L-B <400> 45 acctgtctcg agttttccat ggctcagtcc gccctgaccc agccccgctc ag 52

<210> 46 <211> 43 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide sy3L-A <400> 46 ccagcacggt aagcttcagc acggtcacct tggtgccagt tcc 43

<210> 47 <211> 50 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide 5H-F <400> 47 acctgtcttg aattctccat ggcccaggtg cagctgcagg agtccggccc 50

<210> 48 <211> 47 <212> DNA <213> Artificial sequence <220

<223> Oligonucleotide sy3H-A <400> 48 gcccttggtg ctagcgctgg agacggtcac cagggtgccc tggcccc 47 <210> 49 <211> 10515

<212> DNA <213> Artificial sequence <220> <223> Vector piG-C911-HCgamma1 <220> <221 > misc_feature <222> (1326)..(5076) <223> Stuffer <400> 49 tcgacggatc gggagatctc ccgatcccct atggtgcact ctcagtacaa tctgctctga 60 tgccgcatag ttaagccagt atctgctccc tgcttgtgtg ttggaggtcg ctgagtagtg 120 cgcgagcaaa atttaagcta caacaaggca aggcttgacc gacaattgca tgaagaatct 180 gcttagggtt aggcgttttg cgctgcttcg ctaggtggtc aatattggcc attagccata 240 ttattcattg gttatatagc ataaatcaat attggctatt ggccattgca tacgttgtat 300 ccatatcata atatgtacat ttatattggc tcatgtccaa cattaccgcc atgttgacat 360 tgattattga ctagttatta atagtaatca attacggggt cattagttca tagcccatat 420 atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 480 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 540 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 600 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 660 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 720 atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt 780 gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac 840 caaaatcaac gggactttcc aaaatgtcgt aacaactccg ccccattgac gcaaatgggc 900 ggtaggcgtg tacggtggga ggtctatata agcagagctc gtttagtgaa ccgtcagatc 960 gcctggagac gccatccacg ctgttttgac ctccatagaa gacaccggga ccgatccagc 1020 ctccgcggcc gggaacggtg cattggaagc tggcctggat atcctgactc tcttaggtag 1080 ccttgcagaa gttggtcgtg aggcactggg caggtaagta tcaaggttac aagacaggtt 1140 taaggagatc aatagaaact gggcttgtcg agacagagaa gactcttgcg tttctgatag 1200 gcacctattg gtcttactga catccacttt gcctttctct ccacaggtgt ccactcccag 1260 ttcaattaca gctcgccacc atgggatgga gctgtatcat cctcttcttg gtactgctgc 1320 tggcccagcc ggccagtgac cttgaccggt gcaccacttt tgatgatgtt caagctccta 1380 attacactca acatacttca tctatgaggg gggtttacta tcctgatgaa atttttagat 1440 cggacactct ttatttaact caggatttat ttcttccatt ttattctaat gttacagggt 1500 ttcatactat taatcatacg tttggcaacc ctgtcatacc ttttaaggat ggtatttatt 1560 ttgctgccac agagaaatca aatgttgtcc gtggttgggt ttttggttct accatgaaca 1620 acaagtcaca gtcggtgatt attattaaca attctactaa tgttgttata cgagcatgta 1680 actttgaatt gtgtgacaac cctttctttg ctgtttctaa acccatgggt acacagacac 1740 atactatgat attcgataat gcatttaatt gcactttcga gtacatatct gatgcctttt 1800 cgcttgatgt ttcagaaaag tcaggtaatt ttaaacactt acgagagttt gtgtttaaaa 1860 ataaagatgg gtttctctat gtttataagg gctatcaacc tatagatgta gttcgtgatc 1920 taccttctgg ttttaacact ttgaaaccta tttttaagtt gcctcttggt attaacatta 1980 caaattttag agccattctt acagcctttt cacctgctca agacatttgg ggcacgtcag 2040 ctgcagccta ttttgttggc tatttaaagc caactacatt tatgctcaag tatgatgaaa 2100 atggtacaat cacagatgct gttgattgtt ctcaaaatcc acttgctgaa ctcaaatgct 2160 ctgttaagag ctttgagatt gacaaaggaa tttaccagac ctctaatttc agggttgttc 2220 cctcaggaga tgttgtgaga ttccctaata ttacaaactt gtgtcctttt ggagaggttt 2280 ttaatgctac taaattccct tctgtctatg catgggagag aaaaaaaatt tctaattgtg 2340 ttgctgatta ctctgtgctc tacaactcaa catttttttc aacctttaag tgctatggcg 2400 tttctgccac taagttgaat gatctttgct tctccaatgt ctatgcagat tcttttgtag 2450 tcaagggaga tgatgtaaga caaatagcgc caggacaaac tggtgttatt gctgattata 2520 attataaatt gccagatgat ttcatgggtt gtgtccttgc ttggaatact aggaacattg 2580 atgctacttc aactggtaat tataattata aatataggta tcttagacat ggcaagctta 2640 ggccctttga gagagacata tctaatgtgc ctttctcccc tgatggcaaa ccttgcaccc 2700 cacctgctct taattgttat tggccattaa atgattatgg tttttacacc actactggca 2760 ttggctacca accttacaga gttgtagtac tttcttttga acttttaaat gcaccggcca 2820 cggtttgtgg accaaaatta tccactgacc ttattaagaa ccagtgtgtc aattttaatt 2880 ttaatggact cactggtact ggtgtgttaa ctccttcttc aaagagattt caaccatttc 2940 aacaatttgg ccgtgatgtt tctgatttca ctgattccgt tcgagatcct aaaacatctg 3000 aaatattaga catttcacct tgctcttttg ggggtgtaag tgtaattaca cctggaacaa 3060 atgcttcatc tgaagttgct gttctatatc aagatgttaa ctgcactgat gtttctacag 3120 caattcatgc agatcaactc acaccagctt ggcgcatata ttctactgga aacaatgtat 3180 tccagactca ggcaggctgt cttataggag ctgagcatgt cgacacttct tatgagtgcg 3240 acattcctat tggagctggc atttgtgcta gttaccatac agtttcttta ttacgtagta 3300 ctagccaaaa atctattgtg gcttatacta tgtctttagg tgctgatagt tcaattgctt 3360 actctaataa caccattgct atacctacta acttttcaat tagcattact acagaagtaa 3420 tgcctgtttc tatggctaaa acctccgtag attgtaatat gtacatctgc ggagattcta 3480 ctgaatgtgc taatttgctt ctccaatatg gtagcttttg cacacaacta aatcgtgcac 3540 tctcaggtat tgctgctgaa caggatcgca acacacgtga agtgttcgct caagtcaaac 3600 aaatgtacaa aaccccaact ttgaaatatt ttggtggttt taatttttca caaatattac 3660 ctgaccctct aaagccaact aagaggtctt ttattgagga cttgctcttt aataaggtga 3720 cactcgctga tgctggcttc atgaagcaat atggcgaatg cctaggtgat attaatgcta 3780 gagatctcat ttgtgcgcag aagttcaatg gacttacagt gttgccacct ctgctcactg 3840 atgatatgat tgctgcctac actgctgctc tagttagtgg tactgccact gctggatgga 3900 catttggtgc tggcgctgct cttcaaatac cttttgctat gcaaatggca tataggttca 3960 atggcattgg agttacccaa aatgttctct atgagaacca aaaacaaatc gccaaccaat 4020 ttaacaaggc gattagtcaa attcaagaat cacttacaac aacatcaact gcattgggca 4080 agctgcaaga cgttgttaac cagaatgctc aagcattaaa cacacttgtt aaacaactta 4140 gctctaattt tggtgcaatt tcaagtgtgc taaatgatat cctttcgcga cttgataaag 4200 tcgaggcgga ggtacaaatt gacaggttaa ttacaggcag acttcaaagc cttcaaacct 4250 atgtaacaca acaactaatc agggctgctg aaatcagggc ttctgctaat cttgctgcta 4320 ctaaaatgtc tgagtgtgtt cttggacaat caaaaagagt tgacttttgt ggaaagggct 4380 accaccttat gtccttccca caagcagccc cgcatggtgt tgtcttccta catgtcacgt 4440 atgtgccatc ccaggagagg aacttcacca cagcgccagc aatttgtcat gaaggcaaag 4500 catacttccc tcgtgaaggt gtttttgtgt ttaatggcac ttcttggttt attacacaga 4560 ggaacttctt ttctccacaa ataattacta cagacaatac atttgtctca ggaaattgtg 4620 atgtcgttat tggcatcatt aacaacacag tttatgatcc tctgcaacct gagcttgact 4680 cattcaaaga agagctggac aagtacttca aaaatcatac atcaccagat gttgattttg 4740 gcgacatttc aggcattaac gcttctgtcg tcaacattca aaaagaaatt gaccgcctca 4800 atgaggtcgc taaaaattta aatgaatcac tcattgacct tcaagaactg ggaaaatatg 4860 agcaatatat taaatggcct ctcgacgaac aaaaactcat ctcagaagag gatctgaatg 4920 ctgtgggcca ggacacgcag gaggtcatcg tggtgccaca ctccttgccc tttaaggtgg 4980 tggtgatctc agccatcctg gccctggtgg tgctcaccat catctccctt atcatcctca 5040 tcatgctttg gcagaagaag ccacgttagg cggccgctcg agtgctagca ccaagggccc 5100 cagcgtgttc cccctggccc ccagcagcaa gagcaccagc ggcggcacag ccgccctggg 5150 ctgcctggtg aaggactact tccccgagcc cgtgaccgtg agctggaaca gcggcgcctt 5220 gaccagcggc gtgcacacct tccccgccgt gctgcagagc agcggcctgt acagcctgag 5280 cagcgtggtg accgtgccca gcagcagcct gggcacccag acctacatct gcaacgtgaa 5340 ccacaagccc agcaacacca aggtggacaa acgcgtggag cccaagagct gcgacaagac 5400 ccacacctgc cccccctgcc ctgcccccga gctgctgggc ggaccctccg tgttcctgtt 5460 cccccccaag cccaaggaca ccctcatgat cagccggacc cccgaggtga cctgcgtggt 5520 ggtggacgtg agccacgagg accccgaggt gaagttcaac tggtacgtgg acggcgtgga 5580 ggtgcacaac gccaagacca agccccggga ggagcagtac aacagcacct accgggtggt 5640 gagcgtgctc accgtgctgc accaggactg gctgaacggc aaggagtaca agtgcaaggt 5700 gagcaacaag gccctgcctg cccccatcga gaagaccatc agcaaggcca agggccagcc 5760 ccgggagccc caggtgtaca ccctgccccc cagccgggag gagatgacca agaaccaggt 5820 gtccctcacc tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag 5880 caacggccag cccgagaaca actacaagac caccccccct gtgctggaca gcgacggcag 5940 cttcttcctg tacagcaagc tcaccgtgga caagagccgg tggcagcagg gcaacgtgtt 6000 cagctgcagc gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct 6050 gagccccggc aagtgataat ctagagggcc cgtttaaacc cgctgatcag cctcgactgt 6120 gccttctagt tgccagccat ctgttgtttg cccctccccc gtgccttcct tgaccctgga 6180 aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag 6240 taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga 6300 agacaatagc aggcatgctg gggatgcggt gggctctatg gcttctgagg cggaaagaac 6360 cagctggggc tctagggggt atccccacgc gccctgtagc ggcgcattaa gcgcggcggg 6420 tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt 6480 cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtcaag ctctaaatcg 6540 ggggctccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 6600 ttagggtgat ggttcacgta gtgggccatc gccctgatag acggtttttc gccctttgac 6660 gttggagtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 6720 tatctcggtc tattcttttg atttataagg gattttgccg atttcggcct attggttaaa 6780 aaatgagctg atttaacaaa aatttaacgc gaattaattc tgtggaatgt gtgtcagtta 6840 gggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 6900 tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 6960 atgcatctca attagtcagc aaccatagtc ccgcccctaa ctccgcccat cccgccccta 7020 actccgccca gttccgccca ttctccgccc catggctgac taattttttt tatttatgca 7080 gaggccgagg ccgcctctgc ctctgagcta ttccagaagt agtgaggagg cttttttgga 7140 ggcctaggct tttgcaaaaa gctcccggga gcttgtatat ccattttcgg atctgatcaa 7200 gagacaggat gaggatcgtt tcgcatgatt gaacaagatg gattgcacgc aggttctccg 7260 gccgcttggg tggagaggct attcggctat gactgggcac aacagacaat cggctgctct 7320 gatgccgccg tgttccggct gtcagcgcag gggcgcccgg ttctttttgt caagaccgac 7380 ctgtccggtg ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg 7440 acgggcgttc cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg 7500 ctattgggcg aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa 7550 gtatccatca tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca 7620 ttcgaccacc aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt 7680 gtcgatcagg atgatctgga cgaagagcat caggggctcg cgccagccga actgttcgcc 7740 aggctcaagg cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc 7800 ttgccgaata tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg 7850 ggtgtggcgg accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt 7920 ggcggcgaat gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag 7980 cgcatcgcct tctatcgcct tcttgacgag ttcttctgag cgggactctg gggttcgaaa 8040 tgaccgacca agcgacgccc aacctgccat cacgagattt cgattccacc gccgccttct 8100 atgaaaggtt gggcttcgga atcgttttcc gggacgccgg ctggatgatc ctccagcgcg 8160 gggatctcat gctggagttc ttcgcccacc ccaacttgtt tattgcagct tataatggtt 8220 acaaataaag caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta 8280 gttgtggttt gtccaaactc atcaatgtat cttatcatgt ctgtataccg tcgacctcta 8340 gctagagctt ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca 8400 caattccaca caacatacga gccggaagca taaagtgtaa agcctggggt gcctaatgag 8460 tgagctaact cacattaatt gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt 8520 cgtgccagct gcattaatga atcggccaac gcgcggggag aggcggtttg cgtattgggc 8580 gctcttccgc ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg 8640 tatcagctca ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa 8700 agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg 8760 cgtttttcca taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga 8820 ggtggcgaaa cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg 8880 tgcgctctcc tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg 8940 gaagcgtggc gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc 9000 gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg 9060 gtaactatcg tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca 9120 ctggtaacag gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt 9180 ggcctaacta cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag 9240 ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg 9300 gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 9350 tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg 9420 tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta 9480 aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg 9540 aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg 9600 tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc 9650 gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg 9720 agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg 9780 aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag 9840 gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat 9900 caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc 9960 cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc 10020 ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa 10080 ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac 10140 gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt 10200 cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc 10260 gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa 10320 caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca 10380 tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat 10440 acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 10500 aagtgccacc tgacg 10515

<210> 50 <211> 8777 <212> DNA <213> Artificial sequence <220> <223> Vector piG-C909-Ckappa <220> <221 > misc_feature <222> (1328)..(3860) <223> Stuffer <400> 50 tcgacggatc gggagatctc ccgatcccct atggtgcact ctcagtacaa tctgctctga 60 tgccgcatag ttaagccagt atctgctccc tgcttgtgtg ttggaggtcg ctgagtagtg 120 cgcgagcaaa atttaagcta caacaaggca aggcttgacc gacaattgtt aattaacatg 180 aagaatctgc ttagggttag gcgttttgcg ctgcttcgct aggtggtcaa tattggccat 240 tagccatatt attcattggt tatatagcat aaatcaatat tggctattgg ccattgcata 300 cgttgtatcc atatcataat atgtacattt atattggctc atgtccaaca ttaccgccat 360 gttgacattg attattgact agttattaat agtaatcaat tacggggtca ttagttcata 420 gcccatatat ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 480 ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag 540 ggactttcca ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac 600 atcaagtgta tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg 660 cctggcatta tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg 720 tattagtcat cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat 780 agcggtttga ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt 840 tttggcacca aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc 900 aaatgggcgg taggcgtgta cggtgggagg tctatataag cagagctcgt ttagtgaacc 960 gtcagatcgc ctggagacgc catccacgct gttttgacct ccatagaaga caccgggacc 1020 gatccagcct ccgcggccgg gaacggtgca ttggaatcga tgactctctt aggtagcctt 1080 gcagaagttg gtcgtgaggc actgggcagg taagtatcaa ggttacaaga caggtttaag 1140 gagatcaata gaaactgggc ttgtcgagac agagaagact cttgcgtttc tgataggcac 1200 ctattggtct tactgacatc cactttgcct ttctctccac aggtgtccac tcccagttca 1260 attacagctc gccaccatgc ggctgcccgc ccagctgctg ggccttctca tgctgtgggt 1320 gcccgcctcg agatctatcg atgcatgcca tggtaccaag cttgccacca tgagcagcag 1380 ctcttggctg ctgctgagcc tggtggccgt gacagccgcc cagagcacca tcgaggagca 1440 ggccaagacc ttcctggaca agttcaacca cgaggccgag gacctgttct accagagcag 1500 cctggccagc tggaactaca acaccaacat caccgaggag aacgtgcaga acatgaacaa 1560 cgccggcgac aagtggagcg ccttcctgaa ggagcagagc acactggccc agatgtaccc 1620 cctgcaggag atccagaacc tgaccgtgaa gctgcagctg caggccctgc agcagaacgg 1680 cagcagcgtg ctgagcgagg acaagagcaa gcggctgaac accatcctga acaccatgtc 1740 caccatctac agcaccggca aagtgtgcaa ccccgacaac ccccaggagt gcctgctgct 1800 ggagcccggc ctgaacgaga tcatggccaa cagcctggac tacaacgagc ggctgtgggc 1860 ctgggagagc tggcggagcg aagtgggcaa gcagctgcgg cccctgtacg aggagtacgt 1920 ggtgctgaag aacgagatgg ccagggccaa ccactacgag gactacggcg actactggag 1980 aggcgactac gaagtgaacg gcgtggacgg ctacgactac agcagaggcc agctgatcga 2040 ggacgtggag cacaccttcg aggagatcaa gcctctgtac gagcacctgc acgcctacgt 2100 gcgggccaag ctgatgaacg cctaccccag ctacatcagc cccatcggct gcctgcccgc 2160 ccacctgctg ggcgacatgt ggggccggtt ctggaccaac ctgtacagcc tgaccgtgcc 2220 cttcggccag aagcccaaca tcgacgtgac cgacgccatg gtggaccagg cctgggacgc 2280 ccagcggatc ttcaaggagg ccgagaagtt cttcgtgagc gtgggcctgc ccaacatgac 2340 ccagggcttt tgggagaaca gcatgctgac cgaccccggc aatgtgcaga aggccgtgtg 2400 ccaccccacc gcctgggacc tgggcaaggg cgacttccgg atcctgatgt gcaccaaagt 2460 gaccatggac gacttcctga ccgcccacca cgagatgggc cacatccagt acgacatggc 2520 ctacgccgcc cagcccttcc tgctgcggaa cggcgccaac gagggctttc acgaggccgt 2580 gggcgagatc atgagcctga gcgccgccac ccccaagcac ctgaagagca tcggcctgct 2640 gagccccgac ttccaggagg acaacgagac cgagatcaac ttcctgctga agcaggccct 2700 gaccatcgtg ggcaccctgc ccttcaccta catgctggag aagtggcggt ggatggtgtt 2760 taagggcgag atccccaagg accagtggat gaagaagtgg tgggagatga agcgggagat 2820 cgtgggcgtg gtggagcccg tgccccacga cgagacctac tgcgaccccg ccagcctgtt 2880 ccacgtgagc aacgactact ccttcatccg gtactacacc cggaccctgt accagttcca 2940 gttccaggag gccctgtgcc aggccgccaa gcacgagggc cccctgcaca agtgcgacat 3000 cagcaacagc accgaggccg gacagaaact gttcaacatg ctgcggctgg gcaagagcga 3060 gccctggacc ctggccctgg agaatgtggt gggcgccaag aacatgaatg tgcgccccct 3120 gctgaactac ttcgagcccc tgttcacctg gctgaaggac cagaacaaga acagcttcgt 3180 gggctggagc accgactgga gcccctacgc cgaccagagc atcaaagtgc ggatcagcct 3240 gaagagcgcc ctgggcgaca aggcctacga gtggaacgac aacgagatgt acctgttccg 3300 gagcagcgtg gcctatgcca tgcggcagta cttcctgaaa gtgaagaacc agatgatcct 3360 gttcggcgag gaggacgtga gagtggccaa cctgaagccc cggatcagct tcaacttctt 3420 cgtgaccgcc cccaagaacg tgagcgacat catcccccgg accgaagtgg agaaggccat 3480 ccggatgagc cggagccgga tcaacgacgc cttccggctg aacgacaact ccctggagtt 3540 cctgggcatc cagcccaccc tgggccctcc caaccagccc cccgtgagca tctggctgat 3600 cgtgtttggc gtggtgatgg gcgtgatcgt ggtgggaatc gtgatcctga tcttcaccgg 3660 catccgggac cggaagaaga agaacaaggc ccggagcggc gagaacccct acgccagcat 3720 cgatatcagc aagggcgaga acaaccccgg cttccagaac accgacgacg tgcagaccag 3780 cttctgataa tctagaacga gctcgaattc gaagcttctg cagacgcgtc gacgtcatat 3840 ggatccgata tcgccgtggc ggccgcaccc agcgtgttca tcttcccccc ctccgacgag 3900 cagctgaaga gcggcaccgc cagcgtggtg tgcctgctga acaacttcta cccccgggag 3960 gccaaggtgc agtggaaggt ggacaacgcc ctgcagagcg gcaacagcca ggagagcgtg 4020 accgagcagg acagcaagga ctccacctac agcctgagca gcaccctcac cctgagcaag 4080 gccgactacg agaagcacaa ggtgtacgcc tgcgaggtga cccaccaggg cctgagcagc 4140 cccgtgacca agagcttcaa ccggggcgag tgttaataga cttaagttta aaccgctgat 4200 cagcctcgac tgtgccttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt 4260 ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat 4320 cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag gacagcaagg 4380 gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct atggcttctg 4440 aggcggaaag aaccagctgg ggctctaggg ggtatcccca cgcgccctgt agcggcgcat 4500 taagcgcggc gggtgtggtg gttacgcgca gcgtgaccgc tacacttgcc agcgccctag 4560 cgcccgctcc tttcgctttc ttcccttcct ttctcgccac gttcgccggc tttccccgtc 4620 aagctctaaa tcgggggctc cctttagggt tccgatttag tgctttacgg cacctcgacc 4680 ccaaaaaact tgattagggt gatggttcac gtagtgggcc atcgccctga tagacggttt 4740 ttcgcccttt gacgttggag tccacgttct ttaatagtgg actcttgttc caaactggaa 4800 caacactcaa ccctatctcg gtctattctt ttgatttata agggattttg gccatttcgg 4860 cctattggtt aaaaaatgag ctgatttaac aaaaatttaa cgcgaattaa ttctgtggaa 4920 tgtgtgtcag ttagggtgtg gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag 4980 catgcatctc aattagtcag caaccaggtg tggaaagtcc ccaggctccc cagcaggcag 5040 aagtatgcaa agcatgcatc tcaattagtc agcaaccata gtcccgcccc taactccgcc 5100 catcccgccc ctaactccgc ccagttccgc ccattctccg ccccatggct gactaatttt 5160 ttttatttat gcagaggccg aggccgcctc tgcctctgag ctattccaga agtagtgagg 5220 aggctttttt ggaggcctag gcttttgcaa aaagctcccg ggagcttgta tatccatttt 5280 cggatctgat cagcacgtga tgaaaaagcc tgaactcacc gcgacgtctg tcgagaagtt 5340 tctgatcgaa aagttcgaca gcgtctccga cctgatgcag ctctcggagg gcgaagaatc 5400 tcgtgctttc agcttcgatg taggagggcg tggatatgtc ctgcgggtaa atagctgcgc 5460 cgatggtttc tacaaagatc gttatgttta tcggcacttt gcatcggccg cgctcccgat 5520 tccggaagtg cttgacattg gggaattcag cgagagcctg acctattgca tctcccgccg 5580 tgcacagggt gtcacgttgc aagacctgcc tgaaaccgaa ctgcccgctg ttctgcagcc 5640 ggtcgcggag gccatggatg cgatcgctgc ggccgatctt agccagacga gcgggttcgg 5700 cccattcgga ccacaaggaa tcggtcaata cactacatgg cgtgatttca tatgcgcgat 5760 tgctgatccc catgtgtatc actggcaaac tgtgatggac gacaccgtca gtgcgtccgt 5820 cgcgcaggct ctcgatgagc tgatgctttg ggccgaggac tgccccgaag tccggcacct 5880 cgtgcacgcg gatttcggct ccaacaatgt cctgacggac aatggccgca taacagcggt 5940 cattgactgg agcgaggcga tgttcgggga ttcccaatac gaggtcgcca acatcttctt 6000 ctggaggccg tggttggctt gtatggagca gcagacgcgc tacttcgagc ggaggcatcc 6060 ggagcttgca ggatcgccgc ggctccgggc gtatatgctc cgcattggtc ttgaccaact 6120 ctatcagagc ttggttgacg gcaatttcga tgatgcagct tgggcgcagg gtcgatgcga 6180 cgcaatcgtc cgatccggag ccgggactgt cgggcgtaca caaatcgccc gcagaagcgc 6240 ggccgtctgg accgatggct gtgtagaagt actcgccgat agtggaaacc gacgccccag 6300 cactcgtccg agggcaaagg aatagcacgt gctacgagat ttcgattcca ccgccgcctt 6360 ctatgaaagg ttgggcttcg gaatcgtttt ccgggacgcc ggctggatga tcctccagcg 6420 cggggatctc atgctggagt tcttcgccca ccccaacttg tttattgcag cttataatgg 6480 ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc 6540 tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgacctc 6600 tagctagagc ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct 6660 cacaattcca cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatg 6720 agtgagctaa ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct 6780 gtcgtgccag ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg 6840 gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc 6900 ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg 6960 aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct 7020 ggcgtttttc cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca 7080 gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct 7140 cgtgcgctct cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc 7200 gggaagcgtg gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt 7260 tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc 7320 cggtaactat cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc 7380 cactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg 7440 gtggcctaac tacggctaca ctagaagaac agtatttggt atctgcgctc tgctgaagcc 7500 agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag 7560 cggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 7620 tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt 7680 ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 7740 taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 7800 tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt 7860 cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg caatgatacc 7920 gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc 7980 cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg 8040 ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac 8100 aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg 8160 atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc 8220 tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact 8280 gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 8340 aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat 8400 acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 8460 ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac 8520 tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa 8580 aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 8640 catactcttc ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg 8700 atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg 8760 aaaagtgcca cctgacg 8777

<210> 51 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL1A-Back <400> 51 cagtctgtgc tgactcagcc acc 23

<210> 52 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL1B-Back <400> 52 cagtctgtgy tgacgcagcc gcc 23

<210> 53 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL1C-Back <400> 53 cagtctgtcg tgacgcagcc gcc 23

<210> 54 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL2B-Back <400> 54 cagtctgccc tgactcagcc 20

<210> 55 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL3A-Back <400> 55 tcctatgwgc tgactcagcc acc 23

<210> 56 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL3B-Back <400> 56 tcttctgagc tgactcagga ccc 23

<210> 57 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL4B-Back <400> 57 cagcytgtgc tgactcaatc 20

<210> 58 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL5-Back <400> 58 caggctgtgc tgactcagcc gtc 23 <210> 59

<211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL6-Back <400> 59 aattttatgc tgactcagcc cca 23

<210> 60 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL7/8-Back <400> 60 cagrctgtgg tgacycagga gcc 23

<210> 61 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL9-Back <400> 61 cwgcctgtgc tgactcagcc mcc 23

<210> 62 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL10-Back <400> 62 caggcagggc tgactcag 18

<210> 63 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK1 B-Back <400> 63 gacatccagw tgacccagtc tcc 23

<210> 64 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVK2-Back <400> 64 gatgttgtga tgactcagtc tcc 23

<210> 65 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVK2B2 <400> 65 gatattgtga tgacccagac tcc 23

<210 66 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVK3B-Back <400> 66 gaaattgtgw tgacrcagtc tcc 23

<210 67 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVK5-Back <400> 67 gaaacgacac tcacgcagtc tcc 23

<210 68 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVK6-Back <400 68 gaaattgtgc tgactcagtc tcc 23

<210> 69 <211> 41 <212> DNA <213> Artificial sequence <220>

<223> Primer HuVK1 B-Back-SAL <400 69 tgagcacaca ggtcgacgga catccagwtg acccagtctc c 41

<210> 70 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK2-Back-SAL <400> 70 tgagcacaca ggtcgacgga tgttgtgatg actcagtctc c 41

<210> 71 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK2B2-SAL <400> 71 tgagcacaca ggtcgacgga tattgtgatg acccagactc c 41

<210 72 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK3B-Back-SAL <400> 72 tgagcacaca ggtcgacgga aattgtgwtg acrcagtctc c 41

<210> 73 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK5-Back-SAL <400> 73 tgagcacaca ggtcgacgga aacgacactc acgcagtctc c 41

<210> 74 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVK6-Back-SAL <400> 74 tgagcacaca ggtcgacgga aattgtgctg actcagtctc c 41

<210> 75 <211> 48 <212> DNA <213> Artificial sequence <220 <223> Primer HuJK1-F0R-N0T <400> 75 gagtcattct cgacttgcgg ccgcacgttt gatttccacc ttggtccc 48

<210> 76 <211> 48 <212> DNA <213> Artificial sequence <220 <223> Primer HuJK2-FOR-NOT <400 76 gagtcattct cgacttgcgg ccgcacgttt gatctccagc ttggtccc 48

<210> 77 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Primer HuJK3-FOR-NOT <400> 77 gagtcattct cgacttgcgg ccgcacgttt gatatccact ttggtccc 48

<210> 78 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Primer HuJK4-FOR-NOT <400> 78 gagtcattct cgacttgcgg ccgacgtttg atctccacct tggtccc 47

<210> 79 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Primer HuJK5-FOR-NOT <400> 79 gagtcattct cgacttgcgg ccgcacgttt aatctccagt cgtgtccc 48

<210> 80 <211> 41 <212> DNA <213> Artificial sequence <220 <223> Primer HuVL1 A-Back-SAL <400 80 tgagcacaca ggtcgacgca gtctgtgctg actcagccac c 41

<210> 81 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL1 B-Back-SAL <400> 81 tgagcacaca ggtcgacgca gtctgtgytg acgcagccgc c 41

<210> 82 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL1C-Back-SAL <400> 82 tgagcacaca ggtcgacgca gtctgtcgtg acgcagccgc c 41

<210> 83 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL2B-Back-SAL <400> 83 tgagcacaca ggtcgacgca gtctgccctg actcagcc 38

<210> 84 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL3A-Back-SAL <400> 84 tgagcacaca ggtcgacgtc ctatgwgctg actcagccac c 41

<210> 85 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL3B-Back-SAL <400> 85 tgagcacaca ggtcgacgtc ttctgagctg actcaggacc c 41

<210> 86 <211> 38 <212> DNA <213> Artificial sequence <220 <223> Primer HuVL4B-Back-SAL <400> 86 tgagcacaca ggtcgacgca gcytgtgctg actcaatc 38

<210> 87 <211>41 <212> DNA <213> Artificial sequence <220 <223> Primer HuVL5-Back-SAL <400> 87 tgagcacaca ggtcgacgca ggctgtgctg actcagccgt c 41

<210 88 <211>41 <212> DNA <213> Artificial sequence <220 <223> Primer HuVL6-Back-SAL <400 88 tgagcacaca ggtcgacgaa ttttatgctg actcagcccc a 41

<210> 89 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL7/8-Back-SAL <400> 89 tgagcacaca ggtcgacgca grctgtggtg acycaggagc c 41

<210> 90 <211>41 <212> DNA <213> Artificial sequence <220> <223> Primer HuVL9-Back-SAL <400> 90 tgagcacaca ggtcgacgcw gcctgtgctg actcagccmc c 41

<210 91 <211> 36 <212> DNA <213> Artificial sequence <220 <223> Primer HuVL10-Back-SAL <400 91 tgagcacaca ggtcgacgca ggcagggctg actcag 36

<210> 92 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Primer HuJL1-FOR-NOT <400> 92 gagtcattct cgacttgcgg ccgcacctag gacggtgacc ttggtccc 48

<210> 93 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Primer HuJL2/3-FOR-NOT <400> 93 gagtcattct cgacttgcgg ccgcacctag gacggtcagc ttggtccc 48

<210> 94 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Primer HuJL7-FOR-NOT <400> 94 gagtcattct cgacttgcgg ccgcaccgag gacggtcagc tgggtgcc 48

<210> 95 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer FiuVFH B/7A-Back <400> 95 cagrtgcagc tggtgcartc tgg 23 <210> 96

<211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH1C-Back <400> 96 saggtccagc tggtrcagtc tgg 23

<210> 97 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVH2B-Back <400> 97 cagrtcacct tgaaggagtc tgg 23

<210> 98 <211 > 18 <212> DNA <213> Artificial sequence <220 <223> Primer HuVH3A-Back <400> 98 gaggtgcagc tggtggag 18

<210 99 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH3C-Back <400> 99 gaggtgcagc tggtggagwc ygg 23

<210 100 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH4B-Back <400> 100 caggtgcagc tacagcagtg ggg 23

<210> 101 <211> 23 <212> DNA <213> Artificial sequence <220 <223> Primer HuVH4C-Back <400> 101 cagstgcagc tgcaggagtc sgg 23

<210> 102 <211> 23 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH6A-Back <400> 102 caggtacagc tgcagcagtc agg 23

<210> 103 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH1 B/7A-Back-Sfi <400 103 gtcctcgcaa ctgcggccca gccggccatg gcccagrtgc agctggtgca rtctgg 56

<210> 104 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH1C-Back-Sfi <400> 104 gtcctcgcaa ctgcggccca gccggccatg gccsaggtcc agctggtrca gtctgg 56

<210> 105 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH2B-Back-Sfi <400> 105 gtcctcgcaa ctgcggccca gccggccatg gcccagrtca ccttgaagga gtctgg 56

<210> 106 <211> 51 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH3A-Back-Sfi <400 106 gtcctcgcaa ctgcggccca gccggccatg gccgaggtgc agctggtgga g 51

<210> 107 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH3C-Back-Sfi <400> 107 gtcctcgcaa ctgcggccca gccggccatg gccgaggtgc agctggtgga gwcygg 56

<210> 108 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH4B-Back-Sfi <400> 108 gtcctcgcaa ctgcggccca gccggccatg gcccaggtgc agctacagca gtgggg 56

<210 109 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH4C-Back-Sfi <400> 109 gtcctcgcaa ctgcggccca gccggccatg gcccagstgc agctgcagga gtcsgg 56

<210> 110 <211> 56 <212> DNA <213> Artificial sequence <220> <223> Primer HuVH6A-Back-Sfi <400> 110 gtcctcgcaa ctgcggccca gccggccatg gcccaggtac agctgcagca gtcagg 56

<210> 111 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Primer HuJH1/2-FOR-XholB <400> 111 gagtcattct cgactcgaga crgtgaccag ggtgcc 36

<210 112 <211> 36 <212> DNA <213> Artificial sequence <220 <223> Primer HuJH3-FOR-Xho <400> 112 gagtcattct cgactcgaga cggtgaccat tgtccc 36

<210 113 <211> 36 <212> DNA <213> Artificial sequence <220 <223> Primer HuJH4/5-FOR-Xho <400 113 gagtcattct cgactcgaga cggtgaccag ggttcc 36

<210> 114 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Primer HuJH6-FOR-Xho <400> 114 gagtcattct cgactcgaga cggtgaccgt ggtccc 36

<210> 115 <211> 8792 <212> DNA <213> Artificial sequence <220> <223> Vector plg-C910-Clambda <220> <221 > misc_feature <222> (1330)..(3869) <223> Stuffer <400> 115 tcgacggatc gggagatctc ccgatcccct atggtgcact ctcagtacaa tctgctctga 60 tgccgcatag ttaagccagt atctgctccc tgcttgtgtg ttggaggtcg ctgagtagtg 120 cgcgagcaaa atttaagcta caacaaggca aggcttgacc gacaattgtt aattaacatg 180 aagaatctgc ttagggttag gcgttttgcg ctgcttcgct aggtggtcaa tattggccat 240 tagccatatt attcattggt tatatagcat aaatcaatat tggctattgg ccattgcata 300 cgttgtatcc atatcataat atgtacattt atattggctc atgtccaaca ttaccgccat 360 gttgacattg attattgact agttattaat agtaatcaat tacggggtca ttagttcata 420 gcccatatat ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 480 ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag 540 ggactttcca ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac 600 atcaagtgta tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg 660 cctggcatta tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg 720 tattagtcat cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat 780 agcggtttga ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt 840 tttggcacca aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc 900 aaatgggcgg taggcgtgta cggtgggagg tctatataag cagagctcgt ttagtgaacc 960 gtcagatcgc ctggagacgc catccacgct gttttgacct ccatagaaga caccgggacc 1020 gatccagcct ccgcggccgg gaacggtgca ttggaatcga tgactctctt aggtagcctt 1080 gcagaagttg gtcgtgaggc actgggcagg taagtatcaa ggttacaaga caggtttaag 1140 gagatcaata gaaactgggc ttgtcgagac agagaagact cttgcgtttc tgataggcac 1200 ctattggtct tactgacatc cactttgcct ttctctccac aggtgtccac tcccagttca 1260 attacagctc gccaccatgc ggttctccgc tcagctgctg ggccttctgg tgctgtggat 1320 tcccggcgtc tcgagatcta tcgatgcatg ccatggtacc aagcttgcca ccatgagcag 1380 cagctcttgg ctgctgctga gcctggtggc cgtgacagcc gcccagagca ccatcgagga 1440 gcaggccaag accttcctgg acaagttcaa ccacgaggcc gaggacctgt tctaccagag 1500 cagcctggcc agctggaact acaacaccaa catcaccgag gagaacgtgc agaacatgaa 1560 caacgccggc gacaagtgga gcgccttcct gaaggagcag agcacactgg cccagatgta 1620 ccccctgcag gagatccaga acctgaccgt gaagctgcag ctgcaggccc tgcagcagaa 1680 cggcagcagc gtgctgagcg aggacaagag caagcggctg aacaccatcc tgaacaccat 1740 gtccaccatc tacagcaccg gcaaagtgtg caaccccgac aacccccagg agtgcctgct 1800 gctggagccc ggcctgaacg agatcatggc caacagcctg gactacaacg agcggctgtg 1860 ggcctgggag agctggcgga gcgaagtggg caagcagctg cggcccctgt acgaggagta 1920 cgtggtgctg aagaacgaga tggccagggc caaccactac gaggactacg gcgactactg 1980 gagaggcgac tacgaagtga acggcgtgga cggctacgac tacagcagag gccagctgat 2040 cgaggacgtg gagcacacct tcgaggagat caagcctctg tacgagcacc tgcacgccta 2100 cgtgcgggcc aagctgatga acgcctaccc cagctacatc agccccatcg gctgcctgcc 2160 cgcccacctg ctgggcgaca tgtggggccg gttctggacc aacctgtaca gcctgaccgt 2220 gcccttcggc cagaagccca acatcgacgt gaccgacgcc atggtggacc aggcctggga 2280 cgcccagcgg atcttcaagg aggccgagaa gttcttcgtg agcgtgggcc tgcccaacat 2340 gacccagggc ttttgggaga acagcatgct gaccgacccc ggcaatgtgc agaaggccgt 2400 gtgccacccc accgcctggg acctgggcaa gggcgacttc cggatcctga tgtgcaccaa 2460 agtgaccatg gacgacttcc tgaccgccca ccacgagatg ggccacatcc agtacgacat 2520 ggcctacgcc gcccagccct tcctgctgcg gaacggcgcc aacgagggct ttcacgaggc 2580 cgtgggcgag atcatgagcc tgagcgccgc cacccccaag cacctgaaga gcatcggcct 2640 gctgagcccc gacttccagg aggacaacga gaccgagatc aacttcctgc tgaagcaggc 2700 cctgaccatc gtgggcaccc tgcccttcac ctacatgctg gagaagtggc ggtggatggt 2760 gtttaagggc gagatcccca aggaccagtg gatgaagaag tggtgggaga tgaagcggga 2820 gatcgtgggc gtggtggagc ccgtgcccca cgacgagacc tactgcgacc ccgccagcct 2880 gttccacgtg agcaacgact actccttcat ccggtactac acccggaccc tgtaccagtt 2940 ccagttccag gaggccctgt gccaggccgc caagcacgag ggccccctgc acaagtgcga 3000 catcagcaac agcaccgagg ccggacagaa actgttcaac atgctgcggc tgggcaagag 3060 cgagccctgg accctggccc tggagaatgt ggtgggcgcc aagaacatga atgtgcgccc 3120 cctgctgaac tacttcgagc ccctgttcac ctggctgaag gaccagaaca agaacagctt 3180 cgtgggctgg agcaccgact ggagccccta cgccgaccag agcatcaaag tgcggatcag 3240 cctgaagagc gccctgggcg acaaggccta cgagtggaac gacaacgaga tgtacctgtt 3300 ccggagcagc gtggcctatg ccatgcggca gtacttcctg aaagtgaaga accagatgat 3360 cctgttcggc gaggaggacg tgagagtggc caacctgaag ccccggatca gcttcaactt 3420 cttcgtgacc gcccccaaga acgtgagcga catcatcccc cggaccgaag tggagaaggc 3480 catccggatg agccggagcc ggatcaacga cgccttccgg ctgaacgaca actccctgga 3540 gttcctgggc atccagccca ccctgggccc tcccaaccag ccccccgtga gcatctggct 3600 gatcgtgttt ggcgtggtga tgggcgtgat cgtggtggga atcgtgatcc tgatcttcac 3660 cggcatccgg gaccggaaga agaagaacaa ggcccggagc ggcgagaacc cctacgccag 3720 catcgatatc agcaagggcg agaacaaccc cggcttccag aacaccgacg acgtgcagac 3780 cagcttctga taatctagaa cgagctcgaa ttcgaagctt ctgcagacgc gtcgacgtca 3840 tatggatccg atatcgccgt ggcggccgca ggccagccca aggccgctcc cagcgtgacc 3900 ctgttccccc cctcctccga ggagctgcag gccaacaagg ccaccctggt gtgcctcatc 3960 agcgacttct accctggcgc cgtgaccgtg gcctggaagg ccgacagcag ccccgtgaag 4020 gccggcgtgg agaccaccac ccccagcaag cagagcaaca acaagtacgc cgccagcagc 4080 tacctgagcc tcacccccga gcagtggaag agccaccgga gctacagctg ccaggtgacc 4140 cacgagggca gcaccgtgga gaagaccgtg gcccccaccg agtgcagcta atagacttaa 4200 gtttaaaccg ctgatcagcc tcgactgtgc cttctagttg ccagccatct gttgtttgcc 4260 cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa 4320 atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg 4380 ggcaggacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg 4440 gctctatggc ttctgaggcg gaaagaacca gctggggctc tagggggtat ccccacgcgc 4500 cctgtagcgg cgcattaagc gcggcgggtg tggtggttac gcgcagcgtg accgctacac 4550 ttgccagcgc cctagcgccc gctcctttcg ctttcttccc ttcctttctc gccacgttcg 4620 ccggctttcc ccgtcaagct ctaaatcggg ggctcccttt agggttccga tttagtgctt 4680 tacggcacct cgaccccaaa aaacttgatt agggtgatgg ttcacgtagt gggccatcgc 4740 cctgatagac ggtttttcgc cctttgacgt tggagtccac gttctttaat agtggactct 4800 tgttccaaac tggaacaaca ctcaacccta tctcggtcta ttcttttgat ttataaggga 4860 ttttggccat ttcggcctat tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga 4920 attaattctg tggaatgtgt gtcagttagg gtgtggaaag tccccaggct ccccagcagg 4980 cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa agtccccagg 5040 ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc 5100 gcccctaact ccgcccatcc cgcccctaac tccgcccagt tccgcccatt ctccgcccca 5160 tggctgacta atttttttta tttatgcaga ggccgaggcc gcctctgcct ctgagctatt 5220 ccagaagtag tgaggaggct tttttggagg cctaggcttt tgcaaaaagc tcccgggagc 5280 ttgtatatcc attttcggat ctgatcagca cgtgatgaaa aagcctgaac tcaccgcgac 5340 gtctgtcgag aagtttctga tcgaaaagtt cgacagcgtc tccgacctga tgcagctctc 5400 ggagggcgaa gaatctcgtg ctttcagctt cgatgtagga gggcgtggat atgtcctgcg 5460 ggtaaatagc tgcgccgatg gtttctacaa agatcgttat gtttatcggc actttgcatc 5520 ggccgcgctc ccgattccgg aagtgcttga cattggggaa ttcagcgaga gcctgaccta 5580 ttgcatctcc cgccgtgcac agggtgtcac gttgcaagac ctgcctgaaa ccgaactgcc 5640 cgctgttctg cagccggtcg cggaggccat ggatgcgatc gctgcggccg atcttagcca 5700 gacgagcggg ttcggcccat tcggaccgca aggaatcggt caatacacta catggcgtga 5760 tttcatatgc gcgattgctg atccccatgt gtatcactgg caaactgtga tggacgacac 5820 cgtcagtgcg tccgtcgcgc aggctctcga tgagctgatg ctttgggccg aggactgccc 5880 cgaagtccgg cacctcgtgc acgcggattt cggctccaac aatgtcctga cggacaatgg 5940 ccgcataaca gcggtcattg actggagcga ggcgatgttc ggggattccc aatacgaggt 6000 cgccaacatc ttcttctgga ggccgtggtt ggcttgtatg gagcagcaga cgcgctactt 6060 cgagcggagg catccggagc ttgcaggatc gccgcggctc cgggcgtata tgctccgcat 6120 tggtcttgac caactctatc agagcttggt tgacggcaat ttcgatgatg cagcttgggc 6180 gcagggtcga tgcgacgcaa tcgtccgatc cggagccggg actgtcgggc gtacacaaat 6240 cgcccgcaga agcgcggccg tctggaccga tggctgtgta gaagtactcg ccgatagtgg 6300 aaaccgacgc cccagcactc gtccgagggc aaaggaatag cacgtgctac gagatttcga 6360 ttccaccgcc gccttctatg aaaggttggg cttcggaatc gttttccggg acgccggctg 6420 gatgatcctc cagcgcgggg atctcatgct ggagttcttc gcccacccca acttgtttat 6480 tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt 6540 tttttcactg cattctagtt gtggtttgtc caaactcatc aatgtatctt atcatgtctg 6600 tataccgtcg acctctagct agagcttggc gtaatcatgg tcatagctgt ttcctgtgtg 6660 aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc 6720 ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt 6780 ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg 6840 cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt 6900 tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc 6960 aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 7020 aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa 7080 tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 7140 ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 7200 cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 7260 ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 7320 ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc 7380 gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 7440 agagttcttg aagtggtggc ctaactacgg ctacactaga agaacagtat ttggtatctg 7500 cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca 7560 aaccaccgct ggtagcggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg 7620 atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 7680 acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa 7740 ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta 7800 ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt 7860 tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag 7920 tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca 7980 gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc 8040 tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 8100 tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 8160 ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt 8220 tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat 8280 ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 8340 gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc 8400 ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat 8460 cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 8520 ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 8580 ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 8640 gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta 8700 ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc 8760 gcgcacattt ccccgaaaag tgccacctga eg 8792 <210> 116 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 116 cag gtc cag ctg gtg cag tct gga gca gag gtg aaa aag ccg ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tec ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ege get agt ata gtg gga get acc cac ttt gac tac tgg ggc 336

Ala Arg Arg Ala Ser Ile Val Gly Ala Thr His Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gcc ccc age age aag age acc age ggc ggc aca gee 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc cgg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc cgg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 117 <211> 451 <212> P RT <213> Homo sapiens <400> 117

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ihr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Ala Ser Ile Val Gly Ala Thr His Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn Hls 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 118 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 118 gag gtg cag ctg gtg gag act ggg gga gtc gcg gtc cag cet ggg agg 48

Glu Val Gin Leu Val Glu Thr Gly Gly Val Ala Val Gin Pro Gly Arg 15 10 15 tcc ctg aga etc tee tgt gcg gcg tet gga ttc agt ttc aga gat tat 96

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Arg Asp Tyr 20 25 30 ggc atg cac tgg gtc ege cag get gca ggc aag ggg ctg gag tgg gtg 144

Gly Met His Trp Val Arg Gin Ala Ala Gly Lys Gly Leu Glu Trp Val 35 40 45 gca ttt ata tgg cct cat gga gta aat agg ttt tat gca gac tea atg 192

Ala Phe Ile Trp Pro His Gly Val Asn Arg Phe Tyr Ala Asp Ser Met 50 55 60 gag ggc cga ttc acc ate tee aga gac gat tee aag aat atg ttg tat 240

Glu Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Leu Tyr 65 70 75 80 eta gaa atg aat aat ctg aga acc gaa gac aeg get eta tat tac tgt 288

Leu Glu Met Asn Asn Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 aca aga gat caa gac tat gtc cég aga aag tac ttc gat ett tgg ggc 336

Thr Arg Asp Gin Asp Tyr Val Pro Arg Lys Tyr Phe Asp Leu Trp Gly 100 105 110 egt ggc acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc ace gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc atc age aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 ctc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 119 <211> 451 <212> PRT <213> Homo sapiens <400> 119

Glu Val Gin Leu Val Glu Thr Gly Gly Val Ala Val Gin Pro Gly Arg 15 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Arg Asp Tyr 20 25 30

Gly Met His Trp Val Arg Gin Ala Ala Gly Lys Gly Leu Glu Trp Val 35 40 45

Ala Phe lie Trp Pro His Gly Val Asn Arg Phe Tyr Ala Asp Ser Met 50 55 60

Glu Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Leu Tyr 65 70 75 80

Leu Glu Met Asn Asn Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95

Thr Arg Asp Gin Asp Tyr Val Pro Arg Lys Tyr Phe Asp Leu Trp Gly 100 105 110

Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140

Ala Leu Gly Cys Leu Val Ly^s Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 120 <211 > 1377

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1377) <400> 120 cag gtg cag ctg cag gag teg ggc ccg aga ctg gtg aag cct teg gag 48

Gin Val Gin Leu Gin Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu 15 10 15 acc ctg tcc etc act tgc aat gtc tet gat gac tee ate aeg agt tat 96

Thr Leu Ser Leu Thr Cys Aen Val Ser Asp Asp Ser Ile Ihr Ser Tyr 20 25 30 ggt tac tat tgg ggc tgg atc ege cag ccc cca ggg gag gca ctg gag 144

Gly Tyr Tyr Trp Gly Trp Ile Arg Gin Pro Pro Gly Glu Ala Leu Glu 35 40 45 tgg att ggc aat gtc ttt tac agt ggc atg get tat tac aac ccg tcc 192

Trp Ile Gly Asn Val Phe Tyr Ser Gly Met Ala Tyr Tyr Asn Pro Ser 50 55 60 etc aag agt ega gtc acc ata tta ata gac aca teg aag aaa cag ttt 240

Leu Lys Ser Arg Val Thr Ile Leu Ile Asp Thr Ser Lys Lys Gin Phe 65 70 75 80 tcc ctg aga etc aac tee gtg acc gee geg gac aeg gcc att tat tac 288

Ser Leu Arg Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr 85 90 95 tgt geg aga gtg ccc ttt ctg atg ttt aga gtg aaa att gta cag ggg 336

Cys Ala Arg Val Pro Phe Leu Met Phe Arg Val Lys Ile Val Gin Gly 100 105 110 aeg ggt get ttt gat atc tgg ggc caa ggg aca atg gtc acc gtc teg 384

Thr Gly Ala Phe Asp Ile Trp Gly Gin Gly Thr Met Val Thr Val Ser 115 120 125 agt get age acc aag ggc ccc age gtg ttc ccc ctg gee ccc age age 432

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 130 135 140 aag age acc age ggc ggc aca gcc gcc ctg ggc tgc ctg gtg aag gac 480

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 145 150 155 160 tac ttc ccc gag ccc gtg acc gtg age tgg aac age ggc gcc ttg acc 528

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 165 170 175 age ggc gtg cac acc ttc ccc gcc gtg ctg cag age age ggc ctg tac 576

Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr 180 185 190 age ctg age age gtg gtg acc gtg ccc age age age ctg ggc acc cag 624

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin 195 200 205 acc tac ate tgc aac gtg aac cac aag ccc age aac acc aag gtg gac 672

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 210 215 220 aaa ege gtg gag ccc aag age tgc gac aag acc cac acc tgc ccc ccc 720

Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 225 230 235 240 tgc cct gcc ccc gag ctg ctg ggc gga ccc tcc gtg ttc ctg ttc ccc 768

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 245 250 255 ccc aag ccc aag gac acc etc atg ate age egg acc ccc gag gtg acc 816

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 260 265 270 tgc gtg gtg gtg gac gtg age cac gag gac ccc gag gtg aag ttc aac 864

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 275 280 285 tgg tac gtg gac ggc gtg gag gtg cac aac gee aag acc aag ccc egg 912

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 290 295 300 gag gag cag tac aac age acc tac egg gtg gtg age gtg etc acc gtg 960

Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 305 310 315 320 ctg cac cag gac tgg ctg aac ggc aag gag tac aag tgc aag gtg age 1008

Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 325 330 335 aac aag gee ctg cet gee ccc ate gag aag acc ate age aag gee aag 1056

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 340 345 350 ggc cag ccc egg gag ccc cag gtg tac acc ctg ccc ccc age egg gag 1104

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 355 360 365 gag atg acc aag aac cag gtg tee etc acc tgt ctg gtg aag ggc ttc 1152

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 370 375 380 tac ccc age gac ate gee gtg gag tgg gag age aac ggc cag ccc gag 1200

Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 385 390 395 400 aac aac tac aag acc acc ccc cet gtg ctg gac age gac ggc age ttc 1248

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 405 410 415 ttc ctg tac age aag etc acc gtg gac aag age egg tgg cag cag ggc 1296

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 420 425 430 aac gtg ttc age tgc age gtg atg cac gag gee ctg cac aac cac tac 1344

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 435 440 445 acc cag aag age ctg age ctg age ccc ggc aag 1377

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 121 <211 >459

<212> PRT <213> Homo sapiens <400 121

Gin Val Gin Leu Gin Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu 15 10 15

Thr Leu Ser Leu Thr Cys Asn Val Ser Asp Asp Ser Ile Thr Ser Tyr 20 25 30

Gly Tyr Tyr Trp Gly Trp Ile Arg Gin Pro Pro Gly Glu Ala Leu Glu 35 40 45

Trp Ile Gly Asn Val Phe Tyr Ser Gly Met Ala Tyr Tyr Asn Pro Ser 50 55 60

Leu Lys Ser Arg Val Thr Ile Leu Ile Asp Thr Ser Lys Lys Gin Phe 65 70 75 80

Ser Leu Arg Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr 85 90 95

Cys Ala Arg Val Pro Phe Leu Met Phe Arg Val Lys Ile Val Gin Gly 100 105 110

Thr Gly Ala Phe Asp Ile Trp Gly Gin Gly Thr Met Val Thr Val Ser 115 120 125

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 130 135 140

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 145 150 155 160

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 165 170 175

Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr 180 185 190

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin 195 200 205

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 210 215 220

Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 225 230 235 240

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 245 250 255

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 260 265 270

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 275 280 285

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 290 295 300

Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 305 310 315 320

Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 325 330 335

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 340 345 350

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 355 360 365

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 370 375 380

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 385 390 395 400

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 405 410 415

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 420 425 430

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 435 440 445

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455

<210> 122 <211>1350 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1350) <400> 122 gag gtg cag ctg gtg gag tct ggg gga gac ttg gta cag ccg ggg ggg 48

Glu Val Gin Leu Val Glu Ser Gly Gly Asp Leu Val Gin Pro Gly Gly 1 5 10 15 tcc ctg cga etc tcc tgt gta ggc tct gga ttc acc ttt ggc ege tat 96

Ser Leu Arg Leu Ser Cys Val Gly Ser Gly Phe Thr Phe Gly Arg Tyr 20 25 30 gcc atg agt tgg gtc ege cag get cca ggg aag ggg ctg gag tgg gtc 144

Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 geg tct att aac aat aat gga aat cca tac tac gca gac tcc gtg aag 192

Ala Ser Ile Asn Asn Asn Gly Asn Pro Tyr Tyr Ala Asp Ser Val Lys 50 55 60 ggc cga ttc acc ate tcc gca gac aat tcc aag age aca gtt tat ctg 240

Gly Arg Phe Thr Ile Ser Ala Asp Asn Ser Lys Ser Thr Val Tyr Leu 65 70 75 80 caa atg aat agc ctg aga gcc gaa gac aeg gcc atg tat tac tgt geg 288

Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95 aaa gac cac tat agc agt ggc tgg ccc geg ttt gac cac tgg ggc cag 336

Lys Asp His Tyr Ser Ser Gly Trp Pro Ala Phe Asp His Trp Gly Gin 100 105 110 gga acc ctg gtc acc gtc teg agt get agc acc aag ggc ccc agc gtg 384

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 ttc ccc ctg gcc ccc agc agc aag agc acc agc ggc ggc aca gcc gcc 432

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg agc 480

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 tgg aac agc ggc gcc ttg acc agc ggc gtg cac acc ttc ccc gcc gtg 528

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 ctg cag agc agc ggc ctg tac agc ctg agc agc gtg gtg acc gtg ccc 576

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 agc agc agc ctg ggc acc cag acc tac atc tgc aac gtg aac cac aag 624

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 ccc agc aac acc aag gtg gac aaa ege gtg gag ccc aag agc tgc gac 672

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 aag acc cac acc tgc ccc ccc tgc cct gcc ccc gag ctg ctg ggc gga 720

Lys Thr His Ihr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc ctc atg atc 768

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag 816

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac 864

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 aac gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac egg 912

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300 gtg gtg agc gtg ctc acc gtg ctg cac cag gac tgg ctg aac ggc aag 960

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320 gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc gag 1008

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 aag acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac 1056

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350 acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc ctc 1104

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365 acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg 1152

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg 1200

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac 1248

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac 1296

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc ccc 1344

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445 ggc aag 1350

Gly Lys 450 <210 123 <211> 450 <212> PRT <213> Homo sapiens <400 123

Glu Val Gin Leu Val Glu Ser Gly Gly Asp Leu Val Gin Pro Gly Gly 1 5 10 15

Ser Leu Arg Leu Ser Cys Val Gly Ser Gly Phe Thr Phe Gly Arg Tyr 20 25 30

Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Ala Ser Ile Asn Asn Asn Gly Asn Pro Tyr Tyr Ala Asp Ser Val Lys 50 55 60

Gly Arg Phe Thr Ile Ser Ala Asp Asn Ser Lys Ser Thr Val Tyr Leu 65 70 75 80

Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95

Lys Asp His Tyr Ser Ser Gly Trp Pro Ala Phe Asp His Trp Gly Gin 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Alá 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380

Glu Ser Asn Gly7 Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445

Gly Lys 450 <210 124 <211> 1344 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1344) <400> 124 gag gtg cag ctg gtg gag tct gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ihr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tec ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg agg tac agt aac tec caa ggt atg gac gtc tgg ggc caa ggg acc 336

Ala Arg Tyr Ser Asn Ser Gin Gly Met Asp Val Trp Gly Gin Gly Thr 100 105 110 aeg gtc acc gtc teg agt get age acc aag ggc ccc age gtg ttc ccc 384

Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 ctg gee ccc age age aag age acc age ggc ggc aca gee gee ctg ggc 432

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg aac 480

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg ctg cag 528

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175 age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age 576

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age 624

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lye Pro Ser 195 200 205 aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc 672

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 cac acc tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc gga ccc tcc 720

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg 768

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc 816

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gee 864

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 aag acc aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg S12

Lys Ihr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac 960

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 aag tgc aag gtg age aac aag gee ctg cet gee ccc ate gag aag acc 1008

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 325 330 335 ate age aag gee aag ggc cag ccc egg gag ccc cag gtg tac acc ctg 1056

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350 ccc ccc age egg gag gag atg acc aag aac cag gtg tcc etc acc tgt 1104

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365 ctg gtg aag ggc ttc tac ccc age gac ate gee gtg gag tgg gag age 1152

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 aac ggc cag ccc gag aac aac tac aag acc acc ccc cet gtg ctg gac 1200

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 age gac ggc age ttc ttc ctg tac age aag etc acc gtg gac aag age 1248

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac gag gcc 1296

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 ctg cac aac cac tac acc cag aag agc ctg agc ctg agc ccc ggc aag 1344

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 125 <211> 448 <212> PRT <213> Homo sapiens <400> 125

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ihr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Tyr Ser Asn Ser Gin Gly Met Asp Val Trp Gly Gin Gly Thr 100 105 110

Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly’· Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380

Aon Gly Gin Pro Glu Asn Aon Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210 126 <211 > 1356 <212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(1356) <400> 126 cag gtc cag ctg gta cag tct gga gca gag gtg aaa aag ccg ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct aga tac age tct acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Arg Tyr Ser Ser Thr Ser Tyr 20 25 30 tgg atc ggc tgg gtg ege cag atg ccc ggg gaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Glu Gly Leu Glu Trp Met 35 40 45 ggg atc atc tat cet ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc atc tea gcc gac aag tcc atc age acc gcc tac 240

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg agt agc ctg aag gcc teg gac agc gcc tta tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Ser Ala Leu Tyr Tyr Cys 85 90 95 geg aga ggg gcc gtg get gga aeg gtc ggc aat ggt ttt gat gtc tgg 336

Ala Arg Gly Ala Val Ala Gly Thr Val Gly Asn Gly Phe Asp Val Trp 100 105 110 ggc caa ggg aca atg gtc acc gtc teg agt get agc acc aag ggc ccc 384

Gly Gin Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 agc gtg ttc ccc ctg gcc ccc agc agc aag agc acc agc ggc ggc aca 432

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 gcc gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc 480

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 gtg agc tgg aac agc ggc gcc ttg acc agc ggc gtg cac acc ttc ccc 528

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 gcc gtg ctg cag agc agc ggc ctg tac agc ctg agc agc gtg gtg acc 576

Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 gtg ccc age age age ctg ggc ace cag ace tac ate tgc aac gtg aac 624

Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cvs Asn Val Asn 195 200 205 cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age 672

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 210 215 220 tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg 720

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc 768

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age 816

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag 864

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 gtg cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc 912

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 290 295 300 tac egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac 960

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320 ggc aag gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc 1008

Gly Lys Glu Tyr Lys Cys Lys Val Ser Aon Lys Ala Leu Pro Ala Pro 325 330 335 ate gag aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag 1056

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 340 345 350 gtg tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg 1104

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 355 360 365 tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg 1152

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 gag tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc 1200

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 cct gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc 1248

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 gtg gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg 1296

Val Asp Lys Ser Arg Trp Gin Gin Gly Aon Val Phe Ser Cys Ser Val 420 425 430 atg cac gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg 1344

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 435 440 445 age ccc ggc aag 1356

Ser Pro Gly Lys 450 <210> 127 <211> 452 <212> PRT <213> Homo sapiens <400> 127

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Arg Tyr Ser Ser Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Glu Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Ser Ala Leu Tyr Tyr Cys 85 90 95

Ala Arg Gly Ala Val Ala Gly Thr Val Gly Asn Gly Phe Asp Val Trp 100 105 110

Gly Gin Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175

Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn 195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415

Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 435 440 445

Ser Pro Gly Lys 450 <210> 128 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 128 gag gtg cag ctg gtg gag act gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tee tgt aag ggt tet gga tac age ttt ace age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg gtg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 ggg ate ate tat cet ggt gac tct gat ace aga tac age ccg tee ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc ace ate tea gee gac aag tee ate age ace gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac ace gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ege egt ggt tct ace age tee aeg gac ttt gac tac tgg ggc 336

Ala Arg Arg Arg Gly Ser Thr Ser Ser Thr Asp Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc ace gtc teg agt get age ace aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Alá Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Alá Pro Ile 325 330 335 gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gee ctg cac aac cac tac acc cag aag age ctg age ctg age 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 129 <211 >451 <212> PRT <213> Homo sapiens <400> 129

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Arg Gly Ser Thr Ser Ser Thr Asp Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 130 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 130 cag gtc cag ctg gta cag tct gga gca gag gtg aaa aag ccc ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt agt aca tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate att tat cet ggt gac tct gat acc agg tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gcc gac aag tcc ate age acc gee cac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala His 65 70 75 80 ctg cag tgg age age ctg aag gcc teg gac acc gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg agg cca gga ccc cgt gga tac aac cat ggc ttt gac tac tgg ggc 336

Ala Arg Pro Gly Pro Arg Gly Tyr Asn His Gly Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age ace aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 150 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro He 325 330 335 gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr He Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc cgg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Ihr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc cgg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 131 <211> 451 <212> PRT <213> Homo sapiens <400> 131

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala His 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Pro Gly Pro Arg Gly Tyr Asn His Gly Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 132 <211> 1347

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(1347) <400 132 gag gtg cag ctg gtg gag tct gga gca gag gtg aaa gag ccg ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Glu Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac acc ttt gcc age tat 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Ala Ser Tyr 20 25 30 tgg gtc gcc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Val Ala Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc gtc tea gee gac aag tee ate age ace gee tac 240

Gin Gly Gin Val Thr Val Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga tgg tgg ggc age ttg cat get ttt gat ate tgg ggc caa ggg 336

Ala Arg Trp Trp Gly Ser Leu His Ala Phe Asp Ile Trp Gly Gin Gly 100 105 110 aca atg gtc acc gtc teg agt get age acc aag ggc ccc age gtg ttc 384

Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 ccc ctg gee ccc age age aag age acc age ggc ggc aca gee gcc ctg 432

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg 480

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg ctg 528

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 cag age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age 576

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac aag ccc 624

Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag 672

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 acc cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga ccc 720

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age 768

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac 816

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac 864

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 gee aag acc aag ccc egg gag gag cag tac aac age acc tac egg gtg 912

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 290 295 300 gtg age gtg etc ace gtg ctg cac cag gac tgg ctg aac ggc aag gag 960

Val Ser Val Leu Ihr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc ate gag aag 1008

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac acc 1056

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 340 345 350 ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tcc ctc acc 1104

Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr 355 360 365 tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg gag 1152

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg ctg 1200

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac aag 1248

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac gag 1296

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc ccc ggc 1344

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 aag I347

Lys <210> 133 <211> 449 <212> PRT <213> Homo sapiens <400> 133

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Glu Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Ala Ser Tyr 20 25 30

Trp Val Ala Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Val Ser Alá Asp Lys Ser Ile Ser Thr Alá Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Trp Trp Gly Ser Leu His Ala Phe Asp Ile Trp Gly Gin Gly 100 105 110

Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 290 295 300

Val Ser Val Leu Ihr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 340 345 350

Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr 355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445

Lys <210> 134 <211> 1359

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1359) <40 0> 134 gag gtg cag ctg gtg gag acc gga gca gag gtg caa aag ccc ggg gag 48

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Gin Lys Pro Gly Glu 15 10 15 tct ctg aag ate tee tgt aag ggt tet gga tac acc ttt acc aac tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 tgg ate gee tgg gtg ege cag aag ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Ala Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tet gat acc aga tac age ccg tee ttc 192

Glv lie lie Tyr Pro Gly Asp Ser Asp Ihr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tee ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ega tat tgt act act acc age tgc agt get ggg ttc gac ccc 336

Ala Arg Arg Tyr Cys Thr Thr Thr Ser Cys Ser Ala Gly Phe Asp Pro 100 105 110 tgg ggc cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc 384

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 ccc age gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc 432

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 aca gee gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg 480

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 acc gtg age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc 528

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 ccc gcc gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg 576

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 acc gtg ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg 624

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val 195 200 205 aac cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag 672

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 age tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg 720

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 ctg ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc 768

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 etc atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg 816

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 age cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg 864

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 gag gtg cac aac gcc aag acc aag ccc egg gag gag cag tac aac age 912

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300 acc tac egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg 960

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320 aac ggc aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc 1008

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Alá 325 330 335 ccc ate gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc 1056

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350 cag gtg tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag 1104

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365 gtg tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc 1152

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 gtg gag tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc 1200

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 ccc cet gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc 1248

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 acc gtg gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age 1296

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430 gtg atg cac gag gcc ctg cac aac cac tac acc cag aag age ctg age 1344

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445 ctg age ccc ggc aag 1359

Leu Ser Pro Gly Lys 450 <210> 135 <211> 453 <212> PRT <213> Homo sapiens <400> 135

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Gin Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30

Trp Ile Ala Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Tyr Cys Thr Thr Thr Ser Cys Ser Ala Gly Phe Asp Pro 100 105 110

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Ihr Cys Val Val Val Asp Val 260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445

Leu Ser Pro Gly Lys 450 <210> 136 <211 > 1350

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1350) <400> 136 gag gtg cag ctg gtg gag tct ggg gca gag gtg aaa aag ccg ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt acc aag tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Lys Tyr 20 25 30 tgg ate ggc tgg gtg ege cag aag ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea acc gac aag tec ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Thr Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ctg ggg ggg ggg ata gca gca gca ttt gac tac tgg ggc cag 336

Ala Arg Leu Gly Gly Gly lie Ala Ala Ala Phe Asp Tyr Trp Gly Gin 100 105 110 gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age gtg 384

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee gee 432

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Alá 130 135 140 ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age 480

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gee gtg 528

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc 576

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 age age age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag 624

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac 672

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 aag acc cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga 720

Lys Thr His Ihr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc ctc atg atc 768

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag 816

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac 864

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 aac gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac egg 912

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300 gtg gtg agc gtg ctc acc gtg ctg cac cag gac tgg ctg aac ggc aag 960

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320 gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc gag 1008

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 aag acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac 1056

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350 acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc ctc 1104

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365 acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg 1152

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg 1200

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac 1248

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac 1296

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc ccc 1344

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445 ggc aag 1350

Gly Lys 450 <210 137 <211> 450 <212> PRT <213> Homo sapiens <400> 137

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Lys Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Thr Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Leu Gly Gly Gly He Ala Ala Ala Phe Asp Tyr Trp Gly Gin 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380

Glu Ser Asn Gly7 Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445

Gly Lys 450 <210 138 <211 > 1350 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1350) <400> 138 gag gtg cag ctg gtg gag tcc gga gca gag gtg aaa aag ccg ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tet gga tac acc ttt acc ege tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Arg Tyr 20 25 30 tgg atc ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 gga atc atc tat cet ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 ega ggc cag gtc acc atc tea gcc gac aag tcc atc agc acc gcc tac 240

Arg Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg agc agc ctg aag gcc teg gac acc gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga egt atg ggg get get tct gcc tac ttt gac aac tgg ggc cag 336

Ala Arg Arg Met Gly Ala Ala Ser Ala Tyr Phe Asp Asn Trp Gly Gin 100 105 110 gga acc ctg gtc acc gtc teg agt get agc acc aag ggc ccc agc gtg 384

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 ttc ccc ctg gcc ccc agc agc aag agc acc agc ggc ggc aca gcc gcc 432

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg agc 480

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 tgg aac agc ggc gcc ttg acc agc ggc gtg cac acc ttc ccc gcc gtg 528

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 ctg cag agc agc ggc ctg tac agc ctg agc agc gtg gtg acc gtg ccc 576

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 age age age ctg ggc ace cag ace tac ate tgc aac gtg aac cac aag 624

Ser Ser Ser Leu Gly Thr Gin Ihr Tyr Ile Cys Asn Val Aon Hie Lys 195 200 205 ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac 672

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 aag acc cac acc tgc ccc ccc tgc cct gcc ccc gag ctg ctg ggc gga 720

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc ctc atg atc 768

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg agc cac gag 816

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac 864

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 aac gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac egg 912

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300 gtg gtg agc gtg ctc acc gtg ctg cac cag gac tgg ctg aac ggc aag 960

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320 gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc gag 1008

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 aag acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac 1056

Lys Thr Ile Ser Lys Ala Lys Gly' Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350 acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc ctc 1104

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365 acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg 1152

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg 1200

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac 1248

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac 1296

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg age ccc 1344

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445 ggc aag 1350

Gly Lys 450 <210> 139 <211> 450 <212> PRT <213> Homo sapiens <400> 139

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ihr Phe Ihr Arg Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Arg Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Met Gly Ala Ala Ser Ala Tyr Phe Asp Asn Trp Gly Gin 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445

Gly Lys 450 <210> 140 <211 > 1359 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1359) <400> 140 gag gtg cag ctg gtg gag tct ggg gca gag gtg aaa aag ccg ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac agt ttt acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ihr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gcc gac aag tcc ata age acc gcc tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg acc age ctg aag gcc teg gac acc gcc gtg tat ttc tgt 288

Leu Gin Trp Thr Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Phe Cys 85 90 95 geg aga etc ggc gaa ttc cgt aga act gga aat age tac ttt gac tac 336

Ala Arg Leu Gly Glu Phe Arg Arg Thr Gly Asn Ser Tyr Phe Asp Tyr 100 105 110 tgg ggc cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc 384

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 ccc age gtg ttc ccc ctg gcc ccc age age aag age acc age ggc ggc 432

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 aca gcc gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg 480

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 acc gtg age tgg aac age ggc gee ttg ace age ggc gtg cac ace ttc 528

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 ccc gee gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg 576

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 acc gtg ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg 624

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val 195 200 205 aac cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag 672

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 age tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg 720

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 ctg ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc 768

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 etc atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg 816

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 age cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg 864

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 gag gtg cac aac gee aag acc aag ccc cgg gag gag cag tac aac age 912

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300 acc tac egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg 960

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320 aac ggc aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc 1008

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 ccc ate gag aag acc ate age aag gcc aag ggc cag ccc cgg gag ccc 1056

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350 cag gtg tac acc ctg ccc ccc age cgg gag gag atg acc aag aac cag 1104

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365 gtg tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc 1152

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 gtg gag tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc 1200

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 ccc cet gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc 1248

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 ace gtg gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age 1296

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430 gtg atg cac gag gcc ctg cac aac cac tac acc cag aag age ctg age 1344

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445 ctg age ccc ggc aag 1359

Leu Ser Pro Gly Lys 450 <210> 141 <211> 453 <212> PRT <213> Homo sapiens <400> 141

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Thr Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Phe Cys 85 90 95

Ala Arg Leu Gly Glu Phe Arg Arg Thr Gly Asn Ser Tyr Phe Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Ihr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445

Leu Ser Pro Gly Lys 450 <210> 142 <211 > 1335 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1335) <400> 142 gag gtg cag ctg gtg gag act ggg gga gac ttg gta cag cct ggg ggg 48

Glu Val Gin Leu Val Glu Thr Gly Gly Asp Leu Val Gin Pro Gly Gly 15 10 15 tcc ctg aga etc tcc tgt gca gcc tet gga ttc acc ttt age age tat 96

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 gcc atg ggc tgg gtc ege cag get cca ggg aag ggg ctg gag tgg ett 144

Ala Met Gly Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 teg tac att egg aat gat ggt agt gtc ate tat tac gca gac tet gtg 192

Ser Tyr Ile Arg Asn Asp Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val 50 55 60 aag ggt ega ttc acc atc tcc aga gac aat gcc aag aac tea ctg tat 240

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 ctg caa atg aac age eta aga gcc gag gac aeg get gtg tat tac tgt 288

Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 geg aga aga ggg tac etc gat etc tgg ggc egt gga acc ctg gtc acc 336

Ala Arg Arg Gly Tyr Leu Asp Leu Trp Gly Arg Gly Thr Leu Val Thr 100 105 110 gtc teg agt get age ace aag ggc ccc age gtg ttc ccc ctg gee ccc 384

Val Ser Ser Ala Ser Thr Lye Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125 age age aag age ace age ggc ggc aca gee gee ctg ggc tgc ctg gtg 432

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 aag gac tac ttc ccc gag ccc gtg ace gtg age tgg aac age ggc gcc 480

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Alá 145 150 155 160 ttg ace age ggc gtg cac acc ttc ccc gcc gtg ctg cag age age ggc 528

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly 165 170 175 ctg tac age ctg age age gtg gtg acc gtg ccc age age age ctg ggc 576

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190 acc cag acc tac ate tgc aac gtg aac cac aag ccc age aac acc aag 624

Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205 gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc cac acc tgc 672

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220 ccc ccc tgc cet gee ccc gag ctg ctg ggc gga ccc tcc gtg ttc ctg 720

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 ttc ccc ccc aag ccc aag gac acc etc atg ate age egg acc ccc gag 768

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc gag gtg aag 816

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270 ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gcc aag acc aag 864

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 ccc egg gag gag cag tac aac age acc tac egg gtg gtg age gtg etc 912

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac aag tgc aag S60

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 gtg age aac aag gcc ctg cet gee ccc ate gag aag acc ate age aag 1008

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 325 330 335 gee aag ggc cag ccc cgg gag ccc cag gtg tac acc ctg ccc ccc age 1056

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 340 345 350 egg gag gag atg acc aag aac cag gtg tee etc ace tgt ctg gtg aag 1104

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 355 360 365 ggc ttc tac ccc age gac ate gee gtg gag tgg gag agc aac ggc cag 1152

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380 ccc gag aac aac tac aag acc acc ccc cct gtg ctg gac agc gac ggc 1200

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 agc ttc ttc ctg tac agc aag ctc acc gtg gac aag agc egg tgg cag 1248

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 405 410 415 cag ggc aac gtg ttc agc tgc agc gtg atg cac gag gcc ctg cac aac 1296

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 cac tac acc cag aag agc ctg agc ctg agc ccc ggc aag 1335

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 143 <211 >445 <212> PRT <213> Homo sapiens <400> 143

Glu Val Gin Leu Val Glu Thr Gly Gly Asp Leu Val Gin Pro Gly Gly 15 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30

Ala Met Gly Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Ser Tyr Ile Arg Asn Asp Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80

Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Arg Gly Tyr Leu Asp Leu Trp Gly Arg Gly Thr Leu Val Thr 100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly 165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190

Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 355 360 365

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 405 410 415

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 144 <211 > 1350 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1350) <400> 144 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg 48

Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15 tcc ctg aga gtc tcc tgt gca gcc tct gga ttc acg ttt agt age tat 96

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Ihr Phe Ser Ser Tyr 20 25 30 tgg atg acc tgg gtc ege cag get cca gga aag ggg ctg gag tgg gtg 144

Trp Met Thr Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 gcc aac ata aag aaa gat gga agt gag aaa tat tat gtg gac tct gtg 192

Ala Asn Ile Lys Lys Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 aag ggc ega ttc agc atc tcc aga gac aac gcc aag gat tea ctg tat 240

Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asp Ser Leu Tyr 65 70 75 80 ctg caa atg agc agc ctg aga gcc gag gac acg get gtg tat tac tgt 288

Leu Gin Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 geg agg ggg ggc agc agc teg teg ttt tat tgg tgg ctc tgg ggc aaa 336

Ala Arg Gly Gly Ser Ser Ser Ser Phe Tyr Trp Trp Leu Trp Gly Lys 100 105 110 ggg acc acg gtc acc gtc teg agt get age ace aag ggc ccc age gtg 384

Gly Thr Ihr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee gcc 432

Phe Pro Leu Alá Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age 480

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg 528

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc 576

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 age age age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag 624

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac 672

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 aag acc cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga 720

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg atc 768

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag 816

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac 864

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac egg 912

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300 gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag 960

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320 gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc atc gag 1008

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag gtg tac 1056

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350 acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tee etc 1104

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365 acc tgt ctg gtg aag ggc ttc tac ccc age gac ate gcc gtg gag tgg 1152

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cet gtg 1200

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg gac 1248

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac 1296

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg age ccc 1344

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445 ggc aag 1350

Gly Lys 450 <210> 145 <211> 450 <212> PRT <213> Homo sapiens <400> 145

Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30

Trp Met Thr Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Ala Asn Ile Lys Lys Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60

Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asp Ser Leu Tyr 65 70 75 80

Leu Gin Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Gly Ser Ser Ser Ser Phe Tyr Irp Trp Leu Trp Gly Lys 100 105 110

Gly Thr Thr Val Thr Val Ser Ser Alá Ser Thr Lys Gly Pro Ser Val 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Alá 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá Val 165 170 175

Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190

Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr 340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380

Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415

Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro 435 440 445

Gly Lys 450 <210> 146 <211 > 1353

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 146 cag gtc cag ctg gtg cag tct gga gca gag gtg aaa aag ccg ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tee ate age ace gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ege get agt ata gtg gga get acc cac ttt gac tac tgg ggc 336

Ala Arg Arg Ala Ser Ile Val Gly Ala Thr His Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc ace gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc atc age aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 ctc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 147 <211> 451 <212> PRT <213> Homo sapiens <400> 147

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Alá Asp Lys Ser Ile Ser Thr Alá Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Ala Ser Ile Val Gly Ala Thr His Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Ihr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 148 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 148 gag gtg cag ctg gtg gag act ggg gga ggc ttg gtt caa cct ggg ggg 4g

Glu Val Gin Leu Val Glu Thr Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15 tcc ctg aga etc tcc tgt tea gee tet gga ttc acc ttt age aac tat 96

Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 gcc atg agt tgg gtc cgc cag get cca ggg aag ggg ctg gag tgg gtc 144

Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 tea ggt ate agt ggt agt ggt ggt agg aca tac tac gca gac tee gtg 192

Ser Gly Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55 60 aag ggc egg ttc ace ate tee aga gac aat tee aag aac aeg ctg tat 240

Lys Gly Arg Phe Ihr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 ctg caa atg aac age ctg gga gcc gac gac aeg gcc gta tat tac tgt 288

Leu Gin Met Asn Ser Leu Gly Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 SO 95 geg aaa ggg gta agg geg gga gtc ccg tat tat ttt gac tet tgg ggc 336

Ala Lys Gly Val Arg Ala Gly Val Pro Tyr Tyr Phe Asp Ser Trp Gly 100 105 110 cag gga ace ctg gtc acc gtc teg agt get age ace aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gcc ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

He Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gcc aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cct gee ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg age 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 149 <211> 451

<212> PRT <213> Homo sapiens <400> 149

Glu Val Gin Leu Val Glu Thr Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15

Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30

Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Ser Gly Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80

Leu Gin Met Asn Ser Leu Gly Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Lys Gly Val Arg Ala Gly Val Pro Tyr Tyr Phe Asp Ser Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 150 <211> 1368

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1368) <400> 150 gag gtc cag ctg gta cag tct gga gca gag gtg aaa aag ccg ggg gag 48

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag get tct gga tac agt ttt ace age tac 96

Ser Leu Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 gga ate ate tat ccc ggt gac tct gat ace aga tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc ate ate tea gcc gac aag tcc ate age acc gee tac 240

Gin Gly Gin Val lie lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gcc teg gac acc gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ttt aag aag age tea get get agg ggc tac tac tac tac tac 336

Ala Arg Phe Lys Lys Ser Ser Ala Ala Arg Gly Tyr Tyr Tyr Tyr Tyr 100 105 110 atg gac gtc tgg ggc aaa ggg acc aeg gtc acc gtc teg agt get age 384

Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser 115 120 125 acc aag ggc ccc age gtg ttc ccc ctg gcc ccc age age aag age acc 432

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 age ggc ggc aca gcc gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc 480

Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 gag ccc gtg acc gtg age tgg aac age ggc gee ttg acc age ggc gtg 528

Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 cac acc ttc ccc gcc gtg ctg cag age age ggc ctg tac age ctg age 576

His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 age gtg gtg acc gtg ccc age age age ctg ggc acc cag acc tac atc 624

Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile 195 200 205 tgc aac gtg aac cac aag ccc age aac acc aag gtg gac aaa ege gtg 672

Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 210 215 220 gag ccc aag age tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc 720

Glu Pro Lys Ser Cys Asp Lys Ihr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 ccc gag ctg ctg ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc 768

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 aag gac acc etc atg ate age egg ace ccc gag gtg acc tgc gtg gtg 816

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 gtg gac gtg age cac gag gac ccc gag gtg aag ttc aac tgg tac gtg 864

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 gac ggc gtg gag gtg cac aac gcc aag acc aag ccc egg gag gag cag 912

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 290 295 300 tac aac age acc tac egg gtg gtg age gtg etc acc gtg ctg cac cag 960

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 305 310 315 320 gac tgg ctg aac ggc aag gag tac aag tgc aag gtg age aac aag gcc 1008

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 ctg cct gcc ccc ate gag aag acc ate age aag gcc aag ggc cag ccc 1056

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 340 345 350 egg gag ccc cag gtg tac acc ctg ccc ccc age egg gag gag atg acc 1104

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 aag aac cag gtg tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age 1152

Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly' Phe Tyr Pro Ser 370 375 380 gac ate gcc gtg gag tgg gag age aac ggc cag ccc gag aac aac tac 1200

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 385 390 395 400 aag acc acc ccc cet gtg ctg gac age gac ggc age ttc ttc ctg tac 1248

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 age aag etc acc gtg gac aag age egg tgg cag cag ggc aac gtg ttc 1296

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 420 425 430 age tgc age gtg atg cac gag gcc ctg cac aac cac tac acc cag aag 1344

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 435 440 445 age ctg age ctg age ccc ggc aag 1368

Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210 151 <211> 456 <212> PRT <213> Homo sapiens <400> 151

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Ile Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Phe Lys Lys Ser Ser Ala Ala Arg Gly Tyr Tyr Tyr Tyr Tyr 100 105 110

Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser 115 120 125

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140

Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160

Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175

His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190

Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile 195 200 205

Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 210 215 220

Glu Pro Lys Ser Cys Asp Lys Ihr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 290 295 300

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 305 310 315 320

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 340 345 350

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365

Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 385 390 395 400

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 420 425 430

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 435 440 445

Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 152 <211> 1347 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1347) <400> 152 gag gtc cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tcc gga tac acc ttt age age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ccg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Pro Glu Trp Met 35 40 45 ggg ate ate tat cca ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac agg tcc ate age acc gee tat 240

Gin Gly Gin Val Thr lie Ser Ala Asp Arg Ser Ile Ser Thr Ala Tyr 65 70 75 80 ttg cag tgg age age ctg aag gee teg gac acc gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Alá Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 gcg aga ett aat aca gtt atg gtt ggt ttg gac tac tgg ggc cag gga 336

Ala Arg Leu Asn Thr Val Met Val Gly Leu Asp Tyr Trp Gly Gin Gly 100 105 110 acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age gtg ttc 384

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 ccc ctg gee ccc age age aag age acc age ggc ggc aca gcc gcc ctg 432

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg 480

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg ctg 528

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 cag age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age 576

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 age age ctg ggc ace cag ace tac ate tgc aac gtg aac cac aag ccc 624

Ser Ser Leu Gly Ihr Gin Thr Tyr Ile Cys Aon Val Asn Hin Lyn Pro 195 200 205 agc aac acc aag gtg gac aaa ege gtg gag ccc aag agc tgc gac aag 672

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 acc cac acc tgc ccc ccc tgc cct gcc ccc gag ctg ctg ggc gga ccc 720

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc ctc atg atc agc 768

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg agc cac gag gac 816

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac 864

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac egg gtg 912

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 290 295 300 gtg agc gtg ctc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag 960

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc gag aag 1008

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac acc 1056

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 340 345 350 ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc ctc acc 1104

Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr 355 360 365 tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg gag 1152

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg ctg 1200

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac aag 1248

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac gag 1296

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 gcc ctg cac aac cac tac acc cag aag age ctg age ctg age ccc ggc 1344

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 aag 1347

Lys <210> 153 <211> 449 <212> PRT <213> Homo sapiens <400> 153

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ihr Phe Ser Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Pro Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Arg Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Leu Asn Thr Val Met Val Gly Leu Asp Tyr Trp Gly Gin Gly 100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Ihr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 290 295 300

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 340 345 350

Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr 355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445

Lys <210> 154 <211 > 1341 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1341) <400> 154 cag gtg cag ctg cag gag teg ggg gga ggc gtg gtc cag cet ggg agg 48

Gin Val Gin Leu Gin Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 tcc ctg aga etc tee tgt gca gee tet gga ttc ace ttc agt age tat 96

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 ggc atg cac tgg gtc ege cag get cca ggc aag ggg ctg gag tgg gtg 144

Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 gca gtt ata tea tat gat gga agt aat aaa tac tat gca gac tec gtg 192

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 aag ggc ega ttc acc ate tec aga gac aat tec aag aac aeg ctg tat 240

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 ctg caa atg aac age ctg aga get gag gac aeg get gtg tat tac tgt 288

Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 geg aaa aat gga geg aac get ttt gat ate tgg ggc caa ggg aca atg 336

Ala Lys Asn Gly Ala Asn Ala Phe Asp lie Trp Gly Gin Gly Thr Met 100 105 110 gtc acc gtc teg agt get age acc aag ggc ccc age gtg ttc ccc ctg 384

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 gee ccc age age aag age acc age ggc ggc aca gee gee ctg ggc tgc 432

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg aac age 480

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser

145 150 155 ISO ggc gcc ttg acc age ggc gtg cac acc ttc ccc gee gtg ctg cag age 528

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser 165 170 175 age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age age 576

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age aac 624

Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc cac 672

Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 acc tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc gga ccc tcc gtg 720

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 225 230 235 240 ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg acc 768

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc gag 816

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gcc aag 864

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Alá Lys 275 280 285 acc aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg age 912

Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac aag 960

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 tgc aag gtg age aac aag gcc ctg cet gee ccc ate gag aag acc atc 1008

Cys Lys Val Ser Asn Lys Ala Leu Pro Alá Pro Ile Glu Lys Thr Ile 325 330 335 age aag gee aag ggc cag ccc egg gag ccc cag gtg tac acc ctg ccc 1056

Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 340 345 350 ccc age egg gag gag atg acc aag aac cag gtg tec etc acc tgt ctg 1104

Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 355 360 365 gtg aag ggc ttc tac ccc age gac ate gee gtg gag tgg gag age aac 1152

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 ggc cag ccc gag aac aac tac aag acc acc ccc cet gtg ctg gac age 1200

Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 gac ggc age ttc ttc ctg tac age aag etc acc gtg gac aag age egg 1248

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 tgg cag cag ggc aac gtg ttc age tgc age gtg atg cac gag gcc ctg 1296

Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 cac aac cac tac acc cag aag age ctg age ctg age ccc ggc aag 1341

His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 155 <211> 447 <212> PRT <213> Homo sapiens <400> 155

Gin Val Gin Leu Gin Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30

Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80

Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Lys Asn Gly Ala Asn Ala Phe Asp Ile Trp Gly Gin Gly Thr Met 100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser 165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190

Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205

Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285

Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335

Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 340 345 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380

Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415

Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430

His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 156 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 156 gag gtg cag ctg gtg gag tcc gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tet gga tac age ttc acc age tac 96

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ihr Ser Tyr 20 25 30 tgg ate ggc tgg gtg ege cag ttg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Leu Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tcc acc age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ege egt ggt tct acc age tcc aeg gac ttt gac tac tgg ggc 336

Ala Arg Arg Arg Gly Ser Thr Ser Ser Thr Asp Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Alá Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Alá Pro Ile 325 330 335 gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gee ctg cac aac cac tac acc cag aag age ctg age ctg age 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 157 <211 >451 <212> PRT <213> Homo sapiens <400> 157

Glu Val Gin Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Leu Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Arg Gly Ser Thr Ser Ser Thr Asp Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 158 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 158 cag gtg cag ctg gtg caa tct gga gca gag gtg aaa aag tcc ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Ser Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt ttt gga tac age ttt acc age cag 96

Ser Leu Lys lie Ser Cys Lys Gly Phe Gly Tyr Ser Phe Thr Ser Gin 20 25 30 tgg ate gtc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Val Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tcc ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gcc gac agg tcc ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Arg Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gcc tcc gac aac gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Alá Ser Asp Asn Ala Met Tyr Tyr Cys 85 90 95 gcg agg gcc ctg egg ggg tat age age teg tcc ttt ggc tac tgg ggc 336

Ala Arg Ala Leu Arg Gly Tyr Ser Ser Ser Ser Phe Gly Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age ace aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 150 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro He 325 330 335 gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr He Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc cgg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Ihr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc cgg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 159 <211> 451 <212> PRT <213> Homo sapiens <400> 159

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Ser Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Phe Gly Tyr Ser Phe Thr Ser Gin 20 25 30

Trp Ile Val Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Arg Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Asn Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Ala Leu Arg Gly Tyr Ser Ser Ser Ser Phe Gly Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 160 <211> 1344 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1344) <400> 160 gag gtc cag ctg gtg cag tct ggg get gag gtg aag aag cct ggg gee 48

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 15 10 15 tea gtg aag gtt tee tgc aag gca tct gga tac ace ttc age aac tac 96

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asn Tyr 20 25 30 tat atg cac tgg gtg ega cag gee cct gga caa ggg ett gag tgg atg 144

Tyr Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met 35 40 45 gga ata ate aac cct agt ggt ggt age aca agt tac gca cag aag ttt 192

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60 cag ggc aga ttc acc gtg acc agg gac acg tcc acg age aca gtc tac 240

Gin Gly Arg Phe Ihr Val Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 atg gag ctg age age ctg aga tet gag gac acg gee gtg tat tac tgt 288

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 geg act ega ege ggg cag egg tac ttc cag cac tgg ggc cag ggc acc 336

Ala Thr Arg Arg Gly Gin Arg Tyr Phe Gin His Trp Gly Gin Gly Thr 100 105 110 ctg gtc act gtc teg agt get age acc aag ggc ccc age gtg ttc ccc 384

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 ctg gee ccc age age aag age acc age ggc ggc aca gee gcc ctg ggc 432

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg aac 480

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg ctg cag 528

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175 age age ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age 576

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 age ctg ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age 624

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc 672

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc gga ccc tcc 720

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg 768

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc 816

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gcc 864

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 aag acc aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg S12

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac 960

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 aag tgc aag gtg age aac aag gcc ctg cct gcc ccc ate gag aag acc 1008

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 ate agc aag gcc aag ggc cag ccc egg gag ccc cag gtg tac acc ctg 1056

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350 ccc ccc age egg gag gag atg acc aag aac cag gtg tcc ctc acc tgt 1104

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365 ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag tgg gag agc 1152

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 aac ggc cag ccc gag aac aac tac aag acc acc ccc cct gtg ctg gac 1200

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg gac aag agc 1248

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg cac gag gcc 1296

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 ctg cac aac cac tac acc cag aag agc ctg agc ctg agc ccc ggc aag 1344

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 161 <211> 448 <212> PRT <213> Homo sapiens <400> 161

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 15 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asn Tyr 20 25 30

Tyr Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Phe Thr Val Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Thr Arg Arg Gly Gin Arg Tyr Phe Gin His Trp Gly Gin Gly Thr 100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Ihr 325 330 335

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 162 <211>1353

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 162 cag gta cag ctg cag cag tea ggt cca gga ctg gtg aag ccc teg cag 48

Gin Val Gin Leu Gin Gin Ser Gly Pro Gly Leu Val Lys Pro Ser Gin 15 10 15 ace etc tea etc acc tgt gee ate tcc gga gac agt gtc tet age aac 96

Thr Leu Ser Leu Thr Cys Ala lie Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 aga get get tgg aac tgg ate agg cag tcc cca teg aga ggc ett gag 144

Arg Ala Ala Trp Asn Trp Ile Arg Gin Ser Pro Ser Arg Gly Leu Glu 35 40 45 tgg ctg gga agg aca tac tac agg tcc aag tgg tat aat gat tat gca 192

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60 gta tct gtg aaa agt cga ata age ate aac cca gac gca ttg aag aac 240

Val Ser Val Lys Ser Arg Ile 3er Ile Asn Pro Asp Ala Leu Lys Asn 65 70 75 80 cag ttc tcc ctg cag ctg aac tct gtg act ccc gag gac aeg get gtg 288

Gin Phe Ser Leu Gin Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 tat tac tgt gca aga gat act ggc tgg tac cga ttt gac tcc tgg ggc 336

Tyr Tyr Cys Ala Arg Asp Thr Gly Trp Tyr Arg Phe Asp Ser Trp Gly 100 105 110 cag gga ace ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gcc ccc age age aag age acc agc ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc agc agc agc ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc agc aac acc aag gtg gac aaa ege gtg gag ccc aag agc tgc 672

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc ctc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 atc agc egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg agc cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc ace gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc atc age aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 ctc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg agc 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 163 <211> 451 <212> PRT <213> Homo sapiens <400> 163

Gin Val Gin Leu Gin Gin Ser Gly Pro Gly Leu Val Lys Pro Ser Gin 15 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30

Arg Ala Ala Trp Asn Trp Ile Arg Gin Ser Pro Ser Arg Gly Leu Glu 35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60

Val Ser Val Lys Ser Arg Ile Ser Ile Asn Pro Asp Ala Leu Lys Asn 65 70 75 80

Gin Phe Ser Leu Gin Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95

Tyr Tyr Cys Ala Arg Asp Thr Gly Trp Tyr Arg Phe Asp Ser Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Ly^s Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 164 <211 > 1353 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1353) <400> 164 gag gtc cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tee tgt aag ggt tet gga tac age ttt ace ace tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg atg ate tat cet ggt gac tct gat ace aga tac age ccg tee ttc 192

Gly Met lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc ace ate tea gee gac aag tee ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 gtg aga ccc etc egg age ggg age tee tac ggt atg gac gtc tgg ggc 336

Val Arg Pro Leu Arg Ser Gly Ser Ser Tyr Gly Met Asp Val Trp Gly 100 105 110 caa ggg acc aeg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc aca gee 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac cac 624

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205 aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age tgc 672

Lys Pro Ser Asn Ihr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 768

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 ate age egg ace ccc gag gtg ace tgc gtg gtg gtg gac gtg age cac 816

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gee aag acc aag ccc egg gag gag cag tac aac age acc tac 912

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg age aac aag gee ctg cet gee ccc ate 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie 325 330 335 gag aag acc ate age aag gee aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg tee 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 etc acc tgt ctg gtg aag ggc ttc tac ccc age gac ate gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc cet 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc gtg 1248

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg age 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 165 <211> 451 <212> PRT <213> Homo sapiens <400 165

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Met Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Val Arg Pro Leu Arg Ser Gly Ser Ser Tyr Gly Met Asp Val Trp Gly 100 105 110

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450

<210> 166 <211> 1359 <212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(1359) <400 166 gag gtg cag ctg gtg gag acc gga gca gag gtg caa aag ccc ggg gag 48

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Gin Lys Pro Gly Glu 15 10 15 tct ctg aag ate tee tgt aag ggt tet gga tac acc ttt acc aac tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 tgg ate gee tgg gtg ege cag aag ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Ala Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tee ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gee gac aag tee ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ega tat tgt act act acc age tgc agt get ggg ttc gac ccc 336

Ala Arg Arg Tyr Cys Thr Thr Thr Ser Cys Ser Ala Gly Phe Asp Pro 100 105 110 tgg ggc cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc 384

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 ccc age gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc 432

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 aca gee gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg 480

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 acc gtg age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc 528

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 ccc gcc gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg 576

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 acc gtg ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg 624

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val 195 200 205 aac cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag 672

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 age tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg 720

Ser Cys Asp Lys Ihr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 ctg ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc 768

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 etc atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg 816

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 age cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg 864

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 gag gtg cac aac gcc aag acc aag ccc egg gag gag cag tac aac agc 912

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300 acc tac egg gtg gtg age gtg ctc acc gtg ctg cac cag gac tgg ctg 960

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320 aac ggc aag gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc 1008

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 ccc atc gag aag acc atc agc aag gcc aag ggc cag ccc egg gag ccc 1056

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350 cag gtg tac acc ctg ccc ccc agc egg gag gag atg acc aag aac cag 1104

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365 gtg tcc ctc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc 1152

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 gtg gag tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc 1200

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 ccc cct gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc 1248

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 acc gtg gac aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc 1296

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430 gtg atg cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc 1344

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445 ctg agc ccc ggc aag 1359

Leu Ser Pro Gly Lys 450 <210 167 <211> 453 <212> PRT <213> Homo sapiens <400 167

Glu Val Gin Leu Val Glu Thr Gly Ala Glu Val Gin Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30

Trp Ile Ala Trp Val Arg Gin Lys Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Arg Tyr Cys Thr Thr Thr Ser Cys Ser Ala Gly Phe Asp Pro 100 105 110

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445

Leu Ser Pro Gly Lys 450 <210 168 <211 > 1353 <212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(1353) <400 168 cag gtc cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct ggc tac age ttt acc aac tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30 tgg ate gcc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Ala Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 gga ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gcc gac agg tec ate aac acc gcc tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Arg Ser Ile Asn Thr Ala Tyr 65 70 75 80 eta cag tgg age age ctg aag gcc teg gac acc get atg ttt tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Phe Tyr Cys 85 90 95 geg aga egg etc tat ggt teg ggg aga cca tac ttt gac tac tgg ggc 336

Ala Arg Arg Leu Tyr Gly Ser Gly Arg Pro Tyr Phe Asp Tyr Trp Gly 100 105 110 cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc ccc age 384

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 gtg ttc ccc ctg gcc ccc age age aag age acc age ggc ggc aca gcc 432

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Alá 130 135 140 gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc gtg 480

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 age tgg aac age ggc gee ttg acc age ggc gtg cac acc ttc ccc gcc 528

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Alá 165 170 175 gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc gtg 576

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 ccc age age age ctg ggc ace cag ace tac ate tgc aac gtg aac cac 524

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Aon Val Asn Hie 195 200 205 aag ccc age aac ace aag gtg gac aaa ege gtg gag ccc aag age tgc 572

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 gac aag acc cac acc tgc ccc ccc tgc cct gee ccc gag ctg ctg ggc 720

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc atg 75g

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg agc cac gxg

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag gtg 864

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 cac aac gcc aag acc aag ccc egg gag gag cag tac aac agc acc tac S12

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300 egg gtg gtg agc gtg ctc acc gtg ctg cac cag gac tgg ctg aac ggc 960

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320 aag gag tac aag tgc aag gtg agc aac aag gcc ctg cct gcc ccc atc 1008

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 gag aag acc atc agc aag gcc aag ggc cag ccc egg gag ccc cag gtg 1056

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350 tac acc ctg ccc ccc agc egg gag gag atg acc aag aac cag gtg tcc 1104

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365 ctc acc tgt ctg gtg aag ggc ttc tac ccc agc gac atc gcc gtg gag 1152

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 tgg gag agc aac ggc cag ccc gag aac aac tac aag acc acc ccc cct 1200

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 gtg ctg gac agc gac ggc agc ttc ttc ctg tac agc aag ctc acc gtg 1248

Val Leu Asp Ser Asp Glv Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 gac aag agc egg tgg cag cag ggc aac gtg ttc agc tgc agc gtg atg 1296

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 cac gag gcc ctg cac aac cac tac acc cag aag age ctg age ctg age 1344

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445 ccc ggc aag 1353

Pro Gly Lys 450 <210> 169 <211> 451 <212> PRT <213> Homo sapiens <400> 169

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30

Trp Ile Ala Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Arg Ser Ile Asn Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Phe Tyr Cys 85 90 95

Ala Arg Arg Leu Tyr Gly Ser Gly Arg Pro Tyr Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 435 440 445

Pro Gly Lys 450 <210> 170 <211 > 1356 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1356) <400> 170 gag gtc cag ttg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag 48

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct gga tac age ttt ace aac tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 ggg ate ate tat cet ggt gac tct gat acc aga tac age ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 caa ggc cag gtc acc ate tea gcc gac aag tcc ate age acc gee tac 240

Gin Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gcc teg gac acc gcc atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga cat aeg cag aac aaa aat ggg atg aat act ttt gat ate tgg 336

Ala Arg His Thr Gin Asn Lys Asn Gly Met Asn Thr Phe Asp lie Trp 100 105 110 ggc caa ggg aca atg gtc acc gtc teg agt get age acc aag ggc ccc 384

Gly Gin Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 age gtg ttc ccc ctg gcc ccc age age aag age acc age ggc ggc aca 432

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 gcc gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg acc 480

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 gtg age tgg aac age ggc gee ttg ace age ggc gtg cac ace ttc ccc 528

Val Ser Trp Asn Ser Gly Ala Leu Ihr Ser Gly Val His Thr Phe Pro 165 170 175 gee gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg acc 576

Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 gtg ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg aac 624

Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr île Cys Asn Val Asn 195 200 205 cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag age 672

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 210 215 220 tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg ctg 720

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc etc 768

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg age 816

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg gag 864

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 gtg cac aac gcc aag acc aag ccc egg gag gag cag tac aac age acc 912

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 290 295 300 tac egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg aac 960

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320 ggc aag gag tac aag tgc aag gtg age aac aag gcc ctg cct gcc ccc 1008

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 ate gag aag acc ate age aag gcc aag ggc cag ccc egg gag ccc cag 1056

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 340 345 350 gtg tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag gtg 1104

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 355 360 365 tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age gac atc gcc gtg 1152

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 gag tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc ccc 1200

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 cet gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc acc 1248

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 gtg gac aag age egg tgg cag cag ggc aac gtg ttc age tgc agc gtg 1296

Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val 420 425 430 atg cac gag gcc ctg cac aac cac tac acc cag aag agc ctg agc ctg 1344

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 435 440 445 agc ccc ggc aag 1356

Ser Pro Gly Lys 450 <210> 171 <211> 452 <212> PRT <213> Homo sapiens <400> 171

Glu Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Gin Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg His Thr Gin Asn Lys Asn Gly Met Asn Thr Phe Asp Ile Trp 100 105 110

Gly Gin Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175

Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn 195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415

Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 435 440 445

Ser Pro Gly Lys 450 <210> 172 <211 > 1338 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1338) <400> 172 cag gtg cag eta cag cag tgg ggc gca gga ctg ttg aag cct teg gag 48

Gin Val Gin Leu Gin Gin Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 15 10 15 ace ctg tec etc ace tgc get gtc tat ggt geg tec ttc cgt ggt tac 96

Thr Leu Ser Leu Ihr Cys Ala Val Tyr Gly Ala Ser Phe Arg Gly Tyr 20 25 30 tac tgg age tgg ate ege cag ccc cca ggg aag ggg ctg gag tgg att 144

Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu Trp lie 35 40 45 ggg gaa ate aat cat agt gga age ace aac tac aac ccg tec etc aag 192

Gly Glu lie Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 agt ega gtc acc ata tea gta gac aeg tec aaa aac cag ttc tcc ctg 240

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe Ser Leu 65 70 75 80 aag ctg agt tet gtg acc gcc gca gac aeg get gtg tat tac tgt gcg 288

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 aga ggc ege cct gat tet ttt gat atc tgg ggc caa ggg aca atg gtc 336

Arg Gly Arg Pro Asp Ser Phe Asp Ile Trp Gly Gin Gly Thr Met Val 100 105 110 acc gtc teg agt get age ace aag ggc ccc age gtg ttc ccc ctg gee 334

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 ccc age age aag age acc age ggc ggc aca gee gee ctg ggc tgc ctg 433

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 gtg aag gac tac ttc ccc gag ccc gtg acc gtg age tgg aac age ggc 433

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 gee ttg acc age ggc gtg cac acc ttc ccc gcc gtg ctg cag age age 528

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 165 170 175 ggc ctg tac age ctg age age gtg gtg acc gtg ccc age age age ctg 57g

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 ggc acc cag acc tac ate tgc aac gtg aac cac aag ccc age aac acc 624

Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 aag gtg gac aaa ege gtg gag ccc aag age tgc gac aag acc cac acc 672

Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 tgc ccc ccc tgc cet gee ccc gag ctg ctg ggc gga ccc tcc gtg ttc 720

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 ctg ttc ccc ccc aag ccc aag gac acc etc atg ate age egg acc ccc 768

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 gag gtg acc tgc gtg gtg gtg gac gtg age cac gag gac ccc gag gtg 816

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cac aac gcc aag acc 864

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 aag ccc egg gag gag cag tac aac age acc tac egg gtg gtg age gtg 912

Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 etc acc gtg ctg cac cag gac tgg ctg aac ggc aag gag tac aag tgc 960

Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 aag gtg age aac aag gcc ctg cet gcc ccc ate gag aag acc ate age 1008

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser 325 330 335 aag gcc aag ggc cag ccc egg gag ccc cag gtg tac acc ctg ccc ccc 1056

Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro 340 345 350 age egg gag gag atg ace aag aac cag gtg tee etc ace tgt ctg gtg 1104

Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val 355 360 365 aag ggc ttc tac ccc age gac ate gee gtg gag tgg gag age aac ggc 1152

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 cag ccc gag aac aac tac aag acc acc ccc cet gtg ctg gac age gac 1200

Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 ggc age ttc ttc ctg tac age aag etc acc gtg gac aag age cgg tgg 1248

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 cag cag ggc aac gtg ttc age tgc age gtg atg cac gag gcc ctg cac 1296

Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 aac cac tac acc cag aag age ctg age ctg age ccc ggc aag 1338

Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 173 <211> 446 <212> PRT <213> Homo sapiens <400> 173

Gin Val Gin Leu Gin Gin Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 15 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Ala Ser Phe Arg Gly Tyr 20 25 30

Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45

Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe Ser Leu 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95

Arg Gly Arg Pro Asp Ser Phe Asp Ile Trp Gly Gin Gly Thr Met Val 100 105 110

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 165 170 175

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190

Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205

Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285

Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300

Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335

Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro 340 345 350

Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val 355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380

Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415

Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430

Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 174 <211 > 1359 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(1359) <400> 174 cag gtg cag ctg gtg caa tct gga gca gag gtg aaa aag ccg ggg gag 48

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 15 10 15 tct ctg aag ate tcc tgt aag ggt tct ggt tac age ttt acc aac tac 96

Ser Leu Lys lie Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30 tgg ate ggc tgg gtg ege cag atg ccc ggg aaa ggc ctg gag tgg atg 144

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 gga ate ate tat cet ggt gac tct gat acc aga tac agt ccg tec ttc 192

Gly lie lie Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 ega ggc cag gtc acc ate tea gee gac aag tec ate age acc gee tac 240

Arg Gly Gin Val Thr lie Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 ctg cag tgg age age ctg aag gee teg gac acc gee atg tat tac tgt 288

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 geg aga ett gga tac age tat ggt tac agg ggg cct cac ttt gat tac 336

Ala Arg Leu Gly Tyr Ser Tyr Gly Tyr Arg Gly Pro His Phe Asp Tyr 100 105 110 tgg ggc cag gga acc ctg gtc acc gtc teg agt get age acc aag ggc 384

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 ccc age gtg ttc ccc ctg gee ccc age age aag age acc age ggc ggc 432

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 aca gee gcc ctg ggc tgc ctg gtg aag gac tac ttc ccc gag ccc gtg 480

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 acc gtg age tgg aac age ggc gcc ttg acc age ggc gtg cac acc ttc 528

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 ccc gcc gtg ctg cag age age ggc ctg tac age ctg age age gtg gtg 576

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 acc gtg ccc age age age ctg ggc acc cag acc tac atc tgc aac gtg 624

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val 195 200 205 aac cac aag ccc age aac acc aag gtg gac aaa ege gtg gag ccc aag 672

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 age tgc gac aag acc cac acc tgc ccc ccc tgc cet gcc ccc gag ctg 720

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 ctg ggc gga ccc tcc gtg ttc ctg ttc ccc ccc aag ccc aag gac acc 768

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 etc atg ate age egg acc ccc gag gtg acc tgc gtg gtg gtg gac gtg 816

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 age cac gag gac ccc gag gtg aag ttc aac tgg tac gtg gac ggc gtg 864

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 gag gtg cac aac gee aag acc aag ccc cgg gag gag cag tac aac age 912

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300 acc tac egg gtg gtg age gtg etc acc gtg ctg cac cag gac tgg ctg 960

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320 aac ggc aag gag tac aag tgc aag gtg age aac aag gcc ctg cet gcc 1008

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 ccc ate gag aag acc ate age aag gcc aag ggc cag ccc cgg gag ccc 1056

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350 cag gtg tac acc ctg ccc ccc age egg gag gag atg acc aag aac cag 1104

Gin Val Tyr Ihr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365 gtg tcc etc acc tgt ctg gtg aag ggc ttc tac ccc age gac ate gcc 1152

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 gtg gag tgg gag age aac ggc cag ccc gag aac aac tac aag acc acc 1200

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 ccc cet gtg ctg gac age gac ggc age ttc ttc ctg tac age aag etc 1248

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 acc gtg gac aag age egg tgg cag cag ggc aac gtg ttc age tgc age 1296

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430 gtg atg cac gag gcc ctg cac aac cac tac acc cag aag age ctg age 1344

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445 ctg age ccc ggc aag 1359

Leu Ser Pro Gly Lys 450 <210> 175 <211> 453 <212> PRT <213> Homo sapiens <400> 175

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30

Trp Ile Gly Trp Val Arg Gin Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60

Arg Gly Gin Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80

Leu Gin Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95

Ala Arg Leu Gly Tyr Ser Tyr Gly Tyr Arg Gly Pro His Phe Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 340 345 350

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 435 440 445

Leu Ser Pro Gly Lys 450 <210> 176 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 176 caa tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc agt aag egg ccc tea ggg gtc cct gat ege ttc 192

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc gtc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac aat ttg gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt gcg 336

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 177 <211> 220 <212> PRT <213> Homo sapiens <400> 177

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Alá Gly Ser 85 90 95

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Alá 100 105 110

Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Alá Asp Ser 145 150 155 160

Ser Pro Val Lys Alá Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Alá Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Alá Pro Thr Glu Cys Ser 210 215 220 <210> 178 <211> 648 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(648) <400> 178 cag tct gtg ttg aeg cag ccg ccc tea ctg tee gtg tee cca gga cag 48

Gin Ser Val Leu Ihr Gin Pro Pro Ser Leu Ser Val Ser Pro Gly Gin 15 10 15 aca gee age ate tee tgc tet gga gat aaa tta ggg gat aaa tat gtt 96

Thr Ala Ser Ile Ser Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Val 20 25 30 tcc tgg tat cag cag agg cet ggc cag tcc ccc gtc tta gtc atc tat 144

Ser Trp Tyr Gin Gin Arg Pro Gly Gin Ser Pro Val Leu Val Ile Tyr 35 40 45 cac gat act aag egg ccc tea ggg ate cct gag ega ttc tet ggt acc 192

His Asp Thr Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Thr 50 55 60 aac tet ggg aac aca gee act ctg acc ate age ggg acc cag att ctg 240

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gin Ile Leu 65 70 75 80 gat gag gcc gac tat tac tgt cag gtg tgg gac agg age act gtg gtt 288

Asp Glu Ala Asp Tyr Tyr Cys Gin Val Trp Asp Arg Ser Thr Val Val 85 90 95 ttc ggc gga ggg acc cag etc acc gtt tta agt gcg gcc gea ggc cag 336

Phe Gly Gly Gly Thr Gin Leu Thr Val Leu Ser Ala Ala Ala Gly Gin 100 105 110 ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc tcc tcc gag gag 384

Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate age gac ttc tac 432

Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 cct ggc gee gtg acc gtg gee tgg aag gee gac age age ccc gtg aag 480

Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 gee ggc gtg gag acc acc acc ccc age aag cag age aac aac aag tac 528

Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys Tyr 165 170 175 gee gee age age tac ctg age etc acc ccc gag cag tgg aag age cac 576

Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser His 180 185 190 egg age tac age tgc cag gtg acc cac gag ggc age acc gtg gag aag 624

Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 acc gtg gcc ccc acc gag tgc age 648

Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210 179 <211> 216 <212> PRT <213> Homo sapiens <400 179

Gin Ser Val Leu Thr Gin Pro Pro Ser Leu Ser Val Ser Pro Gly Gin 15 10 15

Thr Ala Ser Ile Ser Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Val 20 25 30

Ser Trp Tyr Gin Gin Arg Pro Gly Gin Ser Pro Val Leu Val Ile Tyr 35 40 45

His Asp Thr Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Thr 50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gin Ile Leu 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gin Val Trp Asp Arg Ser Thr Val Val 85 90 95

Phe Gly Gly Gly Thr Gin Leu Thr Val Leu Ser Ala Ala Ala Gly Gin 100 105 110

Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125

Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140

Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160

Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys Tyr 165 170 175

Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser His 180 185 190

Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205

Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 180 <211> 642 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(642) <400> 180 gaa att gtg ttg acg cag tct cca ggc acc ctg tct ttg tct cca ggg 48

Glu Ile Val Leu Ihr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 15 10 15 gaa aga gcc acc etc tcc tgc agg gcc agt cag agt gtt age age agc 96

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Ser 20 25 30 tac tta gcc tgg tac cag cag aaa cet ggc cag get ccc agg etc etc 144

Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu 35 40 45 atc tat ggt gca tcc age agg gcc act ggc atc cca gac agg ttc agt 192

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 ggc agt ggg tct ggg aca gac ttc act etc acc atc age age cta gag 240

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 cct gaa gat ttt gca gtg tat tac tgt cag cag tat ggt age tea teg 288

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ser Ser Ser 85 90 95 atc acc ttc ggc caa ggg aca ega ctg gag att aaa egt geg gcc gca 336

Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala 100 105 110 ccc agc gtg ttc atc ttc ccc ccc tcc gac gag cag ctg aag agc ggc 384

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly 115 120 125 acc gcc agc gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag gcc 432

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 aag gtg cag tgg aag gtg gac aac gcc ctg cag agc ggc aac agc cag 480

Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin 145 150 155 160 gag agc gtg acc gag cag gac agc aag gac tcc acc tac agc ctg agc 528

Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 agc acc ctc acc ctg agc aag gcc gac tac gag aag cac aag gtg tac 576

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 gcc tgc gag gtg acc cac cag ggc ctg agc agc ccc gtg acc aag agc 624

Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 ttc aac egg ggc gag tgt 642

Phe Asn Arg Gly Glu Cys 210 <210> 181 <211> 214 <212> P RT <213> Homo sapiens <400> 181

Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 15 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Ser 20 25 30

Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu 35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ser Ser Ser 85 90 95

Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140

Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin 145 150 155 160

Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190

Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205

Phe Asn Arg Gly Glu Cys 210 <210> 182 <211> 657

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(657) <400> 182 gac ate cag ttg acc cag tet cca gac tee ctg get gtg tet ctg ggc 48

Asp Ile Gin Leu Thr Gin Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 15 10 15 gag agg gee acc ate aac tgc aag tee age cag agt ett tta tac acc 96

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gin Ser Leu Leu Tyr Thr 20 25 30 tee aat aat aag aac ttc tta get tgg tac caa caa aaa cca gga cag 144

Ser Asn Asn Lys Asn Phe Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin 35 40 45 cet cct aaa ctg etc att tac tgg gta tet acc egg gat tcc ggg gtc 192

Pro Pro Lys Leu Leu Ile Tyr Trp Val Ser Thr Arg Asp Ser Gly Val 50 55 60 cct gac ega ttc agt ggc age ggg tet ggg aca gat ttc act etc acc 240

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 ate age age ctg cag get gag gat gtg gca gtt tat tac tgt cag caa 288

Ile Ser Ser Leu Gin Ala Glu Asp Val Ala Val Tyr Tyr Cys Gin Gin 85 90 95 tat tat act act ccg tac act ttt ggc cag ggg acc aag gtg gag atc 336

Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gin Gly Thr Lys Val Glu Ile 100 105 110 aaa cgt geg gee gca ccc age gtg ttc atc ttc ccc ccc tcc gac gag 384

Lys Arg Ala Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 cag ctg aag age ggc acc gee age gtg gtg tgc ctg ctg aac aac ttc 432

Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 tac ccc egg gag gee aag gtg cag tgg aag gtg gac aac gcc ctg cag 480

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin 145 150 155 160 age ggc aac age cag gag age gtg acc gag cag gac age aag gac tcc 528

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser 165 170 175 acc tac age ctg age age acc etc acc ctg age aag gee gac tac gag 576

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 aag cac aag gtg tac gcc tgc gag gtg acc cac cag ggc ctg age age 624

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser 195 200 205 ccc gtg acc aag age ttc aac egg ggc gag tgt 657

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 183 <211> 219 <212> PRT <213> Homo sapiens <400> 183

Asp Ile Gin Leu Thr Gin Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 15 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gin Ser Leu Leu Tyr Thr 20 25 30

Ser Asn Asn Lys Asn Phe Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin 35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Val Ser Thr Arg Asp Ser Gly Val 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80

Ile Ser Ser Leu Gin Ala Glu Asp Val Ala Val Tyr Tyr Cys Gin Gin 85 90 95

Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gin Gly Thr Lys Val Glu Ile 100 105 110

Lys Arg Ala Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125

Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin 145 150 155 160

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210 184 <211 >663

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(663) <400> 184 cag tct gtg ttg acg cag ccg ccc tea gtg tet ggg gee ccg ggg cag 48

Gin Ser Val Leu Ihr Gin Pro Pro Ser Val Ser Gly Ala Pro Gly Gin 15 10 15 agg gtc ace ate tcc tgc act ggg age age tee aac ate ggg gca ggt 96

Arg Val Ihr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 tat gat gta cac tgg tac cag cag ett cca gga aca gee ccc aaa etc 144

Tyr Asp Val His Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 etc atc tat ggt aac age aat egg ccc tea ggg gtc cet gac ega ttt 192

Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc acc tea gee tcc ctg gee atc agt ggg etc 240

Ser Gly Ser Lys Ser Gly Thr Ser Alá Ser Leu Ala Ile Ser Gly Leu 65 70 75 80 egg tcc ggg gat gag get gat tat tac tgc cag tcc tat gac age age 288

Arg Ser Gly Asp Glu Alá Asp Tyr Tyr Cys Gin Ser Tyr Asp Ser Ser 85 90 95 ctg agt gat gtg gta ttc ggc gga ggg acc aag ctg acc gtc cta ggt 336

Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 geg gee gca ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc 384

Ala Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro 115 120 125 ccc tee tee gag gag ctg cag gee aac aag gcc acc ctg gtg tgc etc 432

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140 atc age gac ttc tac cet ggc gcc gtg acc gtg gcc tgg aag gcc gac 480

Ile Ser Asp Phe Tyr Pro Gly Alá Val Thr Val Ala Trp Lys Alá Asp 145 150 155 160 age age ccc gtg aag gee ggc gtg gag ace ace ace ccc age aag cag 528

Ser Ser Pro Val Lys Ala Gly Val Glu Ihr Ihr Ihr Pro Ser Lys Gin 165 170 175 age aac aac aag tac gee gee age age tac ctg age etc ace ccc gag 576

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190 cag tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc 624

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205 age acc gtg gag aag acc gtg gee ccc acc gag tgc age 663

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 185 <211> 221 <212> PRT <213> Homo sapiens <400> 185

Gin Ser Val Leu Thr Gin Pro Pro Ser Val Ser Gly Ala Pro Gly Gin 15 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30

Tyr Asp Val His Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45

Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu 65 70 75 80

Arg Ser Gly Asp Glu Ala Asp Tyr Tyr Cys Gin Ser Tyr Asp Ser Ser 85 90 95

Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110

Ala Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro 115 120 125

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140

Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp 145 150 155 160

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 165 170 175

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 186 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 186 cag tct gcc ctg act cag cet gcc tcc gtg tct ggg teg cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 aeg ate acc ate tec tgc tct gga ace age agt gac gtt ggt ggt tat 96

Thr lie Thr lie Ser Cys Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aaa egg ccc tea ggg gtt tct aat ege ttc 192

Met He Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc agt tea tct aca ege age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Ser Thr Arg Ser 85 90 95 age act ctg gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt geg 336

Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg ace ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tec tec gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 187 <211> 220 <212> PRT <213> Homo sapiens <400> 187

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Thr Ile Thr Ile Ser Cys Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Ser Thr Arg Ser 85 90 95

Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Alá 100 105 110

Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Alá Asp Ser 145 150 155 160

Ser Pro Val Lys Alá Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Alá Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Alá Pro Thr Glu Cys Ser 210 215 220 <210> 188 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 188 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 gac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asp Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aag egg ccc tea ggg gtc cct gat ege ttc 192

Met lie Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gca age aat 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Ser Asn 85 90 95 agg gat gtg ett ttc ggc gga ggg acc aag ctg acc gtc cta ggt gcg 336

Arg Asp Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tee tee gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc atc 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cct ggc gee gtg acc gtg gee tgg aag gee gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 189 <211 >220

<212> PRT <213> Homo sapiens <400> 189

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asp Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Ser Asn 85 90 95

Arg Asp Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 190 <211> 654

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(654) <400 190 tct tct gag ctg act cag gac cct get gag tet gtg gee ttg gga cag 48

Ser Ser Glu Leu Ihr Gin Asp Pro Ala Glu Ser Val Ala Leu Gly Gin 15 10 15 aca gtc aag atc aca tgc caa gga gac agt etc aga agg tat tat gca 96

Thr Val Lys Ile Ihr Cys Gin Gly Asp Ser Leu Arg Arg Tyr Tyr Ala 20 25 30 agt tgg tac cag cag aag cca gga cag gcc cct gtt ctt gtc atc tat 144

Ser Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Val Leu Val Ile Tyr 35 40 45 ggc aaa aac aac egg ccc tea ggg ate cca gac ega ttc tet ggc tcc 192

Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 agg tea gga aac aca get tcc ttg acc ata act ggg get cag geg gaa 240

Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gin Ala Glu 65 70 75 80 gat gag get gtc tat tac tgt aac tee egg gac age agt ggt aac tet 288

Asp Glu Ala Val Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ser 85 90 95 gtg gtc ttc ggc gga ggg acc aag ctg acc gtc cta ggt geg gcc gca 336

Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala Ala Ala 100 105 110 ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc tcc tcc 384

Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate age gac 432

Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 ttc tac cct ggc gee gtg acc gtg gee tgg aag gee gac age age ccc 480

Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 gtg aag gee ggc gtg gag acc acc acc ccc age aag cag age aac aac 528

Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn 165 170 175 aag tac gee gee age age tac ctg age etc acc ccc gag cag tgg aag 576

Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys 180 185 190 age cac egg age tac age tgc cag gtg acc cac gag ggc age acc gtg 624

Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val 195 200 205 gag aag acc gtg gee ccc acc gag tgc age 654

Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 191 <211> 218 <212> PRT <213> Homo sapiens <400> 191

Ser Ser Glu Leu Thr Gin Asp Pro Ala Glu Ser Val Ala Leu Gly Gin 15 10 15

Thr Val Lys lie Thr Cys Gin Gly Asp Ser Leu Arg Arg Tyr Tyr Ala 20 25 30

Ser Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Val Leu Val Ile Tyr 35 40 45

Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60

Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gin Ala Glu 65 70 75 80

Asp Glu Ala Val Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ser 85 90 95

Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala Ala Ala 100 105 110

Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125

Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140

Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160

Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn 165 170 175

Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys 180 185 190

Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val 195 200 205

Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 192 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 192 cag tct gcc ctg act cag cct gcc tcc gtg tct ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 teg ate acc ate tec tgc act gga ace age agt gac gtt ggt ggt tat 96

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc att aag egg ccc tea ggg gtc cet gat ege ttc 192

Met lie Tyr Asp Val Ile Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac aat gtg gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt geg 336

Asn Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 193 <211> 220 <212> PRT <213> Homo sapiens <400> 193

Gin Ser Ala Leu Ihr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser Ile Thr He Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ile Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95

Asn Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 194 <211> 660

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(660) <400> 194 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aag egg ccc tea ggg gtc cct gat ege ttc 192

Met lie Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc gtc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag tct gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 acc ggt tat gtc ttc gga act ggg acc aag gtc acc gtc eta ggt gcg 336

Thr Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 ace gtg gag aag ace gtg gcc ccc ace gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 195 <211> 220 <212> P RT <213> Homo sapiens <400> 195

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95

Thr Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210 196 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 196 cag tct gtg ttg acg cag ccg ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Val Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga ace age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc act agg egg ccc tea ggg gtc tct tat ege ttc 192

Met Ile Tyr Glu Val Thr Arg Arg Pro Ser Gly Val Ser Tyr Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac acg gcc tcc ctg acc gtc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac aat ttg gtc ttc ggc gga ggg acc aag ctg acc gtc eta ggt gcg 336

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag ace ace ace ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc ace ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag ace gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 197 <211> 220 <212> PRT <213> Homo sapiens <400> 197

Gin Ser Val Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Thr Arg Arg Pro Ser Gly Val Ser Tyr Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 198 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 198 cag tct gtc gtg acg cag ccg ccc tea gtg tet geg gee cca gga cag 48

Gin Ser Val Val Thr Gin Pro Pro Ser Val Ser Ala Ala Pro Gly Gin 15 10 15 aag gtc acc ate tee tgc tct gga age age tee aac att ggg aat aat 96

Lys Val Thr lie Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 tat gta tcc tgg tac cag cag etc cca gga aca gcc ccc aaa etc etc 144

Tyr Val Ser Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 att tat gac aat aat aag ega ccc tea ggg att cet gac ega ttc tct 192

Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 ggc tee aag tct ggc acg tea gcc acc ctg ggc ate acc gga etc cag 240

Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gin 65 70 75 80 act ggg gac gag gcc gat tat tac tgc gga aca tgg gag age age ctg 288

Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Glu Ser Ser Leu 85 90 95 agt get gtg gta ttc ggc gga ggg acc aag ctg acc gtc cta ggt geg 336

Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg ace ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tec tec gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 199 <211> 220 <212> PRT <213> Homo sapiens <400> 199

Gin Ser Val Val Thr Gin Pro Pro Ser Val Ser Ala Ala Pro Gly Gin 15 10 15

Lys Val Thr He Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30

Tyr Val Ser Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45

Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gin 65 70 75 80

Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Glu Ser Ser Leu 85 90 95

Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 200 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 200 cag tct gcc ctg act cag cct gcc tcc gtg tct ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 teg ate acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cac cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin His His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt gat egg ccc tea ggg gtt tct aat ege ttc 192

Met lie Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac geg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Ala Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac aat ttg gtc ttc gga act ggg acc aag gtc ace gtc eta ggt geg 336

Asn Asn Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110 gee gca ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tee tee gag gag ctg cag gee aac aag gee acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gee gtg acc gtg gee tgg aag gee gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 201 <211 >220

<212> PRT <213> Homo sapiens <400> 201

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin His His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Ala Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Alá Gly Ser 85 90 95

Asn Asn Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Alá 100 105 110

Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Alá Asp Ser 145 150 155 160

Ser Pro Val Lys Alá Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Alá Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Alá Pro Thr Glu Cys Ser 210 215 220 <210> 202 <211> 639

<212> DNA <213> Homo sapiens

<220 <221 > CDS <222> (1)..(639) <400 202 gac ate cag atg acc cag tet cca tet tee gtg tet gca tet gta gga 43

Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 15 10 15 gac aga gtc acc ate act tgt egg geg agt cag gga att age age agg 96

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Gly Ile Ser Ser Arg 20 25 30 tta gcc tgg tat cag cag aaa cca ggg aaa gcc cct aag etc ctg ate 144

Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie 35 40 45 tat get gca tee agt ttg caa agt ggg gtc cca tea agg ttc age ggc 192

Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 agt gga tet ggg aca gat ttc act etc ace ate age age ctg cag cct 240

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80 gaa gat ttt gga act tac tat tgt caa cag get aag aat ttc cct egg 288

Glu Asp Phe Gly Thr Tyr Tyr Cys Gin Gin Ala Lys Asn Phe Pro Arg 85 90 95 acc ttc ggc caa ggg aca ega ctg gag att aaa egt geg gcc gca ccc 336

Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110 age gtg ttc ate ttc ccc ccc tcc gac gag cag ctg aag age ggc acc 384

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125 gee age gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag gcc aag 432

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 gtg cag tgg aag gtg gac aac gcc ctg cag age ggc aac age cag gag 480

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160 age gtg acc gag cag gac age aag gac tee acc tac age ctg age age 528

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 acc etc acc ctg age aag gcc gac tac gag aag cac aag gtg tac gcc 576

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 tgc gag gtg acc cac cag ggc ctg age age ccc gtg acc aag age ttc 624

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 aac cgg ggc gag tgt 639

Asn Arg Gly Glu Cys 210 <210> 203 <211> 213 <212> P RT <213> Homo sapiens <400> 203

Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 15 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Gly Ile Ser Ser Arg 20 25 30

Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45

Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80

Glu Asp Phe Gly Thr Tyr Tyr Cys Gin Gin Ala Lys Asn Phe Pro Arg 85 90 95

Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205

Asn Arg Gly Glu Cys 210 <210> 204 <211> 642 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(642) <400> 204 gaa att gtg ttg acg cag tct cca ggc acc ctg tct ttg tct cca ggg 48

Glu Ile Val Leu Ihr Gin Ser Pro Gly Ihr Leu Ser Leu Ser Pro Gly 15 10 15 gaa aga gcc acc etc tcc tgc agg gcc agt cag agt gtt age agc aac 96

Glu Arg Ala Ihr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Asn 20 25 30 tac tta gcc tgg tac cag cag aaa cet ggc cag get ccc agg etc etc 144

Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu 35 40 45 gtc tat ggt gca tcc age agg gcc act ggc atc cca gac agg ttc agt 192

Val Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 ggc agt ggg tct ggg aca gac ttc act etc acc atc agc aga ctg gag 240

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 cct gaa gat ttt gca gtg tat cac tgt cag cag tat get ggc tea ccc 288

Pro Glu Asp Phe Ala Val Tyr His Cys Gin Gin Tyr Ala Gly Ser Pro 85 90 95 tgg acg ttc ggc caa ggg acc aag gtg gag atc aaa egt geg gcc gca 336

Trp Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala 100 105 110 ccc agc gtg ttc atc ttc ccc ccc tcc gac gag cag ctg aag agc ggc 384

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly 115 120 125 acc gcc agc gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag gcc 432

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 aag gtg cag tgg aag gtg gac aac gcc ctg cag agc ggc aac agc cag 480

Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin 145 150 155 160 gag agc gtg acc gag cag gac agc aag gac tcc acc tac agc ctg agc 528

Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 agc acc ctc acc ctg agc aag gcc gac tac gag aag cac aag gtg tac 576

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 gcc tgc gag gtg acc cac cag ggc ctg agc agc ccc gtg acc aag agc 624

Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 ttc aac egg ggc gag tgt 642

Phe Asn Arg Gly Glu Cys 210 <210> 205 <211> 214 <212> P RT <213> Homo sapiens <400> 205

Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 15 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Asn 20 25 30

Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu 35 40 45

Val Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr His Cys Gin Gin Tyr Ala Gly Ser Pro 85 90 95

Trp Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140

Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin 145 150 155 160

Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190

Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205

Phe Asn Arg Gly Glu Cys 210 <210> 206 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 206 caa tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc agt aag egg ccc tea ggg gtc cct gat ege ttc 192

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc gtc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac aat ttg gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt gcg 336

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 ace gtg gag aag ace gtg gcc ccc ace gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 207 <211> 220 <212> PRT <213> Homo sapiens <400> 207

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95

Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 208 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 208 cag tct gcc ctg act cag cct cgc tea gtg tee ggg tet cct gga cag 48

Gin Ser Ala Leu Ihr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc ace ate tcc tgc act gga acc age agt gat att ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr 20 25 30 aac ttt gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Phe Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tct aat cgc ttc 192

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aaa atg gcc tcc ctg acc ate tct ggg ctc 240

Ser Gly Ser Lys Ser Gly Lys Met Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tac tac tgc gcc tea tat aca agc aga 288

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Alá Ser Tyr Thr Ser Arg 85 90 95 age act etc gtc ttc gga act ggg acc aag gtc acc gtc cta ggt gcg 336

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Alá 100 105 110 gcc gca ggc cag ccc aag gcc get ccc agc gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc ctc atc 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 agc gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac agc 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag ace ace ace ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc ace ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag ace gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 209 <211> 220 <212> PRT <213> Homo sapiens <400> 209

Gin Ser Ala Leu Ihr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Ihr Ile Ser Cys Ihr Gly Ihr Ser Ser Asp Ile Gly Gly Tyr 20 25 30

Asn Phe Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Lys Met Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Thr Ser Arg 85 90 95

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 210 <211> 639

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(639) <400 210 gac ate cag atg acc cag tet cca tee tee ctg tet gca tet gta gga 48

Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 gac aga gtc acc ate act tgc egg gca agt cag age att age age tat 96

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Ser Ser Tyr 20 25 30 tta aat tgg tat cag cag aaa cca ggg aaa gcc cet aag etc ctg atc 144

Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 tat get gca tee agt ttg caa agt ggg gtc cca tea agg ttt age ggc 192

Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 agt gga tet ggg aca gat ttc act etc acc ate age age ctg cag cet 240

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80 gaa gat ttt gca act tac tat tgt caa cag get aac agt ttc ccg etc 288

Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ala Asn Ser Phe Pro Leu 85 90 95 act ttc ggc gga ggg acc aag gtg gaa atc aaa egt geg gcc gca ccc 336

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110 age gtg ttc ate ttc ccc ccc tee gac gag cag ctg aag age ggc ace 384

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125 gee age gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag gee aag 432

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 gtg cag tgg aag gtg gac aac gee ctg cag age ggc aac age cag gag 480

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160 age gtg acc gag cag gac age aag gac tee acc tac age ctg age age 528

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 acc etc acc ctg age aag gee gac tac gag aag cac aag gtg tac gcc 576

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Alá 180 185 190 tgc gag gtg acc cac cag ggc ctg age age ccc gtg acc aag age ttc 624

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 aac egg ggc gag tgt 639

Asn Arg Gly Glu Cys 210 <210> 211 <211> 213 <212> PRT <213> Homo sapiens <400> 211

Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Ser Ser Tyr 20 25 30

Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45

Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Alá Asn Ser Phe Pro Leu 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205

Asn Arg Gly Glu Cys 210 <210 212 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 212 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gat gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cac cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin His His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tct aat ege ttc 192

Met lie Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tat aca age age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 age act ett gtc ttc gga act ggg acc aag gtc ace gtc eta ggt geg 336

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110 gee gca ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tee tee gag gag ctg cag gee aac aag gee acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cet ggc gee gtg acc gtg gee tgg aag gee gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 213 <211 >220

<212> PRT <213> Homo sapiens <400> 213

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin His His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 214 <211> 663 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(663) <400> 214 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Ihr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tac 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cgc cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tet gat cgc ttc 192

Met lie Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 50 55 60 tet ggc tec aag tet ggc aac aeg gcc tec ctg acc ate tet ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gaa gac gag get gat tat tac tgc age tea tat aca act ggc 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Gly 85 90 95 age act etc gtg gtc ttc ggc gga ggg acc aag ctg acc gtc eta ggt 336

Ser Thr Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 geg gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc 384

Ala Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro 115 120 125 ccc tec tec gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc 432

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140 ate age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac 480 lie Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp 145 150 155 160 age age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag 528

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 165 170 175 age aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag 576

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190 cag tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc 624

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205 age acc gtg gag aag acc gtg gcc ccc acc gag tgc age 663

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 215 <211> 221 <212> PRT <213> Homo sapiens <400> 215

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Gly 85 90 95

Ser Thr Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110

Ala Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro 115 120 125

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140

Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp 145 150 155 160

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 165 170 175

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210 216 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 216 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc agt aag egg ccc tea ggg gtc cct gat ege ttc 192

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc gtc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc age tea tat gga ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Gly Gly Ser 85 90 95 aac aat gtg gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt gcg 336

Asn Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 217 <211> 220 <212> PRT <213> Homo sapiens <400> 217

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Gly Gly Ser 85 90 95

Asn Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 218 <211> 660

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(660) <400> 218 cag tct gcc ctg act cag cct gcc tcc gtg tct ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 teg ate acc ate tcc tgc act gga acc age agt gac gtt ggt get tat 96

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tct aat ege ttc 192

Met lie Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 aac agt gtg gta ttc ggc gga ggg acc aag etc acc gtc eta ggt geg 336

Asn Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 ace gtg gag aag ace gtg gcc ccc ace gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 219 <211> 220 <212> P RT <213> Homo sapiens <400> 219

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Alá Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Alá Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Alá Gly Ser 85 90 95

Asn Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Alá 100 105 110

Ala Ala Gly Gin Pro Lys Ala Alá Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Alá Asp Ser 145 150 155 160

Ser Pro Val Lys Alá Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Alá Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Alá Pro Thr Glu Cys Ser 210 215 220 <210 220 <211> 639

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(639) <400> 220 gac ate cag ttg acc cag tet cca tet tee gtg tet gca tet gta gga 48

Asp Ile Gin Leu Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 15 10 15 ggc aga gtc acc ate act tgt egg geg agt cag ggt att age age tgg 96

Gly Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Gly Ile Ser Ser Trp 20 25 30 tta gcc tgg tat cag cag aga cca ggg aaa gcc cet aac etc ctg atc 144

Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45 tat ggt gca tcc aac ttg caa agt ggg gtc ccc tea agg ttc age ggc 192

Tyr Gly Ala Ser Asn Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 agt ggg tet ggg aca gat ttc agt etc acc ate age age ctg caa cet 240

Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80 gaa gat ttt gca act tac tac tgt caa cag get aag agt ttc ccg etc 288

Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ala Lys Ser Phe Pro Leu 85 90 95 act ttc ggc ggc ggg acc aag gtg gaa atc aaa egt geg gcc gca ccc 336

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110 age gtg ttc ate ttc ccc ccc tee gac gag cag ctg aag age ggc acc 384

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125 gee age gtg gtg tgc ctg ctg aac aac ttc tac ccc egg gag gcc aag 432

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 gtg cag tgg aag gtg gac aac gcc ctg cag age ggc aac age cag gag 480

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160 age gtg acc gag cag gac age aag gac tee ace tac age ctg age age 528

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 acc etc acc ctg age aag gee gac tac gag aag cac aag gtg tac gcc 576

Thr Leu Thr Leu Ser Lys Alá Asp Tyr Glu Lys His Lys Val Tyr Alá 180 185 190 tgc gag gtg acc cac cag ggc ctg age age ccc gtg acc aag age ttc 624

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 aac egg ggc gag tgt 639

Asn Arg Gly Glu Cys 210 <210> 221 <211> 213

<212> PRT <213> Homo sapiens <400> 221

Asp Ile Gin Leu Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 15 10 15

Gly Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Gly Ile Ser Ser Trp 20 25 30

Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45

Tyr Gly Ala Ser Asn Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60

Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gin Pro 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ala Lys Ser Phe Pro Leu 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Pro 100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140

Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 145 150 155 160

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190

Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205

Asn Arg Gly Glu Cys 210 <210> 222 <211> 657

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(657) <400> 222 gat gtt gtg atg act cag tct cca gac tcc ctg get gtg tet ctg ggc 48

Asp Val Val Met Thr Gin Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 15 10 15 gag agg gcc acc ate aac tgc aag tcc age cag agt gtt ttt tac age 96

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gin Ser Val Phe Tyr Ser 20 25 30 tcc aac aat aag aac tac tta get tgg tac cag cac aaa cca gga cag 144

Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gin His Lys Pro Gly Gin 35 40 45 cct cct aag ttg etc att tac tgg gca tct acc egg caa tcc ggg gtc 192

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gin Ser Gly Val 50 55 60 cct gac ega ttc agt ggc age ggg tct ggg aca gat ttc act etc acc 240

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 ate aac age ctg cag get gaa gat gtg gca gtt tat tac tgt cag caa 288

Ile Asn Ser Leu Gin Ala Glu Asp Val Ala Val Tyr Tyr Cys Gin Gin 85 90 95 tat tat agt act cct ccc act ttc ggc gga ggg acc aag gtg gaa ate 336

Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu He 100 105 110 aaa cgt geg gee gca ccc age gtg ttc ate ttc ccc ccc tee gac gag 384

Lys Arg Ala Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 cag ctg aag age ggc ace gee age gtg gtg tgc ctg ctg aac aac ttc 432

Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 tac ccc egg gag gee aag gtg cag tgg aag gtg gac aac gcc ctg cag 480

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin 145 150 155 160 age ggc aac age cag gag age gtg acc gag cag gac age aag gac tcc 528

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser 165 170 175 acc tac age ctg age age acc etc acc ctg age aag gcc gac tac gag 576

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 aag cac aag gtg tac gcc tgc gag gtg acc cac cag ggc ctg age age 624

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser 195 200 205 ccc gtg acc aag age ttc aac egg ggc gag tgt 657

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 223 <211> 219 <212> PRT <213> Homo sapiens <400> 223

Asp Val Val Met Thr Gin Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 15 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gin Ser Val Phe Tyr Ser 20 25 30

Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gin His Lys Pro Gly Gin 35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gin Ser Gly Val 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80

Ile Asn Ser Leu Gin Ala Glu Asp Val Ala Val Tyr Tyr Cys Gin Gin 85 90 95

Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 100 105 110

Lys Arg Ala Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125

Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin 145 150 155 160

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210 224 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 224 cag tct gcc ctg act cag cct cgc tea gtg tee ggg tet cet gga cag 48

Gin Ser Ala Leu Thr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 gca gtc acc etc tcc tgc aat gga acc agc agg gat gtt ggt ggt tat 96

Ala Val Thr Leu Ser Cys Asn Gly Thr Ser Arg Asp Val Gly Gly Tyr 20 25 30 aat tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc act aag egg ccc tea ggg gtc cct gat cgc ttc 192

Met Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct gga ctc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gat gag get gat tat tac tgc aac tea tac gca ggc age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 aac act tgg gtg ttc ggc gga ggg ace aag ctg ace gtc eta ggt geg 336

Asn Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gee gca ggc cag ccc aag gee get ccc age gtg ace ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tee tee gag gag ctg cag gee aac aag gee acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cet ggc gee gtg acc gtg gee tgg aag gee gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 225 <211 >220

<212> PRT <213> Homo sapiens <400> 225

Gin Ser Ala Leu Thr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ala Val Thr Leu Ser Cys Asn Gly Thr Ser Arg Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95

Asn Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 226 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 226 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Ihr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aag egg ccc tea ggg gtc cet gat ege ttc 192

Met lie Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 tet ggc tec aag tet ggc aac aeg gcc tec ctg acc gtc tet ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 cag tet gag gat gag get gat tat tac tgc age tea tat gca ggc age 288

Gin Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 acc ggt tat gtc ttc gga act ggg acc aag gtc acc gtc eta ggt geg 336

Thr Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tec tec gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 227 <211 >220

<212> PRT <213> Homo sapiens <400> 227

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80

Gin Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95

Thr Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 228 <211> 660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 228 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa caa tac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin Tyr Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tct aat ege ttc 192

Met lie Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tat aca age age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 age act ett gtc ttc gga act ggg acc aag gtc acc gtc eta ggt gcg 336

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu He 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gcc ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 229 <211> 220 <212> PRT <213> Homo sapiens <400> 229

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin Tyr Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95

Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 230 <211> 663

<212> DNA <213> Homo sapiens <220 <221 > CDS <222> (1)..(663) <400 230 cag tct gcc ctg act cag cct ccc tcc gcg tcc ggg tct cct gga cag 48

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc acc ate tcc tgc act gga acc age agt gac att ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr 20 25 30 aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gag gtc agt aat egg ccc cca ggg gtt tct aat ege ttc 192

Met Ile Tyr Glu Val Ser Asn Arg Pro Pro Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac aeg gcc tcc ctg acc ate tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tac tea acc acc 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ser Thr Thr 85 90 95 acc acc ega gtg ata ttc ggc gga ggg acc aag ctg acc gtc eta ggt 336

Thr Thr Arg Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 gcg gcc gca ggc cag ccc aag gcc get ccc age gtg acc ctg ttc ccc 384

Ala Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro 115 120 125 ccc tcc tcc gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc 432

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140 ate age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac 480 lie Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp 145 150 155 160 age age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag 528

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 165 170 175 age aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag 576

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190 cag tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc 624

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205 age ace gtg gag aag ace gtg gcc ccc ace gag tgc age 663

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 231 <211> 221 <212> P RT <213> Homo sapiens <400> 231

Gin Ser Ala Leu Thr Gin Pro Pro Ser Ala Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Glu Val Ser Asn Arg Pro Pro Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ser Thr Thr 85 90 95

Thr Thr Arg Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110

Ala Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro 115 120 125

Pro Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu 130 135 140

Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp 145 150 155 160

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 165 170 175

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu 180 185 190

Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly 195 200 205

Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 232 <211 >660 <212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 232 cag tct gtc gtg acg cag ccg ccc tea gtg tet geg gee cca gga cag 48

Gin Ser Val Val Thr Gin Pro Pro Ser Val Ser Ala Ala Pro Gly Gin 15 10 15 aag gtc acc ate tee tgc tct gga age ace tee aac att ggg aat tat 96

Lys Val Thr lie Ser Cys Ser Gly Ser Thr Ser Asn lie Gly Asn Tyr 20 25 30 tat gta tee tgg tac caa cag etc cca gga aca gee ccc aaa etc etc 144

Tyr Val Ser Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 ate tat gaa aat aat aag ega ccc tea ggg att cct gac ega ttc tct 192

Ile Tyr Glu Asn Asn Lys Arg Pro Ser Gly lie Pro Asp Arg Phe Ser 50 55 60 ggc tee aag tct ggc acg tea gee acc ctg gac ate acc gga etc cag 240

Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gin 65 70 75 80 act ggg gac gag gee gat tat tac tgc gga gca tgg gat ggc age ctg 288

Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Gly Ser Leu 85 90 95 agt get gtg gta etc ggc gga ggc acc cag ctg acc gtc etc ggt geg 336

Ser Ala Val Val Leu Gly Gly Gly Thr Gin Leu Thr Val Leu Gly Ala 100 105 110 gee gca ggc cag ccc aag gee get ccc age gtg acc ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tee tee gag gag ctg cag gee aac aag gee acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140 age gac ttc tac cct ggc gee gtg acc gtg gee tgg aag gee gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gee ggc gtg gag ace ace ace ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gee gee age age tac ctg age etc ace ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg ace cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag ace gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 233 <211> 220 <212> PRT <213> Homo sapiens <400> 233

Gin Ser Val Val Thr Gin Pro Pro Ser Val Ser Ala Ala Pro Gly Gin 15 10 15

Lys Val Thr lie Ser Cys Ser Gly Ser Thr Ser Asn lie Gly Asn Tyr 20 25 30

Tyr Val Ser Trp Tyr Gin Gin Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45

Ile Tyr Glu Asn Asn Lys Arg Pro Ser Gly lie Pro Asp Arg Phe Ser 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gin 65 70 75 80

Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Gly Ser Leu 85 90 95

Ser Ala Val Val Leu Gly Gly Gly Thr Gin Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 234 <211> 660

<212> DNA <213> Homo sapiens <220> <221 > CDS <222> (1)..(660) <400> 234 cag tct gcc ctg act cag cct cgc tea gtg tee ggg tet cct gga cag 48

Gin Ser Ala Leu Ihr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15 tea gtc ace ate tcc tgc act gga ace age agt gat gtt ggt ggt tat 96

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 aac tat gtc tee tgg tac caa caa cac cca ggc aaa gee ccc aaa etc 144

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45 atg att tat gat gtc agt aat egg ccc tea ggg gtt tct aat ege ttc 192

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 tct ggc tcc aag tct ggc aac acg gcc tcc ctg acc atc tct ggg etc 240

Ser Gly Ser Lys Ser Gly Asn Thr Alá Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 cag get gag gac gag get gat tat tac tgc age tea tat aca age age 288

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 age act etc gta ttc ggc gga ggg acc aag ctg acc gtc eta ggt geg 336

Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110 gcc gca ggc cag ccc aag gcc get ccc age gtg ace ctg ttc ccc ccc 384

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125 tec tec gag gag ctg cag gcc aac aag gcc acc ctg gtg tgc etc ate 432

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140 age gac ttc tac cct ggc gcc gtg acc gtg gcc tgg aag gcc gac age 480

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160 age ccc gtg aag gcc ggc gtg gag acc acc acc ccc age aag cag age 528

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175 aac aac aag tac gcc gcc age age tac ctg age etc acc ccc gag cag 576

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190 tgg aag age cac egg age tac age tgc cag gtg acc cac gag ggc age 624

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205 acc gtg gag aag acc gtg gee ccc acc gag tgc age 660

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 235 <211> 220 <212> PRT <213> Homo sapiens <400> 235

Gin Ser Ala Leu Thr Gin Pro Arg Ser Val Ser Gly Ser Pro Gly Gin 15 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95

Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala 100 105 110

Ala Ala Gly Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro 115 120 125

Ser Ser Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile 130 135 140

Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 145 150 155 160

Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser 165 170 175

Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin 180 185 190

Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser 195 200 205

Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220

Claims 1. A human monoclonal antibody that specifically binds to and has opsonic phagocytic killing activity against at least two different Staphylococcus species and against at least 3 different strains of Staphylococcus aureus, characterized in that said antibody is an antibody with a heavy chain comprising the variable region of SEQ. ID. NO. 155 and a light chain comprising the variable region of SEQ. ID. NO. 215. 2. A human monoclonal antibody according to claim 1, characterized in that it has said opsonic phagocytic killing activity when the Staphylococcus species are in logarithmic growth phase and in static phase. 3. A human monoclonal antibody according to claim 1 or 2, characterized in that the Staphylococcus species are selected from the group consisting of S. aureus, S. auricularis, S. capitis, S. caprae, S. caseolyticus, S. chromogenes, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. hyicus, S. intermedium, S. lentus, S. lugdunensis, S. saprophyticus, S. schleiferi, S. sciuri, S. simulans, S. warned, and S. xylosus. 4. An immunoconjugate comprising a human monoclonal antibody according to any one of the claims 1-3, the immu-noconjugate further comprising at least one tag. 5. A nucleic acid molecule encoding a human monoclonal antibody according to any one of the claims 1-3. 6. A vector comprising a nucleic acid molecule according to claim 5. 7. A host cell comprising a vector according to claim 6. 8. A method of producing a human monoclonal antibody according to any one of the claims 1-3, wherein the method comprises the steps of: a) culturing a host cell according to claim 7 underconditions conducive to the expression of the human monoclonal antibody, and optionally, b) recovering the expressed human monoclonal antibody. 9. A pharmaceutical composition comprising a human monoclonal antibody according to any one of the claims 1-3, the pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient. 10. A pharmaceutical composition according to claim 9 further comprising at least one other therapeutic agent.

Patentansprüche 1. Menschlicher monoklonaler Antikörper, derspezifisch an wenigstens zwei unterschiedliche Staphylococcus-Spezies und wenigstens 3 unterschiedliche Stämme von Staphylococcus aureus bindet und opsonisch-phagozytäre Abtötungsaktivität dagegen aufweist, dadurch gekennzeichnet, dass es sich bei dem Antikörper um einen Antikörper mit einer die variable Region der SEQ. ID. NO. 155 umfassenden schweren Kette und einer die variable Region der SEQ. ID. NO. 215 umfassenden leichten Kette handelt. 2. Menschlicher monoklonaler Antikörper nach Anspruch 1, dadurch gekennzeichnet, dass er die opsonisch-phagozytäre Abtötungsaktivität aufweist, wenn sich die Staphylococcus-Spezies in logarithmischer Wachstumsphase und in statischer Phase befinden. 3. Menschlicher monoklonaler Antikörper nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die Staphylococcus-Spezies aus der aus S. aureus, S. auricularis, S. capitis, S. caprae, S. caseolyticus, S. chromogenes, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. hyicus, S. intermedium, S. lentus, S. lugdunensis, S. saprophyticus, S. schleiferi, S. sciuri, S. simulans, S. warnen und S. xylosus bestehenden Gruppe ausgewählt sind. 4. Immunkonjugat, umfassend einen menschlichen monoklonalen Antikörper nach einem der Ansprüche 1-3, wobei das Immunkonjugat ferner wenigstens ein Tag umfasst. 5. Nukleinsäuremolekül, codierend einen menschlichen monoklonalen Antikörper nach einem der Ansprüche 1-3. 6. Vektor, umfassend ein Nukleinsäuremolekül nach Anspruch 5. 7. Wirtszelle, umfassend einen Vektor nach Anspruch 6. 8. Verfahren zur Herstellung eines menschlichen monoklonalen Antikörpers nach einem der Ansprüche 1-3, wobei das Verfahren die Schritte a) Kultivieren einer Wirtszelle nach Anspruch 7 unter der Expression des menschlichen monoklonalen Antikörpers förderlichen Bedingungen und gegebenenfalls b) Gewinnen des exprimierten menschlichen monoklonalen Antikörpers umfasst. 9. Pharmazeutische Zusammensetzung, umfassend einen menschlichen monoklonalen Antikörper nach einem der Ansprüche 1-3, wobei die pharmazeutische Zusammensetzung fernerwenigstens einen pharmazeutisch unbedenklichen Hilfsstoff umfasst. 10. Pharmazeutische Zusammensetzung nach Anspruch 9, ferner umfassend wenigstens ein weiteres Therapeutikum.

Revendications 1. Anticorps monoclonal humain qui se lie spécifiquement à et qui a une activité de destruction phagocytaire opsonisante contre au moins deux espèces différentes de Staphylococcus et contre au moins 3 souches différentes de Staphylococcus aureus, caractérisée en ce que ledit anticorps est un anticorps avec une chaîne lourde comprenant la région variable de SEQ ID n° : 155 et une chaîne légère comprenant la région variable de SEQ ID n° : 215. 2. Anticorps monoclonal humain, selon la revendication 1, caractérisé en ce qu’il a ladite activité de destruction phagocytaire opsonisante quand les espèces staphylococciques sont en phase de croissance logarithmique et en phase statique. 3. Anticorps monoclonal humain, selon la revendication 1 ou la 2, caractérisé en ce que les espèces staphylococciques sont choisies dans le groupe constitué par S. aureus, S. auricularis, S. capitis, S. caprae, S. caseolyticus, S. chro-mogenes, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. hyicus, S. intermedium, S. lentus, S. lugdunensis, S. saprophyticus, S. schleifen, S. sciuri, S. simulans, S. warneri et S. xylosus. 4. Immuno-conjugué comprenant un anticorps monoclonal humain selon l’une quelconque des revendications 1 à 3, l’immuno-conjugué comprenant en outre au moins une étiquette. 5. Molécule d’acide nucléique codant pour un anticorps monoclonal humain selon l’une quelconque des revendications 1 à 3. 6. Vecteur comprenant une molécule d’acide nucléique selon la revendication 5. 7. Cellule hôte comprenant un vecteur selon la revendication 6. 8. Procédé de production d’un anticorps monoclonal humain selon l’une quelconque des revendications 1 à 3, dans laquelle le procédé comprend les étapes consistant à : a) cultiver une cellule hôte, selon la revendication 7, dans des conditions qui conduisent à l’expression de l’anticorps monoclonal humain, et, en option, b) récupérer l’anticorps monoclonal humain exprimé. 9. Composition pharmaceutique comprenant un anticorps monoclonal humain selon l’une quelconque des revendications 1 à 3, la composition pharmaceutique comprenant en outre au moins un excipient acceptable d’un point de vue pharmaceutique. 10. Composition pharmaceutique, selon la revendication 9, comprenant en outre au moins un autre agent thérapeutique.

Claims (3)

1. mmM KùTfôMémKXBÂK stafhylocoçotoic ellimi. dtiáKTM'rÁ»^ is ALKäLM.\MS|3£' Sæ&amp;h&amp;daliæti igéssypinatok I. Humán monok teába ellenanyag, »niily ipeeiflkusaa IpMlk legalább két kütebösö Smpkyteoccos ;&amp;pte éylegalább bá^^ is?8nbbk&amp;Ä|^W^s,CÖCCxä* «ft»ô«s tephôs és velük sæembeK opsxoaikns lagoetetifegs akiviiáss m&amp;. asasstlbllsmexve, ax eUeaaayag aehédánea rasiaimsexia &amp; SEQ. ID. HO. 155 saerimi varié-ül rsgsSyslibnjjybMnGn i&amp;rtabnasxa » SEQ, ID. NO. 215 sxorte variábilis régte %> Ak 1,: igénypont szerte humán monoklonáhs elteanyag, **x«í j«llem«*ve% hogy· mutatja ág opseonlmy ihgpitekns öjóakttvuásk amikor &amp; SíapfeylocoooM fajok kigsrimsitet növekuiSb itesbaa lg statikus fázisban vámsak.
2. 3, As I. vagy 2, igéayponí sxmoti humáa tnonokteáitsí elkmttyag. aazal jellomeavé» bogy s Staphyteoeens fajok g következőkből álló csoportból vâteïîoüak: S. eurem. $< awicuhtris. S', capiiis. S, caprae. S. caseofyâcus. S', istextogesey, S. cofmii, S< epiàemkiis, S. heemvh'tiüm.. 5.· kmini% S. hyicm, $. intermedium. S. hmiust S' htgfhwemis. S, sapmphyUcus. S', schleiß»*. S. Mhu% Mi sMtââm. S. wameri mâ S, xyioi'm,
3. 4. Letmankoajugátum, amely tartalmaz D3, igàsy|Xï»ïok bänndyike szmatí tenâ» jtKnteiotels: ellenanyagot ês tartalmaz legalább egy sónkét is. S< Ntikimssav-molekula, amely 1-3, igénypontok bármelyike szerinti tend» monok teáKs ellenanyagot kódol ik Vektor, sjh«|y tartalmaz 5. 7> öaaílaspjt, Sindy tartalmaz o. 82^^^^· k, Eljárás 1-k igénypontok bármelyike szerinti humán monok teáüs ellenanyag előáll basára, ahol szele járás rnagábrm foglalja a kővetkező lépésekéi: a) ?. igénypont sotentl grtxdasejt ieayeteése á barnán morteteals elteapyng eypmssiójáí elősegítő kőml-nteyek köad-ít és adott esefbeíx biagppfppaÉfbláriMomnokiönáHs elteoaoyag kinyerése, % Oyogyászsti készítmény, amely tartalmaz 1-3. igésypowtok bármelwk« aseárdi humán monokionahs ellenanyagot, és ámeiy gyógyásaailikésisibbenv ; nteiiás legalább egy, gyögyásztekg elfogadható segédanya-· goi is. Í4 A 9 igSoypsIksxferibii sj^^^âSâ^^Sïeê^igâSiÉâ^^ïS^îy' le|rÄbsggy további larSpás lateőyagöí ss iárSálbaabv: